CURRICULUM VITAE

Tamara Minko, Ph. D.
Distinguished Professor and Chair

Department of Pharmaceutics
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020

Office: 848-445-6348
Mobile: 732-927-3433
Fax: 732-445-3134
Email: minko@rci.rutgers.edu
http://www.minkolab.com
http://en.wikipedia.org/wiki/Tamara_Minko

Executive Editor, Advanced Drug Delivery Reviews — http://www.journals.elsevier.com/advanced-drug-delivery-reviews/editorial-board/

Editor, Pharmaceutical Research — http://www.pharmres.org

Google Scholar — http://scholar.google.com/citations?user=G7_qz4kAAAAJ

Personal:

Citizenship: United States
Marital status: Married, one son

Professional Profile and Current Research Interests:

Tamara Minko is a Distinguished Professor and Chair of the Department of Pharmaceutics at Rutgers, The State University of New Jersey, a member of the Cancer Institute of New Jersey and Environmental and Occupational Health Sciences Institute. Dr. Minko's current research interests include nanoscale-based targeted delivery of drugs, peptides, siRNA and antisense oligonucleotides in order to enhance the efficiency of treatment and imaging; nanomedicine; nanoparticle formulation, characterization and testing; preclinical in vitro and in vivo evaluation of anticancer therapeutics; orthotopic and ectopic animal models of cancer, lung diseases and fibrosis; personalized medicine; hypoxia; mechanisms of multidrug resistance and their suppression; intracellular fate and molecular mechanisms of action of drugs; pharmacokinetics and pharmacodynamics. She is an author and co-author of more than 400 publications (peer-reviewed papers, books and textbook chapters, conference proceedings/abstracts, and patents). Many of her papers are well cited and published in prestigious journals with high impact factors including PNAS, Nature Nanotechnology, Cancer Research, Clinical Cancer Research, Advanced Drug Delivery Review, Journal of Controlled Release, Small, ACS Nano, etc. Dr. Minko is a Fellow of AAPS, CRS and AIMBE, recipient of numerous awards, Executive Editor of Advanced Drug Delivery Reviews, Editor of Pharmaceutical Research, member of editorial board of ten scientific journals and a member of Study Sections at NIH, DOD, American Heart Association and other national and international review panels. Her research is supported by grants from NIH, NSF, DOD and other national and international sources.

Appointments, Affiliations and Experience:

Distinguished Professor, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 2011 - Present

Chair, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 2008 – Present

Acting Director, The Graduate Program in Pharmaceutical Science, Rutgers, The State University of New Jersey, 2008 – 2008

Professor, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 2007 – 2011

Associate Professor, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 2003-2007

Assistant Professor, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 2000-2003

Member, Graduate Programs: Pharmaceutical Science and Chemical and Biochemical Engineering, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 2000-Present

Member, Cancer Institute of New Jersey, New Brunswick, New Jersey, 2000-Present

Member, Environmental and Occupational Health Science Institute (EOSHI), Piscataway, NJ, 2000-Present

Adjunct Assistant/Associate Professor, Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, Utah, 2000-2007.

Research Assistant Professor, Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, Utah, 1999-2000

Research Associate, Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, Utah, 1997-1998

Senior Research Specialist, Department of Cardiovascular Genetics, College of Medicine, University of Utah, Salt Lake City, Utah, 1994-1996

Senior Scientific Officer (corresponds to the Associate Professor in the USA), Institute of Physiology, Ukrainian Academy of Sciences, Kiev, Ukraine, 1988-1993

Scientific Officer (corresponds to the Assistant Professor in the USA), Institute of Physiology, Ukrainian Academy of Sciences, Kiev, Ukraine, 1986-1988

Junior Scientific Officer, Institute of Physiology, Ukrainian Academy of Sciences, Kiev, Ukraine, 1984-1986

Ph.D. Graduate Student, Institute of Physiology, Ukrainian Academy of Sciences, Kiev, Ukraine 1980-1984

Lecturer, College of Nursing, Kiev, Ukraine 1977-1980

Education:

Postdoctoral Training, Pharmaceutics and Pharmaceutical Chemistry, Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, Utah, 1997-1998 (Advisor – Jindrich Kopecek, Ph.D., D.Sc., Professor and Chair).

Postdoctoral Training, Cellular and Molecular Biology, Department of Cardiovascular Genetics, School of Medicine, University of Utah, Salt Lake City, Utah, 1994-1996 (Advisor – Roger Williams, M.D., Professor and Chair).

Ph.D., Physiology (Cellular and Molecular), Institute of Physiology Ukrainian Academy of Sciences, Ukraine, 1984 (Advisor – Asya Z. Kolchinskaya, M.D., Ph.D., D.Sc., Professor and Chair).

M.S., Biochemistry (honor), Mordovsky State University, Russia, 1977 (Advisor – Nonna V. Alba, Ph.D., Professor).

Research Support:

Ongoing

1. 04/01/2014 – 03/31/2020 NIH/NCI R01 CA175318 T. Minko – Co-Investigator. A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer. Total - $1,772,855 (Direct - $1,143,750; Indirect -$629,065). A. Hatefi – Principal Investigator.

2. 01/01/2014 – 12/31/2017. NIH/NHLBI R01 HL118312 T. Minko - Principal Investigator. Nanotechnology Approach for Inhalation Treatment of Pulmonary Fibrosis. Total - $1,842,195 (Direct - $1,211,116; Indirect -$631,079).

3. 07/01/10 – 05/31/16. NIH/NCI R01 CA138533, T. Minko - Principal Investigator. Multifunctional Nanotherapeutics for Cancer Treatment and Imaging. Total – $1,605,843 (Direct – $1,153,700; Indirect – $452,143).

Completed

1. 08/01/10 – 07/31/2015. NIH/NCI U54 CA151881, T. Minko - Principal Investigator. Combination Nanotherapeutic Strategies to Overcome Tumor Drug Resistance. Total - $1,331,095 (Direct – $956,310; Indirect $374,784).

2. 07/01/12 – 12/31/14. Busch Biomedical Research Grant, T. Minko – Co-Investigator. Microenvironment and Phenotypic Outcome in Cystic Fibrosis Repair. (Principal Investigator – Dr. M. Gordon, Department of Pharmacology and Toxicology, EMSOP, Rutgers University). Total - $50,000.

3. 12/01/09 – 11/30/13. National Science Foundation CBET 0933966, T. Minko – Co-Principal Investigator. Novel Self Assembly of siRNA for Efficient and Safe Delivery. (Principal Investigator – Dr. H. He, Department of Chemistry, Newark, Rutgers University). Total - $125,000 (Direct – $80,906, Indirect – $44,094).

4. 04/07/06 – 02/28/13. NIH/NCI R01 CA111766, T. Minko – Principal Investigator. Molecular targeting of drug delivery system to cancer. Total – $1,338,205 (Direct – $868,912; Indirect – $471,293).

5. 08/01/09 – 07/31/12. NIH/NCI (ARRA) R01 CA100098, T. Minko – Principal Investigator, Targeted Proapoptotic Anticancer Drug Delivery System. Total – $862,283 (Direct – $645,958; Indirect – $216,325).

6. 07/01/09 – 06/30/12. NIH/NIBIB R01 EB008278, T. Minko – Co-Investigator. Efficient Cellular Delivery of Oligonucleotides. (Principal Investigator – Dr. C. M. Roth, Department of Chemical & Biochemical Engineering, Rutgers University). (Minko budget - $30,000).

7. 09/15/06 – 06/30/11. NIH/NIBIB R01 EB007049, T. Minko – Co- Principal Investigator. Carrier Shape Matters: Filomicelles, Long-circulation, and the EPR effect. (Principal Investigator – Dr. D. Discher, University of Pennsylvania). Total (Minko's budget) – $306,762 (Direct –$198,704; Indirect – $108,048).

8. 07/01/10 – 06/30/11. Department of Defense Lung Cancer Research Program W81XWH-10-1-0347, T. Minko Co-Investigator (Principal Investigator – Dr. O. Taratula, Postdoctoral Research Associate working under the supervision of Dr. Minko). Innovative Strategy for Treatment of Lung Cancer: Inhalatory Co-Delivery of Anticancer drugs and siRNA for Suppression of Cellular Resistance. Total – $114,248 (Direct – $75,000, Indirect – $39,248).

9. 07/07/04 – 07/31/09. NIH/NCI R01 CA100098, T. Minko – Principal Investigator, Targeted Proapoptotic Anticancer Drug Delivery System. Total – $1,000,872 (Direct – $643,648; Indirect – $357,224).

10. 12/01/06 – 09/30/10. United States Israel Binational Science Foundation (BSF) grant # 2005237, T. Minko – US Principal Investigator, Dr. A. Rubinstein – Israel Principal Investigator. Targeting Neoplastic Tissues with Multifunctional Saccharidic Platforms Loaded with Model Anticancer Peptides: A New Approach in Adjuvant Treatment of Microscopic Diseases. Total (Minko's budget) – $34,700 (Direct – $30,180, Indirect – $4,520).

11. 4/01/07 – 06/30/09. The American Lung Association of New Jersey, LCD-23812-N, T. Minko – Principal Investigator. Novel Inhalatory Treatment of Resistant Lung Cancer. Total – $120,000 (Direct – $120,000).

12. 11/01/08 – 10/31/09. Department of Defense Breast Cancer Research Program, T. Minko – Principal Investigator of subcontract. Nanospheric Chemotherapeutic and Chemoprotective Agents. (Principal Investigator – Dr. L. Sheihet, Department of Chemistry, New Brunswick, Rutgers University). Total (Minko's budget) – $35,000 (Direct – $35,000).

13. 03/01/08 – 09/01/08. Enzon Pharmaceuticals, Inc., T. Minko – Principal Investigator. *In vitro* and *in vivo* evaluation of novel anticancer compounds. Total – $20,000 (Direct – $12,945; Indirect – $7,055).

14. 09/15/04 – 08/31/07. NIH/NIBIB R21 EB004000-02, T. Minko – Co- Principal Investigator. Worm-like Micelles for Targeted Delivery and Imaging. (Principal Investigator – Dr. D. Discher, University of Pennsylvania). Total (Minko's budget) – $70,000 (Direct – $45,000; Indirect – $25,000).

15. 08/01/06 – 07/30/07. New Jersey Commission on Science and Technology, T. Minko – Principal Investigator. Treatment of Ovarian Cancer by Intra-abdominal Application of Core-only and Core-shell Nanoparticles with Targeting Peptides Carrying Cargoes of Chemotherapeutics. Total – $15,000 (Direct – $15,000).

16. 12/15/05 – 12/14/06. ALZA Corporation, T. Minko – Principal Investigator. Antitumor Activity of Liposomal Prodrug of Mitomycin C. Total – $80,000 (Direct – $63,492; Indirect – $16,508)**.**

17. 04/01/04 – 03/31/05. Enzon Pharmaceuticals, Inc., T. Minko – Principal Investigator EPR effect of pegylated conjugates. Total – $100,000 (Direct – $90,910; Indirect – $9,090).

18. 07/01/03 – 06/30/05. The American Lung Association, RG-156-N, T. Minko – Principal Investigator. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense. Total – $70,000 (Direct – $70,000).

19. 09/01/04 – 08/31/05, NIH R21 EB003164-01, T. Minko – Co- Principal Investigator, CD47-Display on Nanomaterials – a New Approach to Inhibiting Phagocytosis. (Principal Investigator – Dr. D. Discher, University of Pennsylvania). Total – $49,762 (Direct – $32,001; Indirect – $17,761).

20. 02/15/03 – 02/14/05. NMHEMC Research Foundation, T. Minko – Principal Investigator. Characterization of genetic adaptation to life at high altitude: Adaptation to chronic hypoxia, relevance to disease at sea level. Total – $20,000 (Direct – $20,000)**.**

21. 07/01/03 – 06/30/05. New Jersey State Commission on Cancer Research, T. Minko – Co-Investigator. Prevention of Carboplatin Drug Resistance by Selenium. (Principal Investigator – Dr. L. Rodriguez-Rodriguez, The Cancer Institute of New Jersey). Total – $10,000 (Direct – $10,000)**.**

22. 03/01/04 – 12/31/04. Baxter Healthcare Corp., T. Minko – Principal Investigator. A novel technology to combine anticancer drugs in a least invasive and a cost-effective manner. Total – $5,000 (Direct – $5,000)**.**

23. 07/01/02 – 06/30/03. The Cancer Institute of New Jersey, T. Minko – Principal Investigator, Combination of Bcl-2 antisense oligonucleotides and doxorubicin-potential use in the therapy of breast cancer. Total – $25,000.

24. 07/01/01 – 06/30/03. Charles and Johanna Busch Fund, T. Minko – Principal Investigator. Regulation of caspase-dependent signaling pathways of apoptosis by synthetic Bcl-2 homology 3 domain (BH3) peptide in prostate cancer cells. Total – $20,000.

25. 09/01/02 – 12/31/03. The Blanche and Irving Laurie Foundation, T. Minko – Principal Investigator. Stem cell survival enhancement by suppression of proapoptotic cell death signal pathways. Total – $5,000.

26. 06/01/01 – 05/31/03. New Jersey Research Division of Physicians in Transplantation and Kidney Disease, T. Minko – Principal Investigator. Influence of immumosuppressive agents on cellular viability and apoptosis in stem cells. Total – $5,000.

27. 07/01/02 – 12/31/03. NMHEMC Research Foundation, T. Minko – Principal Investigator. To support research in T. Minko's laboratory. Total – $15,000.

28. 04/01/97 – 01/31/01. NIH R01 CA51578, T. Minko – Co-Investigator. A polymeric drug delivery system for cancer therapy. (Principal Investigator – Dr. J. Kopecek, University of Utah) Total – $1,115,261.

29. 04/01/93 – 03/31/94. NIH IHSEP-02, T. Minko† – Principal Investigator from Europe (Dr. O. Appenzeller – Principal Investigator from USA). Hypoxia, migraine and Lipin. Total – $100,000.

Awards, Honors and Recognitions:

- 2015 New Jersey Health Foundation Excellence in Research Award.
- Fellow (Elected), Controlled Release Society (CRS), 2014 – Present.
- Fellow (Elected), American Institute for Medical and Biological Engineering (AIMBE), 2014 – Present.
- The paper V. Shah, O. Taratula, O. B. Garbuzenko, O. R. Taratula, L. Rodriguez-Rodriguez, **T. Minko**, "Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: an Optimal Delivery of siRNA and Anticancer Drug", Clin. Cancer Res., 19, 6193-6204 (2013) was highlighted at:
  - http://www.fiercedrugdelivery.com/story/rutgers-team-delivers-rna-weaken-drug-resistant-ovarian-cancer/2013-12-11?utm_medium=nl&utm_source=internal
  - http://www.medicalnewstoday.com/articles/269923.php
  - http://www.futurity.org/breakthrough-may-help-ovarian-cancer-survival/
  - http://www.sciencecodex.com/surviving_ovarian_cancer_rutgers_scientists_attack_drug_resistant_cancer_cells-124437
  - http://medicalxpress.com/news/2013-12-drug-delivery-successfully-deadly-ovarian.html
  - http://www.sciencedaily.com/releases/2013/12/131209124111.htm
- The paper O. Taratula, A. Kuzmov, M. Shah, O. B. Garbuzenko, **T. Minko**, "Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA, J Control Release, 171, 349-57 (2013) was highlighted at:
  - http://news.rutgers.edu/news/inhalation-therapy-lung-cancer-shows-promise-rutgers-study/20130625#.Ufx8WW0w8TA.

† Dr. T. Minko's name appears as "Minyailenko" due to the change of the last name.

- http://www.dotmed.com/news/story/12777.
- http://survivornet.ca/en/news/lung_cancer_treatment_may_improve_with_new_chemotherapy_delivery_system.

- Member (Elected), Board of Directors, Controlled Release Society, 2012 – 2014.
- Drug Delivery and Translational Research Outstanding Research Paper Award for Year 2011 (S. Betigeri, O. Garbuzenko, **T. Minko**), 2012.
- Rutgers 2012 Most Innovative Technology Award (**T. Minko**, O. Garbuzenko, M. Zhang, L, Rodriguez), 2012.
- The American Society of Health-System Pharmacists (ASHP) Research and Education Foundation Award (R. Savla, O. Taratula, O. Garbuzenko, T. Minko), 2012.
- Director-at-Large, Controlled Release Society, 2011 – 2014.
- Member (Elected), Board of Scientific Advisers, Controlled Release Society, 2011 – 2012.
- Controlled Release Society Outstanding Pharmaceutical Paper Award, (O. Taratula, M. Shah, O. Garbuzenko, **T. Minko**), 2011.
- The paper O. Taratula, O. B. Garbuzenko, A. M. Chen, **T. Minko**, "Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA, J. Drug Target., 19, 900-914 (2011) was highlighted at Nano Patents and Innovations, November 26, 2011 (http://nanopatentsandinnovations.blogspot.com/2011/11/silica-nanoparticles-for-lung-cancer.html).
- Research paper "Innovative Strategy for Treatment of Lung Cancer: Inhalatory Codelivery of Anticancer Drugs and siRNA for Suppression of Cellular Resistance" (O. Taratula, **T. Minko**) was highlighted at CDMRP Lung Cancer Research Highlights, 2011 (http://cdmrp.army.mil/lcrp/highlights.shtml#2_11).
- Gallo Award for Scientific Excellence, The Cancer Institute of New Jersey for Outstanding Cancer Research (O. Garbuzenko, O. Taratula, **T. Minko**), 2011.
- Controlled Release Society Outstanding Pharmaceutical Paper Award, (O. Taratula, O. B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, **T. Minko**), 2010.
- Member (Elected), Board of Scientific Advisors, Controlled Release Society, 2010-2012.
- The paper O. B. Garbuzenko, M. Saad, V. P. Pozharov, K. R. Reuhl, G. Mainelis, **T. Minko**. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance, Proc. Natl. Acad. Sci. USA, 107, 10737-10742 (2010) was highlighted in PNAS Media Selections (http://www.pnas.org/site/misc/current.shtml#lung); EurekAlert! (http://chinese.eurekalert.org/en/pub_releases/2010-05/potn-052110.php); DOTMED NEWS (http://www.dotmed.com/news/story/12777/); NewScientist Magazine (http://www.newscientist.com/article/mg20627623.800-inhale-lung-chemo-to-limit-organ-damage.html); Ecancermedicalscience (http://www.ecancermedicalscience.com/news-insider-news.asp?itemId=1049).
- New Jersey Pharmaceutical Association for Science and Technology 2010 Student Scholarship Award (M. Zhang, Graduate Student of **T. Minko**), 2010.
- Fellow (Elected), American Association of Pharmaceutical Scientists (AAPS), 2009 – Present.
- The paper A. M. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, **T. Minko**, H. He, Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug Resistant Cancer Cells, Small, 5, 2673-2677 (2009) was highlighted in TopNews (http://www.topnews.in/usa/node?page=36); Bioscience Technology

(http://www.biomedicalproducts.com/News/Feeds/2010/02/disease-research-new-developments-in-nanotechnology-tackle-the-2-bi); OneIndia (http://news.oneindia.in/2010/02/26/nanotechnologyapproach-may-fight-problems-linked-tochemo.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+oneindia-all-news+%28Oneindia+-+News%29).

- AAPS Physical Pharmacy and Biopharmaceutics (PPB) Graduate Student Award (M. Zhang, Graduate Student of **T. Minko**), 2009.
- First Place Poster Award, The Biennial New Jersey Pharmaceutical Conference (M. Zhang, O. Garbuzenko, L. Rodriguez, **T. Minko)**, 2009.
- Second Place Poster Award, The Biennial New Jersey Pharmaceutical Conference (O. Taratula, O. Garbuzenko, Z. Wang, G. Mainelis, **T. Minko)**, 2009.
- The New Jersey Cancer Research Award for Scientific Excellence (O. Taratula, O. B. Garbuzenko, R. Savla, H. He, **T. Minko**), 2009.
- The paper M. Saad, O. B. Garbuzenko, **T. Minko**, Co-delivery of siRNA and an anticancer drug for treatment of multidrug resistant cancer, Nanomedicine, 3, 761-776 (2008) was highlighted in LeadDiscovery (http://www.leaddiscovery.co.uk/articles/19025451/ dailyupdate).
- The paper M. Saad, O. B. Garbuzenko, E. Ber, P. Chandna, J. J. Khandare, V. P. Pozharov, **T. Minko**, Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging?, J. Control. Release, 130, 107-114 (2008) was highlighted in Cover Story by the Editor-in-Chief of the Journal (K. Park, J. Control. Release, 130, 139, 2008) and the figure from the paper was selected for the cover page of the issue.
- The paper M. L. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, **T. Minko**, Surface Modified and Internally Cationic Polyamidoamine Dendrimers for Efficient siRNA Delivery, Bioconjugate Chem., 19, 1396-403 (2008) was highlighted in Pharmacy Choice News (http://www.pharmacychoice.com/news/article.cfm?Article_ID=122774).
- Controlled Release Society Outstanding Pharmaceutical Paper Award, (S. Betigeri, O. B. Garbuzenko, **T. Minko**), 2008.
- AAPS Biotechnology Graduate Student Award (P. Chandna, Graduate Student of **T. Minko**), 2008.
- AAiPS Research Award for the Contribution to Research in the Pharmaceutical Sciences (P. Chandna, Graduate Student of **T. Minko**), 2008.
- Controlled Release Society Outstanding Student Poster Award (P. Chandna, Graduate Student of **T. Minko**), 2008.
- Gallo Award for Scientific Excellence, Presented by The Cancer Institute of New Jersey for Outstanding Cancer Research (M. Saad, Graduate Student of **T. Minko**), 2008.
- Gallo Award for Scientific Excellence, Presented by The Cancer Institute of New Jersey for Outstanding Cancer Research (O. Taratula, Graduate Student of **T. Minko** and H. He), 2008.
- Graduate Student Award, 21st Annual International Symposium "Frontiers of Nanotechnology & Biotechnology: Integration and Invention" (O. Taratula, Graduate Student of **T. Minko** and H. He), 2008.
- Faculty Academic Service Increment Awards, Rutgers, the State University of New Jersey (2001, 2002, 2004, 2005, 2007, 2010, 2011).
- AAPS Biotechnology Graduate Student Award (S. Betigeri, Graduate Student of **T. Minko**), 2007.

- AAiPS Research Award for the Contribution to Research in the Pharmaceutical Sciences (S. Betigeri, Graduate Student of **T. Minko**), 2007.
- The Outstanding Excellence Awards for the best paper presentations in the 27th Anniversary Conference, GRASP 2007 (Oleh Taratula, Graduate Student of **T. Minko** and H. He), 2007.
- The paper J. J. Khandare, **T. Minko**, Polymer-drug conjugates: Progress in polymeric prodrugs, Prog. Polym. Sci., 31, 359-397 (2006) was listed in "Top 25 Hottest Articles of Progress in Polymer Science Journal" by ScienceDirect.
- The paper R. I. Pakunlu, Y. Wang, M. Saad, J. J. Khandare, V. Starovoytov, **T. Minko**, In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug, J. Controlled Rel., 114, 153-162 (2006) was listed in "Top 25 Hottest Articles of Journal of Controlled Release" by ScienceDirect.
- The First Place Advanced Drug Delivery Charles A. Stevens Memorial Award at the Philadelphia Pharmaceutical Forum (R. I. Pakunlu, Graduate Student of **T. Minko**), 2006.
- The paper S. S. Dharap, Y. Wang, P. Chandna, J. J. Khandare, B. Qiu, S. Gunaseelan, P. J. Sinko, S. Stein, A. V. Farmanfarmanian and **T. Minko**, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide, Proc. Natl. Acad. Sci. USA, 102, 12962-12967 (2005) was selected as "Research Highlights" by Nature Reviews Cancer (E. Hutchinson, "Efficient delivery", Nature Reviews Cancer, 5, 10, 2005, P. 759).
- The paper S. S. Dharap, Y. Wang, P. Chandna, J. J. Khandare, B. Qiu, S. Gunaseelan, P. J. Sinko, S. Stein, A. V. Farmanfarmanian and **T. Minko**, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide, Proc. Natl. Acad. Sci. USA, 102, 12962-12967 (2005) was highlighted by Nature News with article titled: Unerring hormone delivers cancer drug. News@Nature. 22 Aug 2005. http://www.nature.com/news/2005/050822/full/050822-2.html) and by Reuters (http://www.oncolink.org/resources/article.cfm?c=3&s=8&ss=23&id=12229&month=08&year=2005).
- AAiPS Research Award for the Contribution to Research in the Pharmaceutical Sciences (P. Chandna, Graduate Student of **T. Minko**), 2005.
- The First Place Biotechnology Charles A. Stevens Memorial Award at the Philadelphia Pharmaceutical Forum (Y. Wang, Graduate Student of **T. Minko**), 2005.
- The Outstanding Excellence Awards for the best paper presentations in the 25th Anniversary Conference, GRASP 2005 (Seema Betigeri and Pooja Chandna, Graduate Students of **T. Minko**), 2005.
- The First Place Biotechnology Charles A. Stevens Memorial Award at the Philadelphia Pharmaceutical Forum (Y. Wang, Graduate Student of **T. Minko**), 2005.
- The paper S. S. Dharap, B. Qiu, G. Williams, P. J. Sinko, S. Stein, **T. Minko**, J. Controlled Rel., 91, 61-73 (2003) was selected as the "Highlights" by Controlled Release Society Newsletter (CRS Newsletter, Vol. 20, No. 3: page 21, 2003).
- The paper S. S. Dharap and **T. Minko**, Pharm. Res., 20, 889-896 (2003) was selected as the "Highlights" by AAPS Newsmagazine, the official publication of the American Association of Pharmaceutical Scientists (AAPS Newsmagazine, Vol.6, No 6: pp.38-39, 2003).
- AAPS Biotechnology Graduate Student Award (S. S. Dharap, Graduate Student of **T. Minko**), 2003.
- Charles A. Stevens Memorial Awards (The First Place) at the Philadelphia Pharmaceutical Forum (S. S. Dharap, Graduate Student of **T. Minko**), 2003.
- Award for an Outstanding Achievement from International Journal of Oncology, Oncology Reports and International Journal of Molecular Medicine, 2002.

- Journal of Applied Physiology of the American Physiological Society chose the paper **T. Minko** at al., J. Appl. Physiol., 93, 1550-1560 (2002) as the "Selected Contribution" and the "Highlighted Topics" of Editorial Commentary.
- AAiPS Research Award for the Contribution to Research in the Pharmaceutical Sciences (S. S. Dharap, Graduate Student of **T. Minko**), 2002.
- Charles A. Stevens Memorial Awards (The Second Place) at the Philadelphia Pharmaceutical Forum (S. S. Dharap, Graduate Student of **T. Minko**), 2002.
- The Jorge Heller Journal of Controlled Release/Controlled Release Society Outstanding Paper Award for 1998 year (**T. Minko**, V. Pozharov, P. Kopeckova, J. Kopecek), 1998.
- Awards of the Biology and Theoretical Medicine Section of the Ukrainian Academy of Sciences, 1984, 1988, 1993.

Recent Professional Activities:

Service to the Professional/Scientific Organizations

- CRS Board Liaison, Preclinical Sciences & Animal Health Division Committee, 2013-2014.
- Member (Elected), Board of Directors, Controlled Release Society, 2012-2014.
- Program Chair, Nanomedicine and Drug Delivery Symposium (NanoDDS'12), 2012
- Member-At-Large (Elected), Controlled Release Society, 2011-2014.
- Member (Elected), Board of Scientific Advisors, Controlled Release Society, 2010-2012.
- Member, Controlled Release Society Journal Subcommittee, 2010-2012.
- Ex-Officio Member, Website Editorial Committee, Controlled Release Society, 2010-2013.
- Program Chair, Bioactive Materials, 36th Annual Meeting of the Controlled Release Society, Copenhagen, Denmark, 2008-2009.
- Member, Controlled Release Society Pharmaceutical Outstanding Paper Award Subcommittee, 2008-2014.
- Abstract Reviewer, Annual Meetings of the American Association of Pharmaceutical Scientists, 2001-Present; Annual Meetings of the Controlled Release of Bioactive Materials, 2003-Present.

Service to the Scientific Journals

- Executive Editor, "Advanced Drug Delivery Reviews", 2014-Present.
- Member of Editorial Board, "Cancer and Clinical Research", 2014-Present.
- Guest Editor of the Special Issue "Tenth International Nanomedicine and Drug Delivery Symposium", "Journal of Controlled Release" (2013, volume 171).
- Guest Editor of the Theme Issue "Nanotechnology Approaches to Overcoming, Suppressing and Preventing Drug Resistance", "Advanced Drug Delivery Reviews" (2013, volume 65).
- Member, Editorial Board, "Journal of Nanopharmaceutics and Drug Delivery", 2012-Present.
- Member, Editorial Board, "Journal of Controlled Release", 2011-Present.
- Member, Editorial Advisory Board, "Pharmaceutical Nanotechnology", 2011-Present.
- Member, Editorial Advisory Board, "Advanced Drug Delivery Reviews", 2010-Present.

- Member, Editorial Advisory Board, "Molecular Pharmaceutics", 2010-Present.
- Member, Editorial Board, "Theranostics", 2010-Present.
- Member, Editorial Advisory Board, "Drug Delivery and Translational Research", 2010-Present.
- Editor, "Pharmaceutical Research", 2008-Present.
- Guest Editor of the Theme Issue "Intracellular Drug Delivery", "Pharmaceutical Research" (2007, volume 24).
- Member, Editorial Board, "Recent Patents on Drug Delivery and Formulation", 2007-Present.
- Member, Editorial Board, "Critical Reviews in Therapeutic Drug Carriers System", 2005-Present.
- Member, Editorial Advisory Board, "Pharmaceutical Research", 2005-2008.
- Ad Hoc Journal Reviewer, Nature Medicine, Cancer Research, Nature Reviews Drug Discovery, Advanced Drug Delivery Review, ASC Nano, Nanomedicine, Journal of Pharmacology and Experimental Therapy, Journal of Controlled Release, Pharmaceutical Research, Molecular Pharmaceutics, Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, European Journal of Pharmaceutical Sciences, Journal of Drug Targeting, Nanomedicine, Cancer Letters, Cancer Therapy, Anti-Cancer Drug, Lung Cancer, Cancer Detection and Prevention, Biomacromolecules, American Journal of Drug Delivery, Journal of Biomedical Materials Research, Journal of Bioactive and Compatible Polymers, Biopharmaceutics and Drug Disposition, Neoplasia, Expert opinion on Drug Delivery, Liver International, European Journal of Medicinal Chemistry, AAPS PharmSci, BioTechniques, Medical Science Monitor, 2000-Present.

Service to the National Institutes of Health, Department of Defense, American Heart Association and International Scientific Review Panels

- Member, NIH Study Section "Nanotechnology" (NANO), 2014 – Present.
- Member, Ad Hoc NIH Study Section "Nanotechnology" (NANO), 2009, 2011, 2012, 2013.
- Reviewer, KACST Research Proposal Competition, 2012, 2013.
- Member, NIH/NCI Study Section "Preclinical Pharmacokinetic and Pharmacological Studies of Anticancer and Other Therapeutic Agents" (RFP N01-CM-07014-39), 2010.
- Member, Ad Hoc NIH Special Emphasis Panel Study Section (ZRG1 BST-Z (10) B), 2007.
- Member, Ad Hoc NIH Study Section "Discovery and Development" (DHHS), 2007 – 2008.
- Member, NIH Study Section "Bioengineering, Technology and Surgical Sciences" (BTSS), 2006 – 2010.
- Member, Ad Hoc NIH Special Emphasis Panel Study Section "Nanotechnology and Nanosciences" (ZRG1 BCMB-R (50)), 2005.
- Member, Ad Hoc NIH/NCI Special Emphasis Panel Study Section "Cancer Nanotechnology Partnerships" (ZCA1 SRRB-C), 2005.
- Member, Ad Hoc NIH Special Emphasis Panel Study Section "Chemical and Bioanalytical Sciences" (ZRG1 F04A (20)), 2005.
- Member, Ad Hoc NIH Special Emphasis Panel Study Section ZRG1 SBIB-G (03), 2004.
- Member, Ad Hoc NIH Study Section "Bioengineering, Technology and Surgical Sciences" (BTSS), 2003.
- Member, American Heart Association Bioengineering and Biotechnology 1 Peer Review Study Group, 2006 – 2007.
- Member, Department of Defense Ovarian Cancer Panel #2 (OC-2), 2006.

- Member, United States Israel Binational Science Foundation (BSF), 2007 – 2008.
- Member, International Review Panel Charged with Assisting the Portuguese Foundation for Science and Technology in evaluating research proposals in areas of Pharmacology, Pharmaceutical Sciences and Biomaterials (Primary reviewer – Drug Delivery; Secondary reviewer - Cancer Pharmacology), 2001-2005.

Scientific/Professional Societies:

- American Institute for Medical and Biological Engineering, 2014 - Present
- American Chemical Society, 2006 - Present
- The International Society for Preventive Oncology, 2002-2006
- American Association of Pharmaceutical Scientists, 1999 -Present
- American Association of Colleges of Pharmacy, 1999 - Present
- Controlled Release Society, 1998 - Present
- Mountain West Chapter Society of Toxicology, 1998-2000
- American Association for Clinical Chemistry, 1995-1996
- International Society for Adaptive Medicine, 1990-1993
- International Society for Pathophysiology, 1990-1993
- Ukrainian Physiological Society, 1984-1993
- Ukrainian Society for Pharmacology and Toxicology, 1984-1993

Service to Rutgers University

- Member, Promotion and Appointment Committee (PRC), Rutgers, The State University of New Jersey, 2015-Present
- Member, Office of Research and Economic Development (ORED) Advisory Committee, Rutgers, The State University of New Jersey, 2014-Present
- Member, Faculty Appeals Board, Rutgers, The State University of New Jersey, 2013-Present
- Member, Conflicts of Interest Committee, Rutgers, The State University of New Jersey, 2013-Present
- Chair, The University's Subcommittee on Emergency Preparedness Plan, Rutgers, The State University of New Jersey, 2010 – 2011
- Vice Chair, The University's Animal Care and Facilities Committee, Rutgers, The State University of New Jersey, 2008 – Present
- Member, Graduate School Biological Sciences Area Committee, Rutgers, The State University of New Jersey, 2008 – Present
- Member, The Search Committee for the Dean of the Graduate School of New Brunswick, Rutgers, The State University of New Jersey, 2007 – 2008
- Member, The Search Committee for the Dean of the Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 2006 – 2007
- Member, The University's Animal Care and Facilities Committee, Rutgers, The State University of New Jersey, 2004 – Present

Service to Ernest Mario School of Pharmacy

- Chair, Facilities and Resources ACPE Self Study Committee, 2011– Present

- Vice-Chair, Curriculum, Educational Goal and Outcomes Assessment Committee, Ernest Mario School of Pharmacy, 2008 – Present
- Member, Budget and Policy Committee, 2008 – Present
- Member, Space and Physical Resources Committee, 2008 – Present
- Member, Organization and Administration Self-Study Focus Group, 2006-2007
- Member, Advisory Committee of Appointment and Promotions, 2005 – Present
- Member, Ad Hoc Committee: Self Study Document for External Review, Ernest Mario School of Pharmacy, 2002 – 2003
- Member, Curriculum, Educational Goal and Outcomes Assessment Committee, Ernest Mario School of Pharmacy, 2000 – 2007

Service to the Department of Pharmaceutics and Graduate Program of Pharmaceutical Science

- Chair, Department of Pharmaceutics, Rutgers, The State University of New Jersey, 2008-Present
- Acting Director, The Graduate Program of Pharmaceutical Science, Rutgers, The State University of New Jersey, 2008
- Member, Admission and Curriculum Committees of the Graduate Program of Pharmaceutical Science, 2005 – Present
- Member, Graduate Students Committees (Independent Research Proposal, Thesis Proposal, Thesis Defense), 2000 – Present

Conference Organizations, Presentations, Lectures and Seminars (2000-Present):

Conference Organizer, Section Chair/Moderator

1. Chair, Session "Nanomedicine", 16th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, February 5, 2013.
2. Chair, Organizing Committee, 10th International Nanomedicine and Drug Delivery Symposium (NanoDDS'12), Atlantic City, NJ, December 5-7, 2012.
3. Member, Organizing Committee and Session Chair, 9th International Nanomedicine and Drug Delivery Symposium (NanoDDS'11), Salt Lake City, UT, October 15-16, 2011.
4. Chair, Session "Oncology and Tumor targeting", 38th Annual Meeting of the Controlled Release Society, National Harbor, MD, August 2, 2011.
5. Program Chair, the 36th Annual Meeting of the Controlled Release Society, Copenhagen, Denmark (2008-2009).
6. Chair, Session "Inhaled Medicine", the 36th Annual Meeting of the Controlled Release Society, Copenhagen, Denmark, July 22, 2009.
7. Section Chair, 2008 NSTI Nanotech 2008 11th Annual Meeting, NCI/NSTI Special Symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment, Boston, MA, June 4, 2008.
8. Chair and Moderator, Section "Nanotechnology Approaches for Bioimaging", the Fourth International Nanomedicine and Drug Delivery Symposium, Omaha, Nebraska, October 9, 2006.
9. Chair, Section "Drug Delivery Systems", the 7th International Biorelated Polymers Symposium at the 232nd American Chemical Society Meeting, San Francisco, California, September 12, 2006.

10. Chair, Section "Biomimetic Carriers", the 33rd Annual Meeting of the Controlled Release Society, Vienna, Austria, July 23, 2006.
11. Conference Organizer and Chair, the Biennial New Jersey Pharmaceutical Conference of 2005 "Contribution of Women in the Pharmaceutical Sciences", East Brunswick, NJ, October 6, 2005.
12. Chair and Moderator, Section "Targeted Delivery of Anticancer Agents", the Third International Nanomedicine and Drug Delivery Symposium, Baltimore, Maryland, September 27, 2005.
13. Chair and Moderator, Section "Receptor Mediated Drug Targeting", 31st International Symposium on Controlled Release of Bioactive Materials, Honolulu. Hawaii, June 12, 2004.
14. Chair, Section "Pharmacology and Biochemistry", 8th World Congress on Advances in Oncology and 6th International Symposium on Molecular Medicine, Hersonissos, Crete, Greece, October 16, 2003.
15. Chair, Section "Pharmacology and Biochemistry", 7th World Congress on Advances in Oncology and 5th International Symposium on Molecular Medicine, Hersonissos, Crete, Greece, October 10, 2002.
16. Chair and Member of the Student Poster Session Committees for the following conferences:

- The Ninth International Nanomedicine and Drug Delivery Symposium, Salt Lake City, UT, October 15-16, 2011.
    - Toward the Development of Drug Delivery Systems, 2nd Annual Meeting of Italian Chapter of AAPS, Perugia, Italy, March 7, 2008.
    - The Fifth International Nanomedicine and Drug Delivery Symposium, Boston, MA, November 2, 2007.
    - GRASP 2007, 27th Annual Meeting, New Brunswick, NJ, June 1-3, 2007.
    - Targeted Nanocarriers and Therapeutics, Institute for Translational Medicine and Therapeutics, The University of Pennsylvania School of Medicine, Philadelphia, PA, November 16, 2006.

Keynote/Plenary/Invited Lectures and Seminars

1. "Nanotechnology Approaches for Personalized and Targeted Treatment of Cancer", AAPS Workshop on Nanotechnology in Personalized Medicine", October 25, 2015, Orlando, FL.
2. "Lipid-Based Microencapsulation for Drug and Gene Delivery in Lung Diseases", 20th International Symposium on Microencapsulation (IMS2015), October 3-5, 2015, Boston, MA.
3. "Advances in Nanomedicine Application for Therapy and Imaging", Evonik Meets Science, North America 2015 Innovations in Drug Delivery Technologies, September 14, 2015, Jersey City, NJ.
4. "Advances in Nanomedicine Application for Therapy and Imaging", First International Nanomedicine Symposium and Workshop: Impact of Nanobiotechnology Applications on the Future of Medicine and Personalized Medicine, August 4, 2015, Albany, NY.
5. "Nanotechnology Approaches for Personalized and Targeted Treatment", First International Nanomedicine Symposium and Workshop: Impact of Nanobiotechnology Applications on the Future of Medicine and Personalized Medicine, August 4, 2015, Albany, NY.
6. "Nanotechnology Approaches for Personalized Treatment of Cancer", 42nd Controlled Release Society Annual Meeting, July 26-29, 2015, Edinburgh, Scotland.
7. "The Best Animal Model for Drug Delivery Studies", 42nd Controlled Release Society Annual Meeting, July 26-29, 2015, Edinburgh, Scotland.
8. "Nanotechnology Approach for Inhalation Treatment of Lung Cancer", Cancer Drug Discovery and Enabling Technologies Symposium, RCIPR, April 10, 2015, Piscataway, NJ.

9. "Nanotechnology Approaches for Personalized Treatment of Cancer", 3rd Nanomedicine Conference, March 13-14, 2015, Los Angeles, CA.
10. "Tumor-Targeted Nanotherapeutics", University of Pittsburgh, March 3, 2015, Pittsburgh, PA.
11. "Tumor-Targeted Nanotherapeutics", Capital Region Cancer Research New Frontiers Symposium 2014: New Strategies and Technologies in Cancer Research, November 14, 2014, Albany, NY.
12. "Nanotechnology Approaches for Personalized Treatment of Cancer ", Targeted therapeutics and Translational Medicine 2014 Symposium, November 12, 2014, Philadelphia, PA.
13. "Drug delivery systems for lungs", NHLBI Workshop: Precision Therapeutics Delivery for Lung Diseases: State of the Art Technologies and Lung Biology, September 24, 2014, Bethesda, MD.
14. "Tumor-Targeted Nanotherapeutics", TechConnect World 2014 Congress, Cancer Nanotechnology II, June 16, 2014, Washington, D.C.
15. "Tumor-Targeted Nanotherapeutics", School of Pharmacy, University of Connecticut, April 29, 2014, Storrs, CT.
16. "Nanotechnology-Based Method for Treatment of Primary Ovarian Cancer and Prevention of Metastases", Molecular Response, April 4, 2014, San Diego, CA.
17. "Tumor-Targeted Nanotherapeutics", 2013 Eastern Pharmaceutical Technology Meeting (EPTM), September 20, 2013, Basking Ridge, NJ.
18. "Targeted Drug Delivery of Chemotherapeutics Utilizing Nanoparticle and Liposomal Formulations", 2013 Medicinal Chemistry Gordon Research Conference, August 6, 2013, New London, NH.
19. "Nanotechnology Strategies to Overcome Drug Resistance", 2nd Nanomedicine for Imaging and Treatment Conference, Cedars-Sinai Medical Center, March 16, 2013, Los Angeles, CA.
20. "Nanotechnology Strategies to Overcome Limitations in Treatment of Challenging Diseases", Biosciences Working Group (BSWG), The MITRE Corporation, January 23, 2013, McLean, VA.
21. "Nanotechnology-Based Targeted Cancer Treatment", 2012 AAPS Annual Meeting, October 17, 2012, Chicago, IL.
22. "Combined Targeted Chemo and Gene Therapy for Tumor Suppression and Prevention of Metastasis", Oligonucleotide Delivery: Biology, Engineering and Development, October 8, 2012, Hernstein, Austria.
23. "Boosting the EPR Effect by Targeting of Nanocarriers to Tumor-Specific Receptors", Workshop "Critical Appraisal of EPR Effect and Intratumoral Distribution of Nanomedicine", 38th Annual Meeting of the Controlled Release Society, July 14, 2012, Quebec City, Canada.
24. "Non-Viral Systemic Delivery of siRNA or Antisense Oligonucleotides Targeted to Jun N-Terminal Kinase 1 Prevents Cellular Hypoxic Damage", 38th Annual Meeting of the Controlled Release Society, July 16, 2012, Quebec City, Canada.
25. "Nanotechnology Strategies to Overcome Multidrug Resistance", School of Pharmacy, Oregon State University, April 19, 2012, Corvallis, OR.
26. "Cancer Stem Cells Specific Therapy: Targeted Nanomedicine for Simultaneous Suppression of CD44 Protein and Cell Death Induction", 9th International Conference and Workshop on Biological Barriers, March 6, 2012, Saarbrucken, Germany.
27. "Molecular Targeting of Drug Delivery Systems to Cancer", Nanomedicine Research Center, Cedars-Sinai Medical Center, November 16, 2011, Los Angeles, CA.
28. "Nanotechnology Strategies to Overcome Limitations in Cancer Treatment", Department of Pharmaceutical Sciences at the University at Buffalo, The State University of New York, October 6, 2011, Buffalo, NY.

29. "Combination of Tumor-Targeted Chemo- and Gene Therapy for Treatment of Primary Ovarian Cancer and Prevention of Metastases", Ovarian Cancer Symposium: "One Force to Make a Difference", June 18, 2011, Princeton, NJ.
30. "Multifunctional and Multicomponent Drug Delivery Systems for Cancer Treatment and Imaging", The 2011 Annual Retreat on Cancer Research in New Jersey, May 26, 20011, Piscataway, NJ.
31. "Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges", The Eighth International Nanomedicine and Drug Delivery Symposium, October 3, 2010, Omaha, NE.
32. "Molecular Targeting of Drug Delivery Systems to Cancer", Gordon Research Conferences: Drug Carriers in Medicine and Biology, August 17, 2010, Waterville Valley, NH.
33. "Nanotechnology Strategies to Overcome Limitations in Cancer Treatment", Particles 2010: Medical/Biochemical Diagnostic, Pharmaceutical, and Drug Delivery Applications of Particle Technology, May 23, 2010, Lake Buena Vista, FL.
34. "Nanotechnology Strategies to Overcome Limitations in Cancer Chemotherapy", Department of Pharmaceutical Sciences, Wayne State University, April 28, 2010, Detroit, MI.
35. "Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges", New York Society of Cosmetic Chemists (NYSCC) Spring Seminar, April 21, 2010, West Orange NJ.
36. "Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges"**,** Clinical Applications of Quantum Dot and Nanoparticle Technology, University of Illinois at Chicago Center for Clinical and Translational Science (CCTS), April 13, 2010, Chicago, IL.
37. "Mechanisms of Cellular Drug Resistance and Strategies to Overcome It", Symposium on Biomedical Polymers for Drug Delivery, March 27, 2010, Salt Lake City, UT.
38. "Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges", University of Wisconsin, March 17, 2010, Madison, WI.
39. "Nanotechnology Strategies to Overcome Limitations in Cancer Chemotherapy", F. Hoffmann-La Roche Ltd, January 29, 2010, Nutley, NJ.
40. "New horizons in treatment of lung cancer: Combinatorial liposomal inhalation delivery of drugs and suppressors of cellular resistance", Liposome advances: Recent trends and progress, December 13, 2009, London, UK.
41. "Targeted multifunctional nanocarriers for tumor treatment and imaging", Annual Meeting of the American Association of Pharmaceutical Scientists, November 11, 2009, Los Angeles, CA.
42. "Inhalatory co-delivery of anticancer drugs and antisense oligonucleotides/siRNA for lung cancer treatment", 35th Annual Meeting of the Controlled Release Society, July 22, 2009, Copenhagen, Denmark.
43. "Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges", 41st Annual Pharmaceutics Graduate Student Research Meeting "Globalization of the Pharmaceutical Industry", June 26, 2009, Purdue University, West Lafayette, IN.
44. "Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges", AAPS Workshop on Evolving Science and Technology in Physical Pharmacy and Biopharmaceutics, May 15, 2009, Baltimore, MD.
45. "Receptor Targeted Nanocarriers for Tumor-Specific Treatment and Imaging", 14th International Symposium on Recent Advances in Drug Delivery Systems, February 18, 2009, Salt Lake City, UT.

46. "Multifunctional Nanotherapeutics for Cancer Treatment", American Association for Cancer Research – American Chemical Society Joint Conference on: Chemistry in Cancer Research: A Vital Partnership in Drug Discovery and Development, February 10, 2009, New Orleans, LA.
47. "Receptor Targeted Nanocarriers for Tumor-Specific Treatment and Imaging", The Provost Interdisciplinary Seminar Series on Targeted Therapeutics and Drug Delivery Systems, The University of Pennsylvania School of Medicine, Philadelphia, PA, January 14, 2009.
48. "Receptor-targeted nanocarriers for tumor-specific treatment and imaging", Birck Nanotechnology Center, Purdue University, West Lafayette, IN, December 11, 2008.
49. "Efficient Co-Delivery of siRNA/Antisense Oligonucleotides and Drug for Lung Cancer Treatment", 36th Annual Scientific Session of the New Jersey Thoracic Society, New Brunswick, NJ, June 6, 2008.
50. "Nanocarriers for Tumor-Targeted Drug Delivery", 2008 NSTI Nanotech 2008 11th Annual Meeting, NCI/NSTI Special Symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment, Boston, MA, June 4, 2008.
51. "Targeted Multifunctional Nanocarriers for Tumor Treatment and Imaging", Toward the Development of Drug Delivery Systems, 2nd Annual Meeting of Italian Chapter of AAPS, Perugia, Italy, March 7, 2008.
52. "Targeted Multifunctional Nanocarriers for Intracellular Drug Delivery", University of Ferrara, Italy, March 6, 2008.
53. "Targeted Multifunctional Nanocarriers for Tumor Treatment and Imaging", School of Pharmacy, University of Rhode Island, Kingston, RI, May 15, 2008.
54. "Tumor – Targeted Anticancer Prodrugs", Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, CA, November 15, 2007.
55. "Targeted Multicomponent Nanocarriers for Cancer Treatment and Diagnostics", The Fifth International Nanomedicine and Drug Delivery Symposium, Boston, MA, November 2, 2007.
56. "Multifunctional Drug Delivery System for Inhalatory Treatment of Lung Cancer", The Biennial New Jersey Pharmaceutical Conference of 2007, New Brunswick, NJ, October 5, 2007.
57. "Targeted Multifunctional Nanocarriers for Intracellular Drug Delivery", Department of Pharmaceutics at the University of Minnesota, Minneapolis, MN, September 20, 2007.
58. "Targeted multicomponent nanocarriers in cancer treatment", the 6th Annual Meeting of the Israeli Chapter of the Controlled Release Society on September 5, 2007, Cesaria, Israel.
59. "Targeted Multifunctional Drug Delivery Systems for Cancer Treatment and Imaging" Chemistry and Chemical Biology Department at Stevens Institute of Technology, Hoboken, NJ., September 12, 2007.
60. "Tumor-Specific Targeting of Drug Delivery Systems for Cancer Therapy and Imaging", 34th Annual Meeting of the Controlled Release Society, Long Beach, CA, July 11, 2007.
61. "Complex Liposomal Drug Delivery System for Inhalatory Treatment of Lung Cancer", 35th Annual Scientific Session of the New Jersey Thoracic Society, New Brunswick, NJ, June 1, 2007.
62. "Targeted Multifunctional Nanocarriers for Intracellular Drug Delivery", Department of Chemistry, Newark, Rutgers, The State University of New Jersey, Newark, NJ, March 30, 2007.
63. "Receptor Targeting of Polymer Therapeutics and Imaging Agents to Tumor", International Symposium on Polymer Therapeutics ISPT-07, Berlin, Germany, February 20, 2007.
64. "Tumor-Specific Targeting of Drug Delivery Systems", Novartis Pharmaceuticals, East Hanover, NJ, November 17, 2006.

65. "Targeted Nanocarriers for Intracellular Drug Delivery", Targeted Nanocarriers and Therapeutics, Institute for Translational Medicine and Therapeutics, The University of Pennsylvania School of Medicine, Philadelphia, PA, November 16, 2006.
66. "Tumor - Targeting Liposomal Complex for Short Interfering RNA Delivery", Georgetown University Medical Center, Washington DC, October 24, 2006.
67. "Targeted Polymeric Prodrug with Multivalent Components for Cancer Therapy", the 7th International Biorelated Polymers Symposium at the 232nd American Chemical Society Meeting, San Francisco, CA, September 12, 2006.
68. "Molecular targeting of drug delivery system to lung cancer", 34th Annual Scientific Session of New Jersey Thoracic Society, New Brunswick, NJ, June 2, 2006.
69. "Targeted Proapoptotic Drug Delivery System for Chemotherapy of Ovarian Cancer", The Cancer Institute of New Jersey, New Brunswick, NJ, May 5, 2006.
70. "Extracellular and intracellular molecular targeting of drug delivery system to cancer", College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, March 31, 2006.
71. "Targeted anticancer polymeric prodrugs", Abbott Laboratories, Abbott Park, IL, March 23, 2006.
72. "Complex drug delivery composition for treating cancer", Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, February 27, 2006.
73. "Advances in targeted drug delivery for cancer treatment", Bristol-Myers Squibb Co., New Brunswick, NJ, February 3, 2006.
74. "Targeted drug delivery systems for cancer therapy", Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago IL, January 11, 2006.
75. "Advanced targeted drug delivery systems for cancer therapy", International Conference on Advances in Pharmaceutical Research and Technology, Mumbai, India, November 25-29, 2005.
76. "Novel approaches in anticancer drug delivery", The Biennial New Jersey Pharmaceutical Conference of 2005 "Contribution of Women in the Pharmaceutical Sciences", East Brunswick, NJ, October 6, 2005.
77. "Delivery system for remediation of cellular hypoxic damage", Third International Nanomedicine and Drug Delivery Symposium, Baltimore, MD, September 26-27, 2005.
78. "Molecular targeting of drug delivery systems to cancer", College of Pharmacy, Howard University, Washington, DC, November 4, 2004.
79. "Targeted delivery of anticancer drugs and peptides by polyethylene glycol conjugates", 7th Symposium on Biomaterials Science, New Brunswick, NJ, October 21-22, 2004.
80. "Extracellular and intracellular molecular targeting of drug delivery system to cancer cells", World Conference on Dosing of Antiinfectivnes – Dosing the Magic Bullets, Nurnberg, Germany, September 9-11, 2004.
81. "A novel multicomponent delivery system to enhance the efficacy of lung cancer therapy", 32nd Annual Scientific Section of the New Jersey Thoracic Society, New Brunswick, NJ, June 4, 2004.
82. "Targeted proapoptotic anticancer drug delivery system", College of Pharmacy, University of Maryland, Baltimore, MD, March 3, 2004.
83. "Molecular targeting of drug delivery systems to cancer cells by peptides and antisense oligonucleotides", College of Pharmacy, University of Kentucky, Lexington, KY, February 27, 2004.
84. "Molecular targeting of cellular resistance in cancer", 8th World Congress on Advances in Oncology and 6th International Symposium on Molecular Medicine, Crete, Greece, October 16, 2003.

85. "Multicomponent drug delivery system for enhancing the efficacy of cancer chemotherapy", Meeting of the New Jersey Center for Biomaterials, New Brunswick, NJ, September 17, 2003.
86. "Molecular targeting of drug delivery systems to cancer cells by peptides and antisense oligonucleotides", Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago IL, April 2, 2003.
87. "Genetic adaptation to life at high altitude: Adaptation to chronic hypoxia, relevance to disease at sea level", University of Lima, Lima, Peru, March 14, 2003.
88. "Advanced targeted drug delivery systems for cancer therapy", Myriad Genetics, Inc., Salt Lake City, UT, March 4, 2003.
89. "Molecular targeting of drug delivery systems to cancer cells by peptides and antisense oligonucleotides", EOHSI, Piscataway, NJ, February 6, 2003.
90. "Targeted proapoptotic drug delivery systems in cancer chemotherapy", 7th World Congress on Advances in Oncology and 5th International Symposium on Molecular Medicine, Hersonissos, Crete, Greece, October 11, 2002.
91. "Targeted proapoptotic drug delivery systems in cancer chemotherapy", Cancer Institute of New Jersey (Breast Cancer Research Program), New Brunswick, NJ, May 2002.
92. "Advanced drug delivery systems in cancer chemotherapy", The Screening Technologies Branch of the Developmental Therapeutics Program in Drug Discovery and Development, National Cancer Institute, Frederick, MD, March 2002.
93. "Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense", 6th International Symposium on Predictive Oncology and Intervention Strategies, Pasteur Institute, Paris, France, February 2002.
94. "Novel drug delivery systems for cancer therapy", Salvona, Dayton, NJ, January 2002.
95. "Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense", GPCC Retreat, The Center for Advanced Biotechnology and Medicine, UMDNJ, Piscataway, NJ, December 2001.
96. "Advanced drug delivery systems in cancer chemotherapy", VectraMed, Princeton, NJ, December 2001.
97. "Enhancing the efficacy of anticancer drugs using multicomponent advanced drug delivery system", The Cancer Institute of New Jersey, New Brunswick, NJ, December 2001.
98. "Advanced drug delivery systems in cancer chemotherapy", Pharmaceutics Conference 2001, East Brunswick, NJ, November 2001.
99. A polymer drug delivery system for cancer therapy, New Jersey Center for Biomaterials, Piscataway, NJ, June 1, 2001.
100. Antitumor activity and cell death signaling pathway of free and polymer-bound doxorubicin. The PH 890, Pharmacy Seminar (Pharmaceutics, Spring 2001), Philadelphia College of Pharmacy, University of the Science, Philadelphia, PA, April 27, 2001.
101. Mechanisms of anticancer action of HPMA copolymer-bound doxorubicin, ENZON, Inc., Piscataway, NJ, November 16, 2000.
102. Mechanism of anticancer action of HPMA copolymer-bound doxorubicin, 40th Microsymposium "Polymers in Medicine", Czech Republic, July 2000, Special Lecture #4.
103. "Cell death signaling pathways and antitumor activity polymer-bound drugs", Department of Pharmacology and Toxicology, School of Pharmacy, University of Utah, Salt Lake City, UT, November 1999.

104. "Adaptation to moderate stress increases the resistance to severe hypoxia", International Symposium on High-Altitude Medicine, Matsumoto, Japan, September 1992.

105. "The criterion for the selection of hypoxic impacts for interval hypoxic training", International Symposium on Interval Hypoxic Training: Efficiency and Mechanisms of Action, Kiev, Ukraine, September 1992.

106. "Oxygen supply-consumption ratio as the criterion of tissue hypoxia", Hypoxia and Ischemia: Basic and Applied Aspects, Berlin, Germany, September 1991.

107. "Primary and secondary disturbances of acid-base homeostasis", Acid-base and Thermal Homeostasis, Syktyvkar, Russia, February 1991.

108. "Influence of adaptation to high altitude hypoxia on the resistance of an organism to oxygen deficiency and stress", Functional Reserves and Adaptation, Kiev, Ukraine, September 1990.

109. "Peculiarities of organism oxygen supply under bronchial asthma in mountains", Usage of Mountain Climate to Treatment and Prophylaxis, Nalchik, Russia, April 1988.

110. "The conformity between oxygen mass transfer and its consumption during hypoxia of different genesis", Regulation of Respiration and Gas Mass Transfer in the Organism, Leningrad, Russia, April 1985.

Oral (Podium) Presentations

1. "Straight to the Target: A Novel Polymeric Prodrug with Multivalent Components for Cancer Therapy", 33rd International Symposium on Controlled Release of Bioactive Materials, Vienna, Austria, July 22-26, 2006.

2. "Hypoxia Inducible Factor - Targeted Anticancer Prodrug", 32nd International Symposium on Controlled Release of Bioactive Materials, Miami, FL, June 18-22, 2005.

3. "Targeted proapoptotic anticancer drug delivery system", 31st International Symposium on Controlled Release of Bioactive Materials, Honolulu. HI, June 15, 2004.

4. "Novel Targeted Drug Delivery Systems Combining Anticancer Drug, Targeting Moiety and Suppressors of Multidrug Resistance and Antiapoptotic Cellular Defense", CRS Winter Symposia & 11th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, March 3-6, 2003.

5. "Molecular targeting of drug delivery systems for ovarian carcinoma therapy", International Symposium on Tumor Targeted Delivery Systems (CRS & NIH), Bethesda, MD, September 24, 2002.

6. "Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense with liposomes containing doxorubicin and antisense oligonucleotides targeting MDR1 and BCL-2 mRNA", 29th Annual Meeting of the Controlled Release Society, Seoul, Korea, July 25, 2002.

7. "Delivery of synthetic BCL-2 homology 3 domain (BH3) peptide by fusion with the Antennapedia internalization sequence in combination with an antiapoptotic drug concurrently enhances apoptosis and inhibits antiapoptotic defenses in human ovarian carcinoma", Gordon Research Conference: Drug Carriers in Medicine and Biology, Ventura, CA, February 2002.

8. "Role of caspases in cellular signal transduction pathways of apoptosis induced by free and HPMA copolymer-bound doxorubicin", The 27th International Symposium on Controlled Release of Bioactive Materials, Paris, France, July 2000.

9. "Cell death signaling pathways, toxicity and antitumor activity of free and polymer-bound doxorubicin", Molecular Genetics in Toxicology, 17th Annual Meeting of Mountain West Chapter of Society of Toxicology, Breckenridge, CO, September 1999.

10. "EPR effect, multidrug resistance and the efficacy of HPMA copolymer-bound adriamycin in solid tumors with high vascularization", The 26th International Symposium on Controlled Release of Bioactive Materials, Boston, MA, June 1999.
11. "Peculiarities of apoptosis induction and cell metabolism in human ovarian carcinoma cell lines exposed to free and HPMA copolymer bound adriamycin", The 25th International Symposium on Controlled Release of Bioactive Materials, Las Vegas, NV, June 1998.
12. "Mechanisms of the increase in the work load after preliminary adaptation to intermittent hypoxia and training", III World Congress of ISAM , Tokyo, Japan, May 1993.
13. "Towards a new way to elevate the resistance against damaging environmental impacts", 1st American – Ukrainian Workshop "Health Care: Clinical and Basic Research", Kiev, Ukraine, June 1993.
14. "Hypoxic acid-base changes, lipid peroxidation and oxygen supply-consumption ratio", 7th International Hypoxia Symposium, Lake Louise, Canada, February 1991.
15. "Adaptation to high altitude limits tissue hypoxia and lipid peroxidation under severe acute environmental hypoxia", International Congress of Mountain Medicine, Crans-Montana, Switzerland, April 1991.
16. "Interrelation of lipid peroxidation and tissue hypoxia under hypoxic states of different genesis", Constituent Congress of International Society for Pathophysiology, Moscow, Russia, May 1991.
17. "Role of primary disturbances of blood buffer capacity in the compensation of metabolic acidosis", Actual Problems of Pathology of Respiration, Kujbyshev, Russia, November 1989.
18. "Factors which determine resistance of blood active reaction under hypoxia", Reactivity and Resistance: Fundamental and Applied Aspects, Kiev, Ukraine, May 1987.
19. "Respiration, circulation, blood acid-base balance and oxygen regimen of organism in women-arid zone lenders with iron deficit anemia under the influence of mountain climate", Human Adaptation in Different Climatogeographic and Industrial Environment, Novosibirsk, Russia, June 1981.
20. "Peculiarities of blood buffering properties and acid base status in girls with secondary anemia", Annual Meeting of Physiological Society: Special and Clinical Physiology of Hypoxic States, Kiev, Ukraine, November 1979.

Oral (Podium) Presentations of the Graduate Students, Postdoctoral Fellows and Researchers from Minko's Lab since Joining Rutgers in 2000

1. "Inhalation treatment of lung cancer: The influence of composition, size and shape of nanocarriers on their lung accumulation and retention", 2015 Annual Retreat in Cancer Research, May 20, 2015, Piscataway, NJ (O. Garbuzenko, G. Mainelis, O.Taratula, T, Minko).
2. "Dendrimer-based multifunctional nanomedicine platforms for targeted delivery of siRNA", 10th International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ (O. Taratula, O. B. Garbizenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, T**.** Minko).
3. "Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary codelivery of anticancer drugs and siRNA", 38th Annual Meeting of the Controlled Release Society, July 31-August 3, 2011, National Harbor, MD (O. Taratula, M. Shah, O. Garbuzenko, T. Minko).
4. "The influence of composition, size, and shape of nanocarriers on their accumulation and retention in lungs after pulmonary (or inhalatorial) delivery", The 2011 Annual Retreat on Cancer Research in New Jersey, May 26, 2011, Piscataway, NJ (O. Garbuzenko, O. Taratula, T. Minko).

5. "Receptor-targeted surface-engineered PPI dendrimer for efficient intracellular and intratumoral siRNA delivery", 37th Annual Meeting of the Controlled Release Society, July 10-14, 2010, Portland, OR (O. Taratula, O. B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, T. Minko).
6. "Combinatorial inhalatory co-delivery of drug and antisense oligonucleotides for treatment of lung cancer", 37th Annual Meeting of the Controlled Release Society, July 10-14, 2010, Portland, OR (O. Garbuzenko, M. Saad, K. Reuhl, G. Mainalis, T. Minko).
7. "Combinatorial local inhalatory treatment of lung cancer", Innovations in Drug Delivery Technologies, The Biennial New Jersey Pharmaceutical Conference of 2009, November 20, 2009, Piscataway, NJ (O. Garbuzenko, M. Saad, V. P. Pozharov, K. R. Reuhl, G. Mainelis, T. Minko).
8. "Dendrimers as Potential siRNA Delivery Vehicles for Efficient Cancer Therapy", Innovations in Drug Delivery Technologies, The Biennial New Jersey Pharmaceutical Conference of 2009, November 20, 2009, Piscataway, NJ (O. Taratula, O. Garbuzenko, T. Minko).
9. "Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most effective for tumor specific treatment and imaging?" in 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY (M. Saad, O. B. Garbuzenko, E. Ber, P. Chandna, J. J. Khandare, V. P. Pozharov, T. Minko).
10. "A novel targeted proapoptotic drug delivery system for efficient anticancer therapy" in 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY (P. Chandna, M. Saad, Y. Wang, E. Ber, J. Khandare, A. A. Vetcher, V. A. Soldatenkov, T. Minko).
11. "JNK1 as a molecular target to limit cellular damage under hypoxia" in 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY (S. Betigeri, O. B. Garbuzenko, T. Minko).
12. "Noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research" in The Annual Retreat on Cancer Research in New Jersey, May 28, 2008, Piscataway, NJ (M. Saad, O. B. Garbuzenko, J. J. Khandare, Y.Wang, A. A. Vetcher, V. A. Soldatenkov, T. Minko).
13. "Toward in vivo targeted delivery of siRNA for efficient cancer therapy" at The Annual Retreat on Cancer Research in New Jersey, , May 28, 2008, Piscataway, NJ (O. Taratula, R.Salva, I. Pandya, H. Geng, A. Wang, T. Minko, H. He).
14. "Targeted nanocarier-based delivery of near-infrared cyanine dye enhances tumor imaging" in the Fourth Nanomedicine and Drug Delivery Symposium, October 10, 2006, Omaha, NE (M. Saad, J. J. Khandare, Y. Wang, T. Minko).
15. "JNK1 as a molecular target to decrease cellular mortality under hypoxia", 25th Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), June 10-12, 2005, New York, NY (S. Betigeri, R. I. Pakunlu, T. Minko).
16. "Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: Novel multicomponent delivery system", 24th Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), June 4-6, 2004, Atlanta, GA (R. I. Pakunlu, Y. Wang, T. Minko).
17. "Potential use of the combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and doxorubicin as a novel anticancer therapy", 24th Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), June 4-6, 2004, Atlanta, GA (Y. Wang, R. I. Pakunlu, T. Minko).
18. "Molecular targeting of drug delivery systems to cancer cells by BH3 and LHRH peptides", 23rd Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), May 30 - June 1, 2003, Richmond, VA (S. S. Dharap, B. Qiu, S. Stein, P. J. Sinko, T. Minko).

Poster Presentations of the Graduate Students, Postdoctoral Fellows and Researchers from Minko's Lab since Joining Rutgers in 2000 – Total: 124.

Teaching Activities (since Joining Rutgers, 2000 – Present):

Undergraduate/Professional (Pharm. D.) and Graduate (Ph.D., M.S.)

- COURSE INFORMATION -								- COURSE EVALUATION -				
									Teaching Effectiveness (Max = 5)		Course Quality (Max = 5)	
S/ Yr	**Course Title**	**Number**	**Cr**	**MOI**	**Aud**	**Resp**	**Enrl**	**Evaluation Responses**	**Instructor**	**Dept Mean**	**Instructor**	**Dept Mean**
FA15	Graduate Seminar in Pharmaceutical Sciences	16:720:601	1	CC Sem	Grad	Total	6	Evaluation is not conducted for the seminar				
FA15	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	8	Evaluation is not conducted for the research course				
SU15	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	8	Evaluation is not conducted for the research course				
SP15	Drug Delivery and Lab	30:721:320	4	CC Lec	UM	Shared 43% *	215	160	4.70	4.24	4.24	4.24
SP15	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	9	Evaluation is not conducted for the research course				
FA14	Introduction to Pharmaceutics and Lab	30:721:496 30:721:498	4	Lec	UM	Shared 12% *	215	170	4.50	4.19	4.19	4.19
FA14	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	10	Evaluation is not conducted for the research course				
FA14	Problems in Pharmaceutics	30:721:496 30:721:498	2	CC Lab	UM	Total	3	Evaluation is not conducted for the research course				
SU14	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	8	Evaluation is not conducted for the research course				
SP14	Molecular and Cellular Pharmaceutics	15:720:614	3	CC Lec	Grad	Total **	21	14	4.79	4.39	4.86	4.45
SP14	Problems in Pharmaceutics	30:721:496 30:721:498	2	CC Lab	UM	Total	4	Evaluation is not conducted for the research course				
SP14	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
SP14	Drug Delivery and Lab	30:721:320	4	Lec	UM	Shared 43% *	212	150	4.49	4.26	4.40	4.20
FA13	Regenerative Medicine	MSBS 5085S	2	Lec	Grad	Shared 9% ***	16	Evaluation was not done for the team taught course				
FA13	Introduction to Pharmaceutics and Lab	30:721:496 30:721:498	4	Lec	UM	Shared 12% *	210	61	4.0	3.92	4.0	3.91
FA13	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	5	Evaluation is not conducted for the research course				
FA13	Problems in Pharmaceutics	30:721:496 30:721:498	2	CC Lab	UM	Total	1	Evaluation is not conducted for the research course				

- COURSE INFORMATION -								- COURSE EVALUATION -				
									Teaching Effectiveness (Max = 5)		Course Quality (Max = 5)	
S/ Yr	**Course Title**	**Number**	**Cr**	**MOI**	**Aud**	**Resp**	**Enrl**	**Evaluation Responses**	**Instructor**	**Dept Mean**	**Instructor**	**Dept Mean**
SU13	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	4	Evaluation is not conducted for the research course				
SP13	Drug Delivery and Lab	30:721:320	4	CC Lec	UM	Shared 43% *	208	68	4.59	4.05	4.43	4.08
SP13	Drug Delivery Fundamentals and Applications	16:125:590	2	Lec	Grad	Shared 10% *	22	Evaluation was not done for the team taught course				
SP13	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	7	Evaluation is not conducted for the research course				
SP13	Problems in Pharmaceutics	30:721:496 30:721:498	2	CC Lab	UM	Total	2	Evaluation is not conducted for the research course				
FA12	Introduction to Pharmaceutics and Lab	30:721:301	4	Lec	UM	Shared 12% *	211	118	4.47	4.36	4.42	4.36
FA12	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	5	Evaluation is not conducted for the research course				
FA12	Problems in Pharmaceutics	30:721:496 30:721:498	2	CC Lab	UM	Total	2	Evaluation is not conducted for the research course				
SU12	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
SU12	Problems in Pharmaceutics	30:721:496 30:721:498	2	CC Lab	UM	Total	2	Evaluation is not conducted for the research course				
SP12	Drug Delivery and Lab	30:721:320	4	CC Lec	UM	Shared 43% *	205	75	4.39	4.22	4.33	4.07
SP12	Drug Delivery Fundamentals and Applications	16:155:590	3	Lec	Grad	Shared 9% **	12	Evaluation was not done for the team taught course				
SP12	Graduate Seminar in Pharmaceutical Sciences	16:720:601	1	CC Sem	Grad	Total	6	6	4.75	4.47	4.75	4.29
SP12	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
SP12	Problems in Pharmaceutics	30:721:496 30:721:498	2	CC Lab	UM	Total	3	Evaluation is not conducted for the research course				
FA11	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
FA11	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total		Evaluation is not conducted for the research course				
FA11	Introduction to Pharmaceutics	30:721:301	3	Lec	UM	Shared 12% *	212	78	4.08	4.14	4.08	4.09
SU11	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
SP11	Drug Delivery and Lab	30:721:320	4	CC Lec	UM	Shared 43% *	230	173	4.61	4.29	4.61	4.31

- COURSE INFORMATION -								- COURSE EVALUATION -				
									Teaching Effectiveness (Max = 5)		Course Quality (Max = 5)	
S/ Yr	**Course Title**	**Number**	**Cr**	**MOI**	**Aud**	**Resp**	**Enrl**	**Evaluation Responses**	**Instructor**	**Dept Mean**	**Instructor**	**Dept Mean**
SP11	Nanotechnology-Based Drug Delivery	16:720:550	3	Lec	Grad	Shared 9% **	12	Evaluation was not done for the team taught course				
SP11	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	4	Evaluation is not conducted for the research course				
SP11	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	7	Evaluation is not conducted for the research course				
FA10	Introduction to Pharmaceutics	30:721:301	3	Lec	UM	Shared 12% *	230	Evaluation was not done for the team taught course				
FA10	Molecular and Cellular Pharmaceutics	15:720:614	3	CC Lec	Grad	Total **	11	7	5.0	4.54	4.86	4.46
FA10	Advanced Pharmaceutics I	16:720:507	3	Lec	Grad	Shared 17% **	7	Evaluation was not done for the team taught course				
FA10	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	5	Evaluation is not conducted for the research course				
FA10	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	5	Evaluation is not conducted for the research course				
FA10	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	2	Evaluation is not conducted for the research course				
SU10	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	5	Evaluation is not conducted for the research course				
SU10	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	1	Evaluation is not conducted for the research course				
SP10	Drug Delivery and Lab	30:721:320	4	Lec	UM	Shared 43% *	220	81	4.60	3.73	4.28	3.44
SP10	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
SP10	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	4	Evaluation is not conducted for the research course				
FA09	Drug Delivery II	30:721:420	3	CC Lec	UM	Shared 71% *	211	91	3.90	4.04	3.74	3.83
FA09	Introduction to Pharmaceutics	30:721:301	3	Lec	UM	Shared 12% *	219	80	3.92	4.04	3.88	3.83
FA09	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
FA09	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	4	Evaluation is not conducted for the research course				
SU09	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
SP09	Pharmaceutical Organic Nanotechnology: Drug Delivery Principals and Applications	16:155:544	3	Lec	Grad	Shared 8% **	20	Evaluation was not done for the team taught course				

- COURSE INFORMATION -								- COURSE EVALUATION -				
									Teaching Effectiveness (Max = 5)		Course Quality (Max = 5)	
S/ Yr	**Course Title**	**Number**	**Cr**	**MOI**	**Aud**	**Resp**	**Enrl**	**Evaluation Responses**	**Instructor**	**Dept Mean**	**Instructor**	**Dept Mean**
SP09	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
SP09	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	4	Evaluation is not conducted for the research course				
FA08	Drug Delivery II	30:721:420	3	CC Lec	UM	Shared 75% *	215	127	4.83	4.46	4.76	4.23
FA08	Advanced Pharmaceutics I	16:720:507	3	Lec	Grad	Shared 17% **	16	14	4.58	4.36	4.62	4.38
FA08	Graduate Seminar in Pharmaceutical Sciences	16:720:601	1	CC Sem	Grad	Total	16	Evaluation is not conducted for the research course				
FA08	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	5	Evaluation is not conducted for the research course				
SU08	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	5	Evaluation is not conducted for the research course				
SP08	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	5	Evaluation is not conducted for the research course				
SP08	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	12	Evaluation is not conducted for the research course				
FA07	Drug Delivery II	30:721:420	3	CC Lec	UM	Shared 75% *	221	107	4.84	4.57	4.80	4.46
FA07	Molecular and Cellular Pharmaceutics	15:720:614	3	CC Lec	Grad	Shared 90% **	15	14	4.93	4.93	4.93	4.93
FA07	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	5	Evaluation is not conducted for the research course				
FA07	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	7	Evaluation is not conducted for the research course				
SU07	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	5	Evaluation is not conducted for the research course				
SU07	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	2	Evaluation is not conducted for the research course				
SP07	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
SP07	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	8	Evaluation is not conducted for the research course				
FA06	Drug Delivery II	30:721:420	3	CC Lec	UM	Shared 75% *	255	142	4.32	4.29	4.20	4.20
FA06	Advanced Pharmaceutics I	16:720:507	3	Lec	Grad	Shared 17% **	13	Evaluation was not done for the team taught course				
FA06	Nanotechnology-Based Drug Delivery	16:720:550	3	Lec	Grad	Shared 9% **	21	Evaluation was not done for the team taught course				

- COURSE INFORMATION -								- COURSE EVALUATION -				
									Teaching Effectiveness (Max = 5)		Course Quality (Max = 5)	
S/ Yr	**Course Title**	**Number**	**Cr**	**MOI**	**Aud**	**Resp**	**Enrl**	**Evaluation Responses**	**Instructor**	**Dept Mean**	**Instructor**	**Dept Mean**
FA06	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	8	Evaluation is not conducted for the research course				
FA06	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation is not conducted for the research course				
SU06	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	7	Evaluation was not done for the research course				
SP06	Drug Delivery I	30:721:320	3	Lec	UM	Shared 9% *	269	Evaluation was not done for the team taught course				
SP06	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	8	Evaluation was not done for the research course				
SP06	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	10	Evaluation was not done for the research course				
FA05	Drug Delivery II	30:721:420	3	CC Lec	UM	Total	254	167	4.76	4.16	4.72	4.06
FA05	Graduate Seminar in Pharmaceutical Sciences	16:720:601	1	CC Sem	Grad	Total	15	Evaluation was not done for the seminar course				
FA05	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation was not done for the research course				
FA05	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	16	Evaluation was not done for the research course				
SU05	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation was not done for the research course				
SU05	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	4	Evaluation was not done for the research course				
SP05	Therapeutic Peptide Delivery	16:720:520	3	Lec	Grad	Shared 8% **	25	Evaluation was not done for the team taught course				
SP05	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	8	Evaluation was not done for the research course				
SP05	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	6	Evaluation was not done for the research course				
FA04	Drug Delivery II	30:721:420	3	CC Lec	UM	Total	209	92	4.61	4.61	4.40	4.40
FA04	Molecular and Cellular Pharmaceutics	15:720:614	3	CC Lec	Grad	Total	25	22	4.77	4.77	4.73	4.73
FA04	Advanced Pharmaceutics I	16:720:507 :01	3	Lec	Grad	Shared 17% **	20	Evaluation was not done for the team taught course				
FA04	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	5	Evaluation was not done for the research course				
FA04	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	8	Evaluation was not done for the research course				

- COURSE INFORMATION -								- COURSE EVALUATION -				
									Teaching Effectiveness (Max = 5)		Course Quality (Max = 5)	
S/ Yr	**Course Title**	**Number**	**Cr**	**MOI**	**Aud**	**Resp**	**Enrl**	**Evaluation Responses**	**Instructor**	**Dept Mean**	**Instructor**	**Dept Mean**
SP04	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	4	Evaluation was not done for the research course				
SP04	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	8	Evaluation was not done for the research course				
FA03	Drug Delivery II	30:721:420	3	CC Lec	UM	Total	168	112	4.71	3.78	4.65	3.59
FA03	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	4	Evaluation was not done for the research course				
FA03	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	9	Evaluation was not done for the research course				
SU03	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	3	Evaluation was not done for the research course				
SP03	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	2	Evaluation was not done for the research course				
FA02	Drug Delivery II	30:721:420	3	CC Lec	UM	Total	126	71	4.74	3.70	4.65	3.72
FA02	Advanced Pharmaceutics I	16:720:507	3	Lec	Grad	Shared 17% **	32	25	4.48	3.70	4.24	3.72
FA02	Graduate Seminar in Pharmaceutical Sciences	16:720:601	1	CC Sem	Grad	Total	8	Evaluation was not done for the seminar course				
FA02	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	3	Evaluation was not done for the research course				
FA02	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	4	Evaluation was not done for the research course				
SU02	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	3	Evaluation was not done for the research course				
SP02	Drug Delivery I	30:721:320	3	Lec	UM	Shared 9% *	202	Evaluation was not done for the team taught course				
SP02	Molecular and Cellular Pharmaceutics	16:720:614	3	CC Lec	Grad	Total **	17	17	4.12	4.29	4.12	4.17
SP02	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	3	Evaluation was not done for the research course				
SP02	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	2	Evaluation was not done for the research course				
FA01	Drug Delivery II	30:721:420	3	Lec	UM	Shared 9% *	174	Evaluation was not done for the team taught course				

- COURSE INFORMATION -								- COURSE EVALUATION -				
									Teaching Effectiveness (Max = 5)		Course Quality (Max = 5)	
S/ Yr	**Course Title**	**Number**	**Cr**	**MOI**	**Aud**	**Resp**	**Enrl**	**Evaluation Responses**	**Instructor**	**Dept Mean**	**Instructor**	**Dept Mean**
FA01	Therapeutic Peptide Delivery	16:720:520	3	Lec	Grad	Shared 8% **	18	Evaluation was not done for the team taught course				
FA01	Graduate Research in Pharmaceutical Sciences	16:720:701	3	CC Lab	Grad	Total	2	Evaluation was not done for the research course				
FA01	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	3	Evaluation was not done for the research course				
SP01	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	1	Evaluation was not done for the research course				
SP01	Drug Delivery I and Lab	30:721:320	3	CC Lec Lab	UM	Total *	187	132	4.30	4.23	4.00	3.97
SP01	Drug Delivery II and Lab	30:721:420	3	CC Lec Lab	UM	Total *	161	110	4.18	4.23	3.92	3.97
SP01	Problems in Pharmaceutics	30:721:496	2	CC Lab	UM	Total	4	Evaluation was not done for the research course				
FA00	Advanced Pharmaceutics I	16:720:507 :01	3	Lec	Grad	Shared 17% **	14	Evaluation was not done for the team taught course				
FA00	Molecular and Cellular Pharmaceutics	15:720:614	3	Lec	Grad	Shared 14% **	18	Evaluation was not done for the team taught course				

* 80 min lecture
** 180 min lecture
*** 120 min lecture
CC – Course Coordinator
Lec – Lecturer
Lab – Laboratory
Sem - Seminar

Doctoral and Master's Theses Supervised

Graduated

Rutgers, The State University of New Jersey

1. Vera Ivanova (Fall 2009-Summer 2015), Defended Ph.D. Thesis ("Nanotechnology Approach for Inhalation Treatment of Pulmonary Fibrosis"), July 2015 (Primary Adviser – T. Minko).
2. Ronak Savla (Fall 2012-Summer 2014), Defended Ph.D. Thesis ("Tumor Responsive Targeted Multifunctional Nanosystems for Cancer Imaging, Chemo- and siRNA Therapy"), June 2014 (Primary Adviser – T. Minko).
3. John C. Praskavich, Jr. (Fall 2009-Summer 2014), Defended M.S. Thesis ("Calcium Voltage-Gated Ion Channels as Biological Targets for Chemoresistance in Ovarian Cancer") (Primary Adviser – T. Minko).
4. Vatsal V. Shah (Fall 2008-Fall 2012), Defended Ph.D. Thesis ("Targeted Nanomedicine Platform for Cancer Stem Cells Specific Therapy"), December 2012 (Primary Adviser – T. Minko).

5. Anasuya Ghosh (Fall 2006-Fall 2012) Defended Ph.D. Thesis ("Salt Solid Dispersions: A Formulation Strategy to Enhance Dissolution Rate of Poorly Water-Soluble Ionic Drugs"), October 2012 (Primary Adviser – T. Minko).
6. Ming Zhang (Spring 2007-Fall 2011), Defended Ph.D. Thesis ("Two-in-One: Combined Targeted Chemo and Gene Therapy for Tumor Suppression and Prevention of Metastases"), January 2012 (Primary Adviser – T. Minko).
7. Pooja Chandna (Fall 2004-Spring 2011), Defended Ph.D. Thesis ("Targeted Proapoptotic Anticancer Drug Delivery Systems"), May 2011 (Primary Adviser – T. Minko).
8. Seema Betigeri (Fall 2003-Spring 2009), Defended Ph.D. Thesis ("Jun N-Terminal Kinase 1 (Jnk1) as a Molecular Target to Limit Cellular Mortality Under Hypoxia"), May 2009 (Primary Adviser – T. Minko).
9. Alex M. Chen (Spring 2004-Spring 2009), Defended Ph.D. Thesis ("Nanotechnology for Efficient Delivery of Short Therapeutic Oligonucleotides and Co-delivery with Chemical Anticancer Drugs for Effective Cancer Therapy"), May 2009 (Co-Adviser – T. Minko).
10. Oleh Taratula (Fall 2003-Fall 2009), Defended Ph.D. Thesis ("Nanotechnology in Developing Multifunctional Non-Viral Gene Delivery Systems"), May 2009 (Co-Adviser – T. Minko).
11. Maha Saad (Fall 2005-Fall 2008), Defended Ph.D. Thesis ("Receptor-Targeted Nanocarriers for Tumor Specific Treatment and Imaging"), October 2008 (Primary Adviser – T. Minko).
12. Yang Wang (Fall 2001-Spring 2007), Defended Ph.D. Thesis ("Hypoxia inducible factor – targeted anticancer prodrug"), May 2007 (Primary Adviser – T. Minko).
13. Refika I. Pakunlu (Spring 2001-Fall 2006), Defended Ph.D. Thesis ("Novel anticancer drug delivery system for molecular targeting of pup and nonpump cellular resistance"), May 2007 (Primary Adviser – T. Minko).
14. Sreeja Jayant (Spring 2005-Fall 2007), Defended M.S. Thesis ("Molecular modeling, design, synthesis and evaluation of targeted polymeric prodrugs"), May 2007 (Primary Adviser – T. Minko).
15. Sonia S. Dharap (Fall 2000-Spring 2005), Defended Ph.D. Thesis ("Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides"), May 2005 (Primary Adviser – T. Minko).

Ukrainian Academy of Sciences

1. Olga Ezhova (Spring 1989-Spring 1993), Defended Ph.D. Thesis ("Phospholipid Composition of Lungs and Biomechanics of Breathing Under Hypoxia"), May 1993 (Primary Adviser – T. Minko).
2. Victor Bystrjukov (Fall 1988-Fall 1992), Defended Ph.D. Thesis ("Breathing Pattern and Energy Supply Under Adaptation to Environmental Factors"), October 1992 (Primary Adviser – T. Minko).
3. Elena Kovalenko (Spring 1983-Spring 1985), Defended M.S. Thesis ("Peculiarities of Acid Base Balance under Acute Hemorrhage"), May 1985 (Primary Adviser – T. Minko).
4. Olga Tranko (Spring 1983-Spring 1985), Defended M.S. Thesis ("Pharmacological Correction of Lipid Peroxidation"), May 1985 (Primary Adviser – T. Minko).

Current

1. Sumayah Al-Mahmood (Spring 2014-Present), Pursuing M.S. (Primary Adviser – T. Minko).
2. Justin Sapiezynski (Fall 2013-Present), Pursuing Ph.D. (Primary Adviser – T. Minko).
3. Noor Z Kbah (Fall 2013-Present), Pursuing M.S. (Primary Adviser – T. Minko).
4. Gaurang Patel (Spring 2013-Present), Pursuing Ph.D. (Primary Adviser – T. Minko).
5. Andriy Kuzmov (Fall 2012-Present), Pursuing Pharm.D./Ph.D. (Primary Adviser – T. Minko).

6. Pinak B. Khatri (Fall 2012-Present), Pursuing Ph.D. (Primary Adviser – T. Minko).
7. Milin Shah (Spring 2009-Present), Pursuing Ph.D. (Primary Adviser – T. Minko).
8. Carl Allenspach (Spring 2008-Present), Pursuing Ph.D. (Primary Adviser – T. Minko).

Undergraduate (Professional Pharm. D.) Honors Program Student

1. Andriy Kuzmov (Spring 2011 - Spring 2013), Honors Thesis Title: "Lipid Nanoparticles for Inhalation Treatment of Lung Cancer".
2. Ronak Savla (Fall 2007 - Spring 2010), Honors Thesis Title: "Targeted Quantum Dot Delivery of Doxorubicin."

Training of Postdoctoral Fellows/Researchers

1. Natalia Progrebnyak, Ph.D. (2015-Present)
2. Oleh Taratula, Ph.D. (2009-2011)
3. Mahesh Patil, Ph.D. (2007-2008)
4. Olga B. Garbuzenko, Ph.D. (2006-Present)
5. Elizabeth Ber, Ph.D. (2005-2008)
6. Jayant Khandare, Ph.D. (2004-2006)
7. Anthony T. Fabbricatore, Ph.D. (2000-2001)

Visiting Professor

1. A. Rubinstein, Ph.D., Professor, Hebrew University, Jerusalem, Israel (Sabbatical, January – October 2004).

Visiting Students

1. Jue Gong, China Pharmaceutical University, Spring 2014.
2. Ting Xu, China Pharmaceutical University, Spring 2013.
3. Lauren Henderson, RISE Rutgers/UMDNJ Summer Program, Summer 2011.
4. V. Rani, Chemical/Biochemical Engineering, Rutgers, The State University of New Jersey, Summer 2005.
5. W. Tsao, Bioengineering, John Hopkins University, Summer 2003.

Patents:

1. Nanotechnology Approach for Inhalation Treatment of Fibrosis. Contributors**: T. Minko,** O. Garbuzenko, V. Ivanova, Provisional Patent Application, RU Tech ID No. 2012-145, 2012.
2. Compositions and methods for delivering nucleic acid molecules and treating cancer. Contributors**: T. Minko,** L. Rodriguez-Rodriguez, O. B. Garbuzenko, O. Taratula, International Application No.: PCT/US2011/048078 (filed August 17, 2011).
3. E2F as a Target of Hormone Refractory Prostate Cancer. Contributors: E2F1 as an anticancer target. Contributors: J. R. Bertino, D. Banerjee, **T. Minko**, O. B. Garbuzenko, X. Xie, J. E. Kerrigan, E. E. Abali, K. W. Scotto, United States Patent 8,822,421 (issued Sep 2, 2014).

4. Complex drug delivery composition and method for treating cancer. Contributors: **T. Minko**, P. J. Sinko, S. Stein, United States Patent 8,124,051 (issued February, 28, 2012).
5. Enhanced Oral and Transcompartmental Delivery of Therapeutic or Diagnostic Agents. Contributors: S. Ramanathan, S. Stein, M. Leibowitz, P. J. Sinko, **T. Minko**, G. C. Williams, G. Zhang, X. Zhang, S. Pooyan, S. H. Park, B. Qiu, P. Paranjpe, United States Patent 7,740,882 (issued June 22, 2010).
6. Method for prophylaxis and treatment of the hypoxic states in experiment. Contributors: O. V. Stefanov, S. O. Bryhinskyi, V. K. Lishko, V. P. Pozharov, T. D. Miniailenko (**Minko**), E. V. Rozova, M. M. Seredenko, O. V. Zubarenko, V. Y. Kondratiuk, V. O. Yukhymets, B. V. Radionov, M. I. Linnyk, Ukrainian Patent 1912, 1994**.**
7. The method of liposomes manufacturing. A. Stefanov, T. Minyailenko (**Minko**)**,** V. Pozharov, M. Seredenko, V. Lishko, E. Rozova. USSR Patent 1424167, 1988.

Bibliography:

Peer-Reviewed Papers – 135; Books/Book and Textbook Chapters/Book Reviews – 20; Extended Abstracts/Conference Proceedings – 64; Abstracts – 259.

The papers have been cited 6003 times (8244 times since 2010) and regularly highlighted by different sources. Hirsch factor is 46.

Peer-Reviewed Papers

1. R. Savla, V. Ivanova, **T. Minko**, Nanoparticle Design Considerations for Various Imaging Purposes, Nanomedicine: Nanotechnology, Biology, and Medicine, submitted.
2. A. Kuzmov, **T. Minko**, Nanotechnology Approaches for Inhalation Treatment of Lung Diseases, J Control Release, 2015 Aug 18, [Epub ahead of print]. PMID: 26297206.
3. M. Shah, V. Shah, A. Ghosh, Z. Zhang, **T. Minko**, Molecular inclusion complexes of β-cyclodextrin derivatives enhance aqueous solubility and cellular internalization of paclitaxel: Preformulation and in vitro assessments, J Pharm Pharmacol., 2, 8-25 (2015) PMID: 25950011.
4. R. N. Jain, X. Huang, S. Das, R. Silva, V. Ivanova, **T. Minko**, T. Asefa, Functionalized Mesoporous Silica Nanoparticles for Glucose- and pH-Stimulated Release of Insulin, Z. Anorg. Allg. Chem. (Zeitschrift fur anorganische und allgemeine Chemie, ZAAC, Journal of inorganic and general chemistry), in press (2015).
5. L. Y. Peddada, O. B. Garbuzenko, D. I. Devore, **T. Minko**, C. M. Roth, Delivery of antisense oligonucleotides using poly(alkylene oxide)-poly(propylacrylic acid) graft copolymers in conjunction with cationic liposomes, J Control Release. 194C, 103-112 (2014) PMID: 25192441.
6. O. B. Garbuzenko, J. Winkler, M. S. Tomassone, **T. Minko**, Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs, Langmuir, 30(43), 12941-12949 (2014) PMID: 25300552.
7. R. Savla, O. B. Garbuzenko, S. Chen, L. Rodriguez-Rodriguez, **T. Minko,** Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy, Pharm Res, 31(12), 3487-3502 (2014) PMID:24919932, PMCID: PMC4224753.
8. X. Huang, Z. Tao, J. C. Praskavich, A. Goswami, J. F. Al-Sharab, **T. Minko**, V. Polshettiwar, T. Asefa, Dendritic silica microspheres (KCC-1) with fibrous pore structure possess high DNA adsorption capacity and effectively deliver genes in vitro, Langmuir, 30(36), 10886-10898 (2014) PMID: 25188675.

9. X. Huang, A. Goswami, X. Zou, S. Hayes, V. Shah, **T. Minko**, Z. Tao, T. Asefa, Nanostructured TiO2 catalyzed oxidations of caffeine and isocaffeine and their cytotoxicity and genotoxicity towards ovarian cancer cells, BioNanoScience, 4, 27-36 (2014).

10. R. Savla, V. Ivanova, **T. Minko**, Nanoparticles in the development of therapeutic cancer vaccines, Pharmaceutical Nanotechnology, 2, 2-22 (2014).

11. X. Xie, N. Bansal, T. Shaik, J. E. Kerrigan, **T. Minko**, O. Garbuzenko, E. E. Abali, N. Johnson-Farley, D. Banerjee, K. W. Scotto, J. R. Bertino, A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts, Oncotarget, 5, 901-907 (2014) PMID: 24658650, PMCID: PMC4011592.

12. O. B. Garbuzenko, G. Mainelis, O. Taratula, **T. Minko**, Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention, Cancer Biol Med, 11(1), 44-55 (2014) PMID:24738038, PMCID: PMC3969800.

13. **T. Minko**, Nanotechnology Approaches to Overcoming, Suppressing and Preventing Drug Resistance, Adv Drug Deliv Rev, 65(13-14), 1665-1666 (2013) PMID: 24177352.

14. **T. Minko**, L. Rodriguez-Rodriguez, V. Pozharov, Nanotechnology approaches for personalized treatment of multidrug resistant cancers, Adv Drug Deliv Rev, 65, 1880-1895 (2013) PMID: 24120655.

15. R. Savla, **T. Minko**, Nanotechnology approaches for inhalation treatment of fibrosis, J Drug Target, 21(10), 914-925 (2013) PMID: 23978292, PMCID: PMC4219586.

16. G. Mainelis, S. Seshadri, O. B. Garbuzenko, Z. Wang, **T. Minko**, Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal anti-cancer drugs and nucleic acids to mice, J Aerosol Med Pulm Drug Deliv, 26(6), 345-354 (2013) PMID: 23530772, PMCID: PMC3889495.

17. V. Shah, O. Taratula, O. B. Garbuzenko, O. R. Taratula, L. Rodriguez-Rodriguez, **T. Minko**, Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: an Optimal Delivery of siRNA and Anticancer Drug, Clin. Cancer Res., 19(22), 6193-6204 (2013) PMID: 24036854. PMC3846837.

18. O. Taratula, A. Kuzmov, M. Shah, O. B. Garbuzenko, **T. Minko**, Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA, J Control Release, 171(3), 349-357 (2013) PMID: 23648833, PMCID: PMC3766401.

19. **Minko T**., Hatefi A., Preface-tenth international nanomedicine and drug delivery symposium (NanoDDS'12), J Control Release, 171, 259-260 (2013). PMID: 23954371.

20. X. Xie, J. E. Kerrigan, **T. Minko**, O. Garbuzenko, K. C. Lee, A. Scarborough, E. E. Abali, T. Budak-Alpdogan, N. Johnson-Farley, D. Banerjee, K. W. Scotto, J. R. Bertino, Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer, Cancer Biol Ther, 14, 742-751 (2013) PMID: 23792570. PMCID: PMC3841214.

21. V. Shah, O. Taratula, O. B. Garbuzenko, M. L. Patil, R. Savla, M. Zhang, **T. Minko**, Genotoxicity of nanocarriers with different composition, architecture, size, molecular weight and charge, Current Drug Discovery Technologies, 10(1), 8-15 (2013) PMID: 22564170, PMCID: PMC3899095.

22. V. Ivanova, O. B. Garbuzenko, K. R. Reuhl, D. C. Reimer, V. P. Pozharov, **T. Minko**, Inhalation Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2, Eur J Pharm Biopharm, 84, 335-344 (2013) PMID: 23228437, PMCID: PMC3660419.

23. M. Zhang, O. B. Garbuzenko, K. R. Reuhl, L. Rodriguez-Rodriguez, **T. Minko**, Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases, Nanomedicine (Lond), 7(2), 185-197 (2012) PMID: 22339132.

24. L. Sheihet, O. B. Garbuzenko, J. Bushman, M. K. Gounder, **T. Minko**, J. Kohn, Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: In vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor. Eur J Pharm Sci. 45(3), 320-329 (2012) PMID: 22155544.

25. O. Taratula, O. B. Garbuzenko, A. M. Chen, **T. Minko**, Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA, J. Drug Target., 19(10), 900-914 (2011) PMID: 21981718.

26. M. Nadler-Milbauer, L. Apter, Y. Haupt, S. Haupt, Y. Barenholz, **T. Minko**, A. Rubinstein, Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer, J. Drug Target., 19(10), 859-873 (2011) PMID: 22082104.

27. S. Betigeri, M. Zhang, O. Garbuzenko, **T. Minko**, Non-viral delivery of siRNA or antisense oligonucleotides targeted to Jun N-Terminal Kinase 1 prevents cellular hypoxic damage, Drug Deliv. and Transl. Res., 1, 13–24 (2011) PMID: 21461383, PMCID: PMC3063508.

28. Savla R., Taratula O., Garbuzenko O., **Minko T.**, Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer, J Control Release, 153(1), 16-22 (2011) PMID: 21342659.

29. M. L. Patil, M. Zhang, O. B. Garbuzenko, **T. Minko**, Multifunctional triblock nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular delivery of siRNA and potent gene silencing, ACS Nano, 5(3), 1877-1887 (2011) PMID: 21322531, PMCID: PMC3062392.

30. O. Taratula, R. Savla, H. He, **T. Minko**, Poly(propyleneimine) dendrimers as potential siRNA delivery nanocarrier: from structure to function, Int. J. Nanotechnology, 8, 36 – 52 (2011).

31. O. Taratula, R. Savla, Y. A. Wang, H. He, **T. Minko**, Multifunctional nanomedicine platform for cancer specific delivery of siRNA by supermagnetic iron oxide nanoparticles/dendrimer complexes, Curr. Drug Delivery, 8(1), 59-69 (2011) PMID: 21034421.

32. N. Dayan, V. Shah, **T. Minko**, Preliminary evaluation of the genotoxic potential of a hydrophilic polymer with three preservation systems, Int J Cosmet Sci, 33, 497-502 (2011) PMID: 21696404.

33. N. Dayan, V. Shah, **T. Minko**, Genotoxic potential evaluation of a cosmetic insoluble substance by the micronuclei assay, J. Cosmet. Sci., 62, 29-39 (2011) PMID 21443843.

34. N. Dayan, V. Shah, **T. Minko**, Correlation between cell viability and DNA damage: Studying chromosomal effect of cosmetic substances, J. Cosmetic Sci., 62, 70-71 (2011).

35. P. Chandna, J. J. Khandare, E. Ber, L. Rodriguez-Rodriguez, **T. Minko**, Targeted multicomponent polymer-peptide-drug conjugates for treatment of primary and metastatic cancers, Pharm. Res., 27, 2296-2306 (2010).

36. O. B. Garbuzenko, M. Saad, V. P. Pozharov, K. R. Reuhl, G. Mainelis, **T. Minko**. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance, Proc. Natl. Acad. Sci. USA, 107, 10737-10742 (2010).

37. A. M. Chen, O. Taratula, D. Wei, H.-I. Yen, T. Thomas, T. J. Thomas, **T. Minko**, H. He, Labile Catalytic Packaging of DNA siRNA: Control of Gold Nanoparticles out of DNA siRNA Complexes, ACS Nano, 4, 3679-3688 (2010).

38. **T. Minko**, M. L. Patil, M. Zhang, J. J. Khandare, M. Saad, P. Chandna, O. Taratula, LHRH-targeted nanoparticles for cancer therapeutics, Methods Mol Biol., 624, 281-294 (2010).

39. **T. Minko**, HPMA copolymers for modulating cellular signaling and overcoming multidrug resistance, Adv. Drug Deliver. Rev., 62, 192-202 (2010).

40. D. A. Christian, O. B. Garbuzenko, **T. Minko**, D. E. Discher, Polymer Vesicles with a Red Cell-like Surface Charge: Microvascular imaging and in vivo Tracking with Near-Infrared Fluorescence, Macromol. Rapid Commun., 31, 135-141 (2010).

41. A. M. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, **T. Minko**, H. He, Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug Resistant Cancer Cells, Small, 5, 2673-2677 (2009).

42. O. Taratula, O. B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, **T. Minko**, Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery, J. Control. Release, 140, 284-293 (2009).

43. M. L. Patil, M. Zhang, O. Taratula, O. B. Garbuzenko, H. He, **T. Minko**, Internally Cationic Polyamidoamine PAMAM-OH Dendrimers for siRNA Delivery: Effect of the Degree of Quaternization and Cancer Targeting, Biomacromolecules, 10, 258-266 (2009).

44. O. B. Garbuzenko, M. Saad, S. Betigeri, M. Zhang, A. A. Vetcher, V. A. Soldatenkov, D. C. Reimer, **T. Minko**, Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug, Pharm. Research, 26, 382-394 (2009).

45. D. Christian, S. Cai, O. Garbuzenko, T. Harada, A. Zajac, **T. Minko**, D. Discher, Flexible Filaments for in vivo Imaging and Delivery: Persistent Circulation of Filomicelles Opens the Dosage Window for Sustained Tumor Shrinkage, Mol. Pharm., 6, 1343-1352 (2009).

46. Z. Keresztessy, M. Bodnar, E. Ber, I. Hajdu, M. Zhang, J. F. Hartmann, **T. Minko**, J. Borbely, Self-Assembling Chitosan/Poly-γ-Glutamic Acid Nanoparticles for Targeted Drug Delivery, Colloid and Polymer Science, 287, 759–765 (2009).

47. M. Saad, O. B. Garbuzenko, **T. Minko**, Co-delivery of siRNA and an anticancer drug for treatment of multidrug resistant cancer, Nanomedicine (Lond), 3, 761-776 (2008).

48. M. Saad, O. B. Garbuzenko, E. Ber, P. Chandna, J. J. Khandare, V. P. Pozharov, **T. Minko**, Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging? J. Control. Release, 130, 107-114 (2008).

49. M. L. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, **T. Minko**, Surface Modified and Internally Cationic Polyamidoamine Dendrimers for Efficient siRNA Delivery, Bioconjugate Chem., 19, 1396-403 (2008).

50. Y. Wang, M. Saad, R. I. Pakunlu, J. J. Khandare, O. B. Garbuzenko, A. A. Vetcher, V. A. Soldatenkov, V. P. Pozharov, **T. Minko**, Non-viral nanoscale-based delivery of antisense oligonucleotides targeted to HIF1 alpha enhances the efficacy of chemotherapy in drug resistant tumor, Clin. Cancer Res., 14, 3607-3616 (2008).

51. S. Jayant, J. J. Khandare, Y. Wang, A. P. Singh, N. Vorsa, **T. Minko**, Targeted sialic acid - doxorubicin prodrugs for intracellular delivery and cancer treatment, Pharm. Res., 24, 2120-2130 (2007).

52. **T. Minko**, Intracellular delivery, Pharm. Res., 24, 2097-2098 (2007).

53. P. Chandna, M. Saad, E. Ber, J. J. Khandare, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, Targeted proapoptotic anticancer drug delivery system, Mol. Pharm., 4,668-678 (2007).

54. S. Zalipsky, M. Saad, R. Kiwan, E. Ber, N. Yu, **T. Minko**, Antitumor activity of new liposomal prodrug of Mitomycin C in multidrug resistant solid tumor: Insights of the mechanism of action, J. Drug Target., 15, 518-530 (2007).

55. Y. Geng, P. Dalhaimer, S. Cai, R. Tsai, M. Tewari, **T. Minko**, D. E. Discher, Shape effects of filaments versus spherical particles in flow and drug delivery, Nature Nanotech., 2, 249 – 255 (2007).

56. J. J. Khandare, **T. Minko**, Antibodies and peptides in cancer therapy, Crit. Rev. Ther. Drug Carrier Syst., 23, 401-435 (2006).

57. J. J. Khandare, S. Jayant, A. Singh, P. Chandna, Y. Wang, N. Vorsa, **T. Minko**, Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel, Bioconjugate Chem., 17, 1464-1472 (2006).

58. **T. Minko**, R. I. Pakunlu, Y. Wang, J. J. Khandare, M. Saad, New generation of liposomal drugs for cancer, Anticancer Agents Med. Chem., 6, 537-552 (2006).

59. F. Ahmed, R. I. Pakunlu, A. Brannan, F. Bates, **T. Minko**, D. E. Discher, Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors by inducing apoptosis in proportion to accumulated drug, J. Controlled Rel., 116, 150-158 (2006).

60. R. I Pakunlu, Y. Wang, M. Saad, J. J. Khandare, V. Starovoytov, **T. Minko**, In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug, J. Controlled Rel., 114, 153-162 (2006).

61. S. Betigeri, R.I. Pakunlu, Y. Wang, J.J. Khandare, **T. Minko**, JNK1 as a molecular target to limit cellular mortality under hypoxia, Mol. Pharm., 3, 424-430 (2006).

62. J. J. Khandare, P. Chandna, Y. Wang, V. P. Pozharov, **T. Minko**, Novel polymeric prodrug with multivalent components for cancer therapy, J. Pharmacol. Exp. Ther., 317, 929-937 (2006).

63. J. J. Khandare, **T. Minko**, Polymer-drug conjugates: Progress in polymeric prodrugs, Prog. Polym. Sci., 31, 359-397 (2006).

64. S. S. Dharap, P. Chandna, Y. Wang, J. J. Khandare, B. Qiu, S. Stein, **T. Minko**, Molecular targeting of BCL2 and BCLXL proteins by synthetic BH3 peptide enhances the efficacy of chemotherapy, J. Pharmacol. Exp. Ther. 316, 992-998 (2006).

65. O. Appenzeller, **T. Minko**, C. Qualls, V. Pozharov, J. Gamboa, A. Gamboa, R. F. Pakunlu, Chronic hypoxia in Andeans; are there lessons for neurology at sea level? J Neurol Sci., 247, 93-99 (2006).

66. F. Ahmed, R. I. Pakunlu, G. Srinivas, A. Brannan, F. Bates, M. L. Klein, **T. Minko**, D. E. Discher, Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation, Mol. Pharm, 3, 340-350 (2006).

67. O. Appenzeller, **T. Minko**, C. Qualls, V. Pozharov, J. Gamboa, A. Gamboa, Y. Wang, Gene expression, hypoxia and aging in the high Andis; lessons for medicine at sea level?, High Alt. Med. Biol., 16, 217-22 (2006).

68. O. Appenzeller, **T. Minko**, C. Qualls, V. Pozharov, J. Gamboa, A. Gamboa, Y. Wang. Gene expression, autonomic function and chronic hypoxia: Lessons from the Andis, Clin Auton Res., 16, 217-222 (2006).

69. S. S. Dharap, Y. Wang, P. Chandna, J. J. Khandare, B. Qiu, S. Gunaseelan, P. J. Sinko, S. Stein, A. V. Farmanfarmanian, **T. Minko**, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide, Proc. Natl. Acad. Sci. USA, 102, 12962-12967 (2005).

70. D. Yu, P. Peng, S. S. Dharap, Y. Wang, M. Mehlig, P. Chandna, H. Zhao, D. Filpula, K. Yang, V. Borowski, G. Borchard, Z. Zhang, **T. Minko**, Antitumor activity of poly(ethylene glycol) – camptothecin conjugate: the inhibition of tumor growth in vivo, J. Controlled Rel., 110, 90-102 (2005).

71. O. Appenzeller, **T. Minko**, C. Qualls, V. Pozharov, J. Gamboa, A. Gamboa, Y. Wang, Migraine in the Andes and headache at sea level, Cephalalgia, 25, 1117-1121 (2005).

72. **T. Minko**, Soluble polymer conjugates for drug delivery, Drug Discovery Today, 2, 15-20 (2005).

73. **T. Minko**, Y. Wang, V. Pozharov, Remediation of cellular hypoxic damage by pharmacological agents, Curr. Pharm. Des., 11, 3185-3199 (2005).

74. **T. Minko**, E. V. Batrakova, S. Li, Y. Li, R. I. Pakunlu, V. Yu. Alakhov, A. V. Kabanov, Pluronic Block Copolymer Formulation with Doxorubicin Induces Apoptosis in Drug-Resistant Cancer Cells, J. Controlled Rel., 105, 269-278 (2005).

75. Y. Wang, **T. Minko**, A novel cancer therapy: Liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides in combination with hypoxia and doxorubicin, Biochem. Pharmacol., 68, 2031-2042 (2004).

76. R. I. Pakunlu, Y. Wang, W. Tsao, V. Pozharov, T. J. Cook, **T. Minko**, Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system, Cancer Res., 64, 6214-6224 (2004).

77. **T. Minko**, S. S. Dharap, R. I. Pakunlu, Y. Wang, Molecular targeting of drug delivery systems to cancer, Curr. Drug Targets, 5, 389-406 (2004).

78. Y. Wang, R. I. Pakunlu, W. Tsao, V. Pozharov, **T. Minko**, Bimodal effect of hypoxia in cancer: the role of hypoxia inducible factor in apoptosis, Mol. Pharm., 1, 156-165 (2004).

79. **T. Minko**, Drug targeting to the colon with lectins and neoglycoconjugates, Adv. Drug Deliver. Rev., 56, 491-509 (2004).

80. S. Jin, A. S. Mathis, K. Gioia, **T. Minko**, G. S. Friedman, J. A. Rosenblatt, F. Peng, G. T. Knipp, The effect of tacrolimus on the expression of macrophage scavenger and nuclear hormone receptors in THP-1 derived human macrophages, Transplantation, 77, 1281-1287 (2004).

81. S. Jin, A. S. Mathis, J, Rosenblatt, **T. Minko**, G. S. Friedman, K. Goia, G. T. Knipp, Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: Macrophage scavenger receptor regulation, Transplantation, 77, 497-504 (2004).

82. David, P. Kopeckova, **T. Minko**, A, Rubinstein, J. Kopecek, The involvement of endogenous lectins in mediating the antitumor activity of targetable HPMA copolymer-doxorubicin conjugates in human colon adenocarcinoma and hepatocarcinoma cells, Eur. J. Cancer, 40, 148-157 (2004).

83. S. S. Dharap, B. Qiu, G. Williams, P. J. Sinko, S. Stein, **T. Minko**, Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides, J. Controlled Rel., 91, 61-73 (2003).

84. **T. Minko**, S. S. Dharap, A. T. Fabbricatore, Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense, Cancer Detect. Prev., 27, 193-202 (2003).

85. S. S. Dharap, **T. Minko**, Targeted proapoptotic LHRH-BH3 peptide, Pharm. Res., 20, 889-896 (2003).

86. R. I. Pakunlu, T. J. Cook, **T. Minko**, Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin, Pharm. Res., 20, 351-359 (2003).

87. W. K. Nichols, R. Mehta, K. Skordos, K. Mace, A. M.A. Pfeifer, B. A. Carr, **T. Minko**, S. W. Burchiel, G. S. Yost, 3-Methylindole-Induced Toxicity to Human Bronchial Epithelial Cell Lines, Toxicol. Sci., 71, 229-236 (2003).

88. O. Appenzeller, **T. Minko**, V. Pozharov, M. Bonfichi, L. Malcovati, J. Gamboa, L. Bernardi, Gene expression in the Andes and neurology at sea level, J. Neurol. Sci., 207, 37-41 (2003).

89. C. M. Peterson, J.-G. Shiah, Y. Sun, P. Kopeckova, **T. Minko**, R. C. Straight, J. Kopecek, HPMA copolymer delivery of chemotherapy and photodynamic therapy in ovarian cancer, Adv. Exp. Med. Biol., 519, 101-123 (2003).

90. **T. Minko**, A. Stefanov, V. Pozharov, Lung hypoxia: Antioxidant and antiapoptotic effects of liposomal alpha tocopherol, J. Appl. Physiol., 93, 1550-1560 (2002).

91. **T. Minko**, P. Paranjpe, B. Qiu, A. Lalloo, R. Won, S. Stein, P. J. Sinko, Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug resistant human ovarian carcinoma cells, Cancer Chemoth. Pharm., 50, 143-150 (2002).

92. **T. Minko**, Enhancing the efficacy of anticancer drugs using complex multicomponent advanced drug delivery systems, Business Briefing: Future Drug Discovery, 12, 134-136 (2001).

93. **T. Minko**, S. S. Dharap, R. I. Pakunlu, J. L. Colaizzi, Advanced drug delivery systems in cancer chemotherapy, Disease Management Clin. Outcomes, 3, 48-54 (2001).

94. **T. Minko**, P. Kopeckova, J. Kopecek, Preliminary evaluation of caspase-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells, J. Controlled Rel., 71, 227-237 (2001).

95. J. Kopecek, P. Kopeckova, **T. Minko**, Z-R. Lu, C. M. Peterson, Water soluble polymers in tumor targeted delivery, J. Controlled Rel., 74, 147-158 (2001).

96. Y. Kasuya, Z-R. Lu, P. Kopeckova, **T. Minko**, S. E. Tabibi, J. Kopecek, Synthesis and characterization of HPMA copolymer aminopropylgeldanamycin conjugates, J. Controlled Rel., 74, 203-211 (2001).

97. **T. Minko**, P. Kopeckova, J. Kopecek, Antitumor activity and apoptosis signaling pathways of HPMA copolymer-bound doxorubicin, J. Controlled Rel., 74, 370-370 (2001).

98. **T. Minko**, P. Kopeckova, J. Kopecek, Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma, Int. J. Cancer, 86, 108-117 (2000).

99. **T. Minko**, P. Kopeckova, V. Pozharov, K. Jensen, J. Kopecek, The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in experimental resistant solid tumor, Pharm. Res. 17, 505-514 (2000).

100. M. Demoy, **T. Minko**, P. Kopeckova, J. Kopecek, Time- and concentration-dependent apoptosis and necrosis induced by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells, J. Controlled Rel., 69, 185-196 (2000).

101. J. Kopecek, P. Kopeckova, **T. Minko**, Z-R. Lu, HPMA copolymer-anticancer drug conjugates: Design, activity, and mechanism of action, Eur. J. Pharm. Biopharm, 50, 61-81 (2000).

102. K. Kunath, P. Kopeckova, **T. Minko**, J. Kopecek, HPMA copolymer-anticancer drug-OV-TL16 Antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line, Eur. J. Pharm. Biopharm, 49, 11-15 (2000).

103. D. Wang, P. Kopeckova, **T. Minko**, V. Nanayakkara, J. Kopecek, Synthesis of starlike N-(2-Hydroxypropyl)methacrylamide copolymers: Potential drug curriers, Biomacromolecules, 1, 313-319 (2000).

104. **T. Minko**, P. Kopeckova, J. Kopecek, Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells, Pharm. Res., 16, 986-996 (1999).

105. **T. Minko**, P. Kopeckova, J. Kopecek, Chronic exposure to HPMA copolymer bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line, J. Controlled Rel., 59, 133-148 (1999).

106. W.-M. Choi, P. Kopeckova, **T. Minko**, J. Kopecek, Synthesis of HPMA copolymer containing adriamycin bound via an acid-labile spacer and its activity toward human ovarian carcinoma cells, J. Bioact. Comp. Polym., 14, 447-556 (1999).

107. **T. Minko**, P. Kopeckova, V. Pozharov, J. Kopecek, HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line, J. Controlled Rel. 54, 223-233 (1998).

108. F. Meerson, V. Pozharov, T. Minyailenko **(Minko)**, Superresistance against hypoxia after preliminary adaptation to repeated stress, J. Appl. Physiol. 76, 1856-1861 (1994).

109. V. Pozharov, T. Minyailenko **(Minko)**, Lipid peroxidation during severe hypoxia: possible mechanisms of the activation, Hypoxia Medical J. N3, 14-17 (1993).

110. F. Z. Meerson, V. P. Pozharov, T. D. Miniailenko **(Minko)**, L. Yu Golubeva, Adaptation to stress can enhance animal resistance to sublethal hypoxia to a greater extent than adaptation to hypoxia, Bull. Experim. Biol. Med. 116, 574-577 (1993).

111. F. Z. Meerson, T.D. Miniailenko **(Minko)**, V. P. Pozharov, Development of super-resistance to hypoxic hypoxia during adaptation to short-term stress, Bull. Experim. Biol. Med. 115, 132-135 (1993).

112. F. Z. Meerson, V. P. Pozharov, T.D. Miniailenko **(Minko)**, E. Ya. Vorontsova, S.A. Radzievsky, Correlation between the antihypoxic effect of adaptation to stress and the course of electrostimulation, Bull. Experim. Biol. Med. 115, 339-342 (1993).

113. F. Z. Meerson, T.D. Miniailenko **(Minko)**, V. P. Pozharov, Super-resistance to hypoxic hypoxia in adaptation to stress exposure: its possible mechanisms, Aviakosm. Ecol. Med. 27, 44-48 (1993).

114. F. Z. Meerson, V. P. Pozharov, T. D. Minyailenko **(Minko)**, Animal resistance to sublethal hypoxia may be raised more by adaptation to stress than by adaptation to hypoxia, Bull. Experim. Biol. Med. 116, 1467-1471 (1993).

115. F. Z. Meerson, V. P. Pozharov, T. D. Minyailenko **(Minko)**, Antihypoxic effect of adaptation to stress and of adaptation to electrostimulation – a comparative study, Bull. Experim. Biol. Med. 115, 349-354 (1993).

116. F. Z. Meerson, T. D. Minyailenko **(Minko)**, V. P. Pozharov, Development of superresistance to hypoxia under the effect of adaptation to short-term stress exposure, Bull. Experim. Biol. Med. 115, 123-126 (1993).

117. N. G. Sidoryak, T. Miniailenko **(Minko)**, Influence of prolonged injection of sodium nitrite on oxygen transport function and acid-base status of blood, Pharmacol. Toxicol., 54, p. 88-92 (1991).

118. T. Minyailenko **(Minko)**, V. Pozharov, M. Seredenko, Oxygen supply-consumption ratio as the criterion of tissue hypoxia, Wiss. Zeitschrift der Humboldt-Univ. zu Berlin, R. Medizin. 40, 97-102 (1991).

119. M. M. Seredenko, T. D. Miniailenko **(Minko)**, E. B. Velikanov, A. V. Koryakin, A. A. Rezayev, Influence of breathing mixture of air with industrial natural gas contained hydrogen sulfide on glycolysis and lipid peroxidation in rats, Physiol. J. 37, 71-74 (1991).

120. T. Minyailenko **(Minko)**, V. Pozharov, M. Seredenko, Severe hypoxia activates lipid peroxidation in the rat brain, Chem. Phys. Lipids 55, 25-28 (1990).

121. V. Pozharov, T. Miniailenko **(Minko)**, A. Stefanov, S. Bryginsky, M. Seredenko, V. Lishko, Physiological mechanisms of antihypoxic effect of liposomes, Sechenov Physiol. J. USSR 76, 897-902 (1990).

122. Stefanov, V. Pozharov, T. Miniailenko **(Minko)**, S. Bryginsky, M. Seredenko, V. Lishko, The Biological effect of liposomes in hypoxic states of different etiologies, Vestnik Acad. Med. Sci. USSR N6, 47-51 (1990).

123. V. P. Pozharov, T. D. Miniailenko **(Minko)**, M.M. Seredenko, A.V. Stefanov, E. V. Kasyanova, V. K. Lishko, F. Z. Meerson, Stress lung syndrome and its correction by phospholipids, Dokl. Acad. Sci. USSR 310, 754-757 (1990).

124. F. Z. Meerson, T. D. Miniailenko **(Minko)**, V. P. Pozharov, M.M. Seredenko, Disorders of external respiration and oxygen transport and utilization in stress, Pathol. Physiol. Experim. Therapy 6, 20-26 (1989).
125. V. R. Tyutyunnik, V. P. Pozharov, T. D. Miniailenko **(Minko)**, M. I. Kalinsky, V. K. Lishko, M. M. Seredenko, A. V. Stefanov, Usage of liposomal adrenalin for correction of hypoxia under an exercise, Theory and Practice of Physical Culture N2, 42-45 (1989).
126. M. M. Seredenko, V. P. Pozharov, T. D. Miniailenko **(Minko)**, V. I. Boyko, L. A. Grabovsky, External respiration, gas exchange and blood acid-base balance in dogs with hyperthermia, Physiol. J. 35, 21-25 (1989).
127. N. G. Sidoryak, T. D. Miniailenko **(Minko)**, Changes in the blood acid-base status in rats under acute hemic hypoxia, Hemathol. Transfusiol., 11, 64-68 (1988).
128. M. M. Seredenko, A. A. Moybenko, T. D. Miniailenko **(Minko)**, V. P. Pozharov, L.A. Grabovsky, E.G. Bidkov, The development of the hypoxic state and the lung blood oxygenation during hyperthermia, Sechenov Physiol. J. USSR 74, 987-994 (1988).
129. S. A. Bryginsky, A. V. Zubarenko, V. K. Lishko, T. D. Miniailenko **(Minko)**, V. P. Pozharov, E. V. Rozova, M. M. Seredenko, A. V. Stefanov, Using of liposomes for correction of respiratory hypoxia under experimental pneumonia, Bull. Experim. Biol. Med. 106, 421-423 (1988).
130. M. M. Seredenko, B. Ya. Reznik, A. V. Zubarenko, T. D. Miniailenko **(Minko)**, V. P. Pozharov, E. V. Rozova, A. P. Khirsa, Peculiarities of the hypoxic state development in children with bronchial asthma, Physiol. J. 33, 62-66 (1987).
131. M. M. Seredenko, T. D. Miniailenko **(Minko)**, V. P. Pozharov, Peculiarities of the development and compensation of secondary tissue hypoxia during exercise, Human Physiol. 13, 831-838 (1987).
132. S. A. Bryginskiy, A. V. Zubarenko, V. K. Lishko, T. D. Miniailenko **(Minko)**, V. P. Pozharov, B. Ya. Reznik, E. V. Rozova, M. M. Seredenko, A. V. Stefanov, Characteristics of the hypoxic state after administration of liposomes, Dokl. Acad. Sci. USSR 291, 1022-1024 (1986).
133. M. M. Seredenko, V. P. Pozharov, T. D. Miniailenko **(Minko)**, R. F. Bespal'chaya, Features of blood oxygenation in the lungs in acute graded blood loss, Physiol. J. 32, 344-350 (1986).
134. I. Lanovenko, T. D. Miniailenko **(Minko)**, M. M. Seredenko, System mechanisms of the development and compensation of acute hemic hypoxia under experimental methemoglobinemia, Pathol. Phisiol. Experim. Therapy 3 LHRH-Targeted Nanoparticles for Cancer, 50-53 (1986).
135. M. M. Filippov, T. D. Miniailenko **(Minko)**, Mass transfer of CO_2 and acid-base balance under exercise at sea level and mountain, Ukrainian Biochem. J. 52, 171-174 (1980).

Book and Textbook Chapters

1. J. Khandare, S. Banerjee, **T. Minko**, Nanopreparations for Cancer Treatment and Diagnostics, In: Frontiers in Nanobiomedical Research, Volume 3, Handbook of Nanobiomedical Research, V. P. Torchilin, Ed., World Scientific, 2014, pp. 2352.
2. **T. Minko**, Receptor Mediated Delivery Systems for Cancer Therapeutic, In: Advances in Delivery Science and Technology, R. A. Siegel, S. Juergen, M. Rathbone Eds., CRS Press, Springer, 2012, Part 4, pp. 329-355.
3. S. Cai, D. A. Christian, M. Tewari, **T. Minko**, D. E. Discher. Anti-Cancer Polymerosomes (Chapter 9), In: Polymer-based Nanostructures: Medical Applications (RSC Nanoscience & Nanotechnology), P. Broz, Ed., RSC Publishing, 2010, pp. 300-314.

4. **T. Minko**, J. J. Khandare, A. A. Vetcher, V. A. Soldatenkov, O. B. Garbuzenko, M. Saad, V. P. Pozharov, Multifunctional nanotherapeutics for cancer (Chapter 10), In: Multifunctional Pharmaceutical Nanocarriers, V. P. Torchilin, Ed., Springer, 2008, pp. 309-335.
5. **T. Minko**, J. J. Khandare, S. Jayant, Polymeric Drugs (Chapter 14), In.: Macromolecular Engineering: From Precise Macromolecular Synthesis to Macroscopic Material Properties and Application, Volume 4, K. Matyjaszewski, Y. Gnanou, L. Leibler, Eds., WILEY-VCH Verlag GmbH & Co., 2007, pp. 2541-2595.
6. **T. Minko**, Hypoxia-induced lung damage and alpha tocopherol, In.: The Encyclopedia of Vitamin E, V. R. Preedy and R. Watson, Eds, CAB International, 2006, pp. 699-708.
7. **T. Minko**, Chapter 22, Drug delivery systems, In: Martin's Physical Pharmacy and Pharmaceutical Sciences 5th Edition, P. J. Sinko, Ed., Lippincott Williams and Wilkins, 2006, pp. 629-680.
8. **T. Minko**, Chapter 17, Colloids, In: Martin's Physical Pharmacy and Pharmaceutical Sciences 5th Editionn, P. J. Sinko, Ed., Lippincott Williams and Wilkins, 2006, pp. 469-498.
9. **T. Minko**, Chapter 16, Interfacial Phenomena, In: Martin's Physical Pharmacy and Pharmaceutical Sciences 5th Editionn, P. J. Sinko, Ed., Lippincott Williams and Wilkins, 2006, pp. 437-467.
10. **T. Minko**. Mechanisms of cellular drug resistance and strategies to overcome it, In: Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids, R. I. Mahato, Ed, CRC Press, Boca Raton, London, New York, Washington, D.C., 2005, pp. 461-492.
11. **T. Minko**, P. Kopeckova, J. Kopecek, Mechanism of anticancer action of HPMA copolymer-bound doxorubicin, In: Polymers in Medicine, Kahovec J., Ed., Wiley-VCH, 2001, pp. 35-47.
12. F. Meerson, **T. Minko**, V. Pozharov, E. Vorontsova, E. Ustinova, Effect of combined adaptation to stress and intermittent hypoxia on the development of experimental myocardial infarction, in: Adaptation Biology and Medicine, Vol. 1, B. K. Sharma, N. Takeda, N.K. Ganguly, P.K. Singal, Eds., Narosa Publishing House, 1997, pp. 419-426.
13. T. D. Miniailenko **(Minko)**, Mechanisms of blood acid-base status regulation, in: Development and Compensation Mechanisms of Hemic Hypoxia, M. M. Seredenko, Ed., Naukova Dumka, 1987, pp. 103-118.
14. M. M. Seredenko, T. D. Miniailenko **(Minko)**, V. P. Pozharov, Hemic hypoxia after the blood loss: Development of hypoxia, in: Development and Compensation Mechanisms of Hemic Hypoxia, M. M. Seredenko, Ed., Naukova Dumka, 1987, pp. 82-97.
15. M. M. Seredenko, T. D. Miniailenko **(Minko)**, V. P. Pozharov, E. V. Rozova, N. G. Sidoryak, Hemic hypoxia in methemoglobinemia: Development and compensation of hypoxia, in: Development and Compensation Mechanisms of Hemic Hypoxia, M. M. Seredenko, Ed., Naukova Dumka, 1987, pp. 5-18.
16. M. M. Seredenko, T. D. Miniailenko **(Minko)**, V. P. Pozharov, V. P. Rozova, N. G. Sidor'ak, Peculiarities of the hypoxia development during methemoglobinemia at sea level and in mountains, in: Adaptation and Resistance of an Organism in Mountains, P. V. Beloshitskiy, Ed., Naukova Dumka, 1986, pp. 84-96.
17. P. V. Beloshitskiy, A. Z. Kolchinskaya, A. P. Andreeva, A. N. Krasyuk, N. V. Makarenko, L. N Voronina, A. A. Zamchiy, V. M. Kienko, T. A. Kerdeeva, T. D. Miniailenko **(Minko)**, P. A. Radzievskiy, N. V. Shtuchenko, Treatment of patients with iron-deficient anemia living in arid zone in high altitudes, in: Adaptation and Resistance of an Organism in the Mountains, P. V. Beloshitskiy, Ed., Naukova Dumka, 1986, pp. 105-124.
18. T. D. Minyailenko **(Minko)**, Changes in acid-base status and blood gases tension under hypoxia of different genesis, Naukova Dumka, 1984, pp. 1-23.

19. T. D. Miniailenko **(Minko)**, Changes in blood acid-base status under hypoxic hypoxia, in: Secondary Tissue Hypoxia, A. Z. Kolchinskaya, Ed., Naukova Dumka, 1983, pp. 43-52.

Book Reviews

1. **T. Minko**, Book review: Apoptosis and Autoimmunity. From Mechanisms to Treatments, J.R. Kalden and M. Herrmann, Eds. Wiley-VCH. 2003. 381 pp., Pharmaceutical Research, vol. 20, Dec.: 2041, 2003.

Extended Abstracts/Conference Proceedings

1. **T. Minko**, A. Kuzmov, J. Sapiezynski, O. Taratula, V. Shah, M. Zhang, O. B. Garbuzenko, S. R. Pine, L. Rodriguez-Rodriguez, Nanotechnology Approaches for Personalized Treatment of Cancer, 42nd Annual Meeting & Exposition of the Controlled Release Society, July 26-29, Edinburgh, Scotland.
2. V. Ivanova, O. B. Garbuzenko, R. Rustamov, G. Mainelis, **T. Minko**, Local lung co-delivery of siRNA and drug, 41st Annual Meeting & Exposition of the Controlled Release Society, July 13-16, 2014, Chicago, Illinois, #144.
3. R. Savla, O. Garbuzenko, L. Rodriguez-Rodriguez, **T. Minko**, Targeted nanoparticle-based system for cancer imaging and diagnosis, 41st Annual Meeting & Exposition of the Controlled Release Society, July 13-16, 2014, Chicago, Illinois, #640.
4. M. Shah, V. Shah, **T. Minko**, Water soluble formulations of paclitaxel, 41st Annual Meeting & Exposition of the Controlled Release Society, July 13-16, 2014, Chicago, Illinois, #661.
5. A. Kuzmov, O. Taratula, O. B. Garbuzenko, M. Shah, V. Shah, **T. Minko**, Lipid nanoparticles for inhalation co-delivery of anticancer drug and siRNA, 39th Annual Meeting of the Controlled Release Society, July 15-18, 2012, Quebec City, Canada, #261.
6. V. Ivanova, O. B. Garbuzenko, K. R. Reuhl, **T. Minko**, Liposomal form of prostaglandin E2 for inhalation treatment of pulmonary fibrosis, 39th Annual Meeting of the Controlled Release Society, July 15-18, 2012, Quebec City, Canada, #372.
7. O. Taratula, A. Kuzmov, M. Shah, O. Garbuzenko, **T. Minko**, Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA, Nanomedicine and Drug Delivery Symposium, NanoDDS'11, October 15-16, 2011, Salt Lake City, Utah, p. 50-51.
8. O. Taratula, M. Shah, O. Garbuzenko, **T. Minko**, Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA, 38th Annual Meeting of the Controlled Release Society, July 31 - August 3, 2011, National Harbor, Maryland, #15.
9. O. Garbuzenko, O. Taratula, **T. Minko**, The influence of composition, size, and shape of nanocarriers on their accumulation and retention in lungs after pulmonary or intravenous delivery, 38th Annual Meeting of the Controlled Release Society, July 31 - August 3, 2011, National Harbor, Maryland.
10. O. Taratula, O. B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, **T. Minko**, Receptor-targeted surface-engineered PPI dendrimer for efficient intracellular and intratumoral siRNA delivery, 37th Annual Meeting of the Controlled Release Society, July 10-14, 2010, Portland, Oregon, #202.
11. O. Garbuzenko, M. Saad, K. Reuhl, G. Mainalis, **T. Minko**, Combinatorial inhalatory co-delivery of drug and antisense oligonucleotides for treatment of lung cancer, 37th Annual Meeting of the Controlled Release Society, July 10-14, 2010, Portland, Oregon, #110.
12. **T. Minko**, Mechanisms of cellular drug resistance and strategies to overcome it, Symposium on Biomedical Polymers for Drug Delivery, March 26-27, 2010, Salt Lake City, Utah, p. 19.

13. **T. Minko**, G. Mainelis, O. Garbuzenko, S. Seshadri, Inhalatory co-delivery of anticancer drugs and antisense oligonucleotides/siRNA for lung cancer treatment, 36th Annual Meeting of the Controlled Release Society, July 18-22, 2009, Copenhagen, Denmark, #136.

14. O. Garbuzenko, M. Saad, S. Betigeri, M. Zhang, A. A. Vetcher, V. A. Soldatenkov, D. C. Reimer, **T. Minko**, Distribution and retention of anticancer drug, antisense oligonucleotides and siRNA after their systemic and local liposomal delivery, Annual meeting NanoIsrael, March 30-31, 2009, Jerusalem, Israel.

15. **T. Minko**, O. Garbuzenko, O. Taratula, M. Zhang, M. Saad, P. Chandna, M. Patil, J. Khandare, H. He, A. Chen, Receptor Targeted Nanocarriers for Tumor-Specific Treatment and Imaging, 14th International Symposium on Recent Advances in Drug Delivery Systems, February 15-18, 2009, Salt Lake City, UT, p.49-50.

16. **T. Minko**, O. Garbuzenko, O. Taratula, M. Zhang, M. Saad, P. Chandna, M. Patil, J. Khandare, H. He, A. Chen, Multifunctional Nanotherapeutics for Cancer Treatment, American Association for Cancer Research – American Chemical Society Joint Conference on: Chemistry in Cancer Research: A Vital Partnership in Drug Discovery and Development, February 8-11, 2009, New Orleans, LA.

17. M. Zhang, M. L. Patil, S. Betigeri, O. Taratula, H. He, **T. Minko**, Synthesis and evaluation of modified PAMAM dendrimer as efficient siRNA delivery system, 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY, #229.

18. O. Garbuzenko, M. Saad, S. Betigeri, E. Ber, M. Zhang, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, Influence of size, charge, shape, and route of liposomes administration on their cellular uptake, tumor and organs distribution in mice with subcutaneous and orthotropic models of ovarian and lung carcinomas, 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY, #763.

19. M. Saad, O. B. Garbuzenko, E. Ber, P. Chandna, J. J. Khandare, V. P. Pozharov, **T. Minko**, Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most effective for tumor specific treatment and imaging?, 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY, #92.

20. Chandna, M. Saad, Y. Wang, E. Ber, J. Khandare, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, A novel targeted proapoptotic drug delivery system for efficient anticancer therapy, 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY, #616.

21. S. Betigeri, O. B. Garbuzenko, **T. Minko**, JNK1 as a molecular target to limit cellular damage under hypoxia, 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY, #30.

22. O. Taratula, P. Kirkpatrick, R. Savla, I. Pandya, **T. Minko**, H. He, Toward in vivo targeting delivery of siRNA for efficient cancer therapy, 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY, #874.

23. R. Savla, O. Taratula, I. Pandya, A. Wang, **T. Minko**, H. He, Multifunctional siRNA delivery system for cancer therapy, 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY, #191.

24. M. Chen, O. Taratula, D. Wei, **T. Minko**, H. He, Labile catalytic packaging and delivering of short interference RNA to cancer cells: Control of gold nanoparticles "out" of siRNA complexes, NSTI Nanotech 2008 11th Annual Meeting, June 1-5, 2008, Boston, MA, pp. 342-345.

25. O. Taratula, P. Kirkpatrick, R.Salva, I. Pandya, **T. Minko**, H. He, Toward in vivo targeting delivery of siRNA for efficient cancer therapy, NSTI Nanotech 2008 11th Annual Meeting, June 1-5, 2008, Boston, MA, pp. 346-349.

26. O. Taratula, R. Salva, I. Pandya, A. Wang, **T. Minko**, H. He, Multifunctional siRNA delivery system for cancer therapy, NSTI Nanotech 2008 11th Annual Meeting, June 1-5, 2008, Boston, MA, pp. 349-352.

27. **T. Minko**, P. Chandna, S. S. Dharap, O. Garbuzenko, J. J. Khandare, R. I. Pakunlu, M. Saad, Y. Wang, Tumor-specific targeting of drug delivery systems for cancer therapy and imaging, 34th Annual Meeting of the Controlled Release Society, July 7-11, 2007, Long Beach, CA, # 162.

28. Shenshen, **T. Minko**, D. E. Discher, Poly(ethilene oxide)-poly(ε-caprolactone) micelles in different morphologies: Advantages of worm-like micelles for delivery of paclitaxel in lung cancer therapy, 34th Annual Meeting of the Controlled Release Society, July 7-11, 2007, Long Beach, CA, #7.

29. **T. Minko**, J. J. Khandare, P. Chandna, S. S. Dharap, Y. Wang, Targeted polymeric prodrug with multivalent components for cancer therapy, 7th International Biorelated Polymers Symposium on Drug Delivery, Biosurfaces, Hydrogels, Nanostructures, Tissue Engineering and Biomaterials, ACS National Meeting, San Francisco, CA, September 10-15, 2006, Polymer Preprints, 47, 199-200 (2006).

30. **T. Minko**, J. J. Khandare, P. Chandna, S. S. Dharap, Y. Wang, Straight to the Target: A Novel Polymeric Prodrug with Multivalent Components for Cancer Therapy, 33 International Symposium on Controlled Release of Bioactive Materials, Vienna, Austria, July 22-26, 2006, No 58.

31. **T. Minko**, Y. Wang, J. J. Khandare, Hypoxia Inducible Factor - Targeted Anticancer Prodrug, 32 International Symposium on Controlled Release of Bioactive Materials, Miami, FL, June 18-22, 2005, No 72.

32. E. Batrakova, **T. Minko**, S. Li, Y. Li, R. Pakunlu, V. Alakhov, A. Kabanov, Pluronic block copolymer formulation with doxorubicin induces apoptosis in drug-resistant cancer cells, 32 International Symposium on Controlled Release of Bioactive Materials, Miami, FL, June 18-22, 2005, No 242.

33. **T. Minko**, S. S. Dharap, S. Gunaseelan, P. J. Sinko, S. Stein, B. Qiu, Targeted delivery of anticancer drugs and peptides by polyethylene glycol conjugates, 7th Symposium on Biomaterials Science, New Brunswick, NJ, October 21-22, 2004, p. 34-35.

34. **T. Minko**, S. S. Dharap, S. Gunaseelan, S. Stein, P. J. Sinko, R. I. Pakunlu, Y. Wang, B. Qiu, Targeted proapoptotic anticancer drug delivery system, 31 International Symposium on Controlled Release of Bioactive Materials, Honolulu. HI, June 12-16, 2004, #108.

35. K. Lalloo, R. J. Paranjpe, **T. Minko**, P. J. Sinko, Liposomal camptothecins exhibit enhanced cytotoxicity, 30th International Symposium on Controlled Release of Bioactive Materials, Glasgow, Scotland, United Kingdom, July 2003, #183.

36. **T. Minko**, P. Sinko, S Stein, S. S. Dharap, B. Qiu, A. T. Fabbricatore, Y. Wang, Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides, CRS & NCI International Symposium on Tumor Targeted Delivery Systems, National Cancer Institute, Rockville, MD, September 23-25, 2002, pp. 6-9.

37. **T. Minko**, T. J. Cook, R. I. Pakunlu, Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense with liposomes containing doxorubicin and antisense oligonucleotides targeting mdr1 and bcl-2 mRNA, 29th International Symposium on Controlled Release of Bioactive Materials, Seoul, Korea, July 20-25, 2002, pp. 322-323.

38. Marin, M. Muniruzzaman, **T. Minko**, N. Rapoport, Acoustic activation of micellar drug delivery: effect of pulsed ultrasound, 10th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, February 19-22, 2001, pp 186-187.

39. P. Kopeckova, **T. Minko**, Z.-R. Lu, J. Kopecek, Bioconjugates for the Treatment of Cancer, 28th International Symposium on Controlled Release of Bioactive Materials, San Diego, CA, June 24-27, 2001, pp. 71-72.

40. J. Kopecek, P. Kopeckova, **T. Minko**, Z.-R. Lu, C. M. Peterson, Water soluble polymers in tumor targeted delivery, Int. Symposium on Tumor Targeted Delivery Systems, National Institute of Health, Bethesda, MD, September 25-27, 2000, pp. 1-4.

41. **T. Minko**, P. Kopeckova, J. Kopecek, Role of caspases in cellular signal transduction pathways of apoptosis induced by free and HPMA copolymer-bound doxorubicin, The 27th International Symposium on Controlled Release of Bioactive Materials, Paris, France, 2000, pp.71-72.

42. M. Demoy, **T. Minko**, P. Kopeckova, J. Kopecek, Apoptosis induction by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells, The 27th International Symposium on Controlled Release of Bioactive Materials, Paris, France, 2000, pp. 203-204.

43. Wang, P. Kopeckova, **T. Minko**, V. Nanayakkara, J. Kopecek, Synthesis of star-like poly[N-(2-hydroxypropyl)methacrylamide] using PAMAM dendrimer as the core, ACS National Meeting, San Francisco, CA, Polymer Preprints, 41, 994-995, 2000.

44. **T. Minko**, P. Kopeckova, J. Kopecek, EPR effect, multidrug resistance and the efficacy of HPMA copolymer-bound adriamycin in solid tumors with high vascularization, The 26th International Symposium on Controlled Release of Bioactive Materials, Boston, MA, 1999, pp. 46-47.

45. J. Kopecek, P. Kopeckova, **T. Minko**, HPMA copolymer anticancer drugs: Mechanism of action on cellular and subcellular levels, The 26th International Symposium on Controlled Release of Bioactive Materials, Boston, MA, 1999, pp. 24-25.

46. **T. Minko**, P. Kopeckova, J. Kopecek, Signaling pathways of multidrug resistance and apoptosis in human ovarian carcinoma cells exposed to free and HPMA copolymer-bound adriamycin, 9th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, 1999, pp. 215-216.

47. **T. Minko**, P. Kopeckova, V. Pozharov, J. Kopecek, Peculiarities of apoptosis induction and cell metabolism in human ovarian carcinoma cell lines exposed to free and HPMA copolymer bound adriamycin, The 25th International Symposium on Controlled Release of Bioactive Materials, Las Vegas, NV, 1998, pp. 99-100.

48. **T. Minko**, V. Pozharov, A. Stefanov, Use of liposomes for vitamin E delivery: Antihypoxic and antioxidant effects, 8th International Symposium on Resent Advances in Drug Delivery Systems, Salt Lake City, UT, 1997, pp. 252-253.

49. T. Minyailenko **(Minko)**, V. Pozharov, V. Bystrjukov, O. Ezhova, F. Meerson, Adaptation to moderate stress increases the resistance to severe hypoxia, in: High-Altitude Medicine, G.Ueda, J.T.Reeves, M.Sekiguchi, Eds., Shinshu University Press, 1992, pp. 70-74.

50. T. Serebrovskaya, Z. Serebrovskaya, G. Afonina, T. Minyailenko **(Minko)**, Effect of intermittent hypoxic training on human respiration, free radical process and immune system, in: High-Altitude Medicine, G.Ueda, J.T.Reeves, M.Sekiguchi, Eds., Shinshu University Press, 1992, pp. 77-82.

51. V. Pozharov, T. Minyailenko **(Minko)**, O. Ezhova, V. Bystrjukov, A. Sidorenko, Changes in the respiratory sensitivity to carbon dioxide under severe hypoxia, in: High-Altitude Medicine, G.Ueda, J.T.Reeves, M.Sekiguchi, Eds., Shinshu University Press, 1992 pp. 123-127

52. V. P. Pozharov, T. D. Minyailenko **(Minko)**, V. A. Bystrjukov, O. A. Ezhova, Mechanisms of an increase in the fitness to work during training to intermittent high-altitude hypoxia, in: Interval Hypoxic Training: Efficiency and Mechanisms of Action, A. Z. Kolchinskaya, Ed., Naukova Dumka, 1992, pp. 136-139.

53. T.D. Minyailenko **(Minko)**, V. P. Pozharov, The criterion for the selection of hypoxic impacts for interval hypoxic training, in: Interval Hypoxic Training: Efficiency and Mechanisms of Action, A. Z. Kolchinskaya, Ed., Naukova Dumka, 1992, pp. 132-135.

54. T. D. Minyailenko **(Minko)**, Primary and secondary disturbances of acid-base homeostasis, in: Acid-base and Thermal Homeostasis, Irzhak L. I., Ed., Syktyvkar University Press, 1991, pp. 57-61.

55. M. M. Seredenko, N. G. Sidoryak, T. D. Minyailenko **(Minko)**, V. A. Bystrjukov, Acid-base homeostasis under hemic hypoxia, in: Acid-base and Thermal Homeostasis, Irzhak L. I., Ed., Syktyvkar University Press, 1991, pp. 80-86.

56. M.M. Seredenko, V.A. Bystrjukov, V.P. Pozharov, T.D. Miniailenko **(Minko)**, V.R. Tyutyunnik, Peculiarities of the reaction on exercise trained and untrained rats with different types of breathing, in: Exercise Hypoxia: Digital Models, Prognosis and Correction, A. Z. Kolchinskaya, Ed., Naukova Dumka, 1990, pp. 71-73.

57. V. P. Pozharov, T. D. Minyailenko, Compensative and adaptive shifts of respiration, gas exchange and blood acid-base status during hypoxia of different genesis, in: Compensative and Adaptive Reactions of Organism Under Hypoxia, V. A. Vorontsov, Ed., Kujbyshev University Press, 1989, pp. 49-51.

58. M.M. Seredenko, T.D. Minyailenko **(Minko)**, V. P. Pozharov, E.V. Rozova, V.K. Lishko, A.V. Stefanov, S.A. Bryginsky, Optimization of respiratory function during hypoxia by liposomes injection, in: Directions in Optimization of Respiratory Function Under Exercise, Pathology and Extreme States, I. S. Breslav, Ed., Kalinin University Press, 1989, pp. 132-137.

59. T. D. Minyailenko **(Minko)**, V. P. Pozharov, M. M. Seredenko, P. A Radzievsky., N. V. Shtuchenko, Peculiarities of organism oxygen supply under bronchial asthma in mountains, in: Usage of Mountain Climate to Treatment and Prophylaxis, P. V. Beloshitskiy, Ed, Nalchik University Press, 1988, pp. 42- 46.

60. V. Ya. Gayday, N. I. Grinenko, E. V. Golobova, G. A. Borisko, A. Z. Kolchinskaya , T. D. Minyailenko **(Minko)**, E. I. Plehanov, P. A. Radzievskiy, I. N. Ryzhova, I. F. Sazanchuk, I. G. Sidorenko, M. M. Filippov, S. H., Cherevatova, N. V. Shtuchenko, Peculiarities of physiological adaptation in thirteen years old children under exercise and psycho-emotional impacts, Health Protection of Children and Teenagers, Vol. 2, Zdorov'ya, 1980, pp. 10-14.

61. Z. Kolchinskaya , Yu. A. Krupko- Bol'shova, V. A. Antikova, I. B. Vovk, V. P. Dudarev, K. F. Zhikhareva, A. N. Krasyuk, V. V. Matsinin, T. D. Minyailenko **(Minko)**, P. A. Radzievskiy, N. V. Shtuchenko, Treatment of patients with secondary anemia by high mountain climate, in: Molecular Aspects of Adaptation to Hypoxia, A. Z. Kolchinskaya, Ed., Naukova Dumka, 1979, pp. 238-246.

62. Z. Kolchinskaya, V. P. Dudarev, A. G. Misyura, I. N. Man'kovskaya, N. N. Nagnibeda, S. A. Gulyar, I. F. Sokolyanskiy, V. A. Kozak, I. I. Lanovenko, M. M. Filippov, A. A. Ivashkevich, V. M. Alekseyev, K. F. Zhikhareva, V. P. Kryzhanoivskiy, T. D. Minyailenko **(Minko)**, E. V. Lauer, P. A. Radzievskiy, N. V. Shtuchenko , Yu. V. Strelkov, Characteristics of hypoxic states, in: Special and Clinical Physiology of Hypoxic States, v.1., A. Z. Kolchinskaya, Ed., Naukova Dumka, 1979, pp. 16-20.

63. Yu. A. Krupko-Bol'shova, I. B. Vovk, K. F. Zhikhareva, V. P. Dudarev, P. V. Baloshitskiy, N. V. Shtuchenko, A. N. Krasyuk, M. M. Filippov, P. A. Radzievskiy, T. D. Minyailenko **(Minko)**, Threatment of patients with juvenile hemorrhage by the method of stepwise acclimatization in the high mountain environment, in: Special and Clinical Physiology of Hypoxic States, v.1., A. Z. Kolchinskaya, Ed., Naukova Dumka, 1979, pp. 260-263.

64. T. D. Minyailenko **(Minko)**, Peculiarities of blood buffering properties and acid base status in girls with secondary anemia, in: Special and Clinical Physiology of Hypoxic States, v.1, A. Z. Kolchinskaya, Ed., Naukova Dumka, 1979, pp. 126-130.

Abstracts

1. **T. Minko**, A. Kuzmov, J. Sapiezynski, D. Zholobak, E. Mats, S. Degaonkar, B. Shah, O. Taratula, V. Shah, M. Zhang, O. B. Garbuzenko, L. Rodriguez-Rodriguez, Nanotechnology Approaches for Personalized and Targeted Treatment of Cancer, AAPS Workshop on Nanotechnology in Personalized Medicine, October 25, 2015, Orlando, FL.

2. A. Kuzmov, **T. Minko**, Genetic profiling of non-small cell lung cancer with various gefitinib sensitivity, 2015 AAPS Annual Meeting and Exposition, Otober 25-29, 2015, Orlando, FL, R6360.
3. J. Sapiezynski, O. B. Garbuzenko, L. Rodriguez-Rodriguez, **T. Minko**, Gene/protein expression and single-nucleotide polymorphism in tissue samples isolated from patients with ovarian cancer, 2015 AAPS Annual Meeting and Exposition, Otober 25-29, 2015, Orlando, FL, R6349.
4. M. Dorrani, O. Garbuzenko, **T. Minko**, B. Michiak-Kohn, Development of topical hydrogel system for treatment of melanoma, 2015 AAPS Annual Meeting and Exposition, Otober 25-29, 2015, Orlando, FL, T3067.
5. **T. Minko**, A. Kuzmov, R. Savla, O. B. Garbuzenko, O. Taratula, J. J. Khandare, M. Patil, V. Shah, M. Zhang, K. R. Reuhl, L. Rodriguez-Rodriguez, Advances in Nanomedicine Applications for Therapy and Imaging, First International Nanomedicine Symposium and Workshop: Impact of Nanobiotechnology Applications on the Future of Medicine and Personalized Medicine, August 4, 2015, Albany, NY.
6. J. Sapiezynski, J. Gong, S. John, O. B. Garbuzenko, L. Rodriguez-Rodriguez, **T, Minko**, Biomarkers for personalized selection of targets for treatment of ovarian cancer. 2015 Annual Retreat in Cancer Research, May 20, 2015, Piscataway, NJ, P98.
7. A. Kuzmov , **T. Minko**, Genetic profiling of non-small cell lung cancer with varying susceptibility to gefitinib, 2015 Annual Retreat in Cancer Research, May 20, 2015, Piscataway, NJ, P90.
8. R. Savla, O. B. Garbuzenko, S. Chen, L. Rodriguez-Rodriguez, **T, Minko**, Responsive theragnostic nanoparticle system for cancer diagnostics and therapy, 2015 Annual Retreat in Cancer Research, May 20, 2015, Piscataway, NJ, P80.
9. O. Garbuzenko, G. Mainelis, O.Taratula, **T, Minko**, Inhalation treatment of lung cancer: The influence of composition, size and shape of nanocarriers on their lung accumulation and retention, 2015 Annual Retreat in Cancer Research, May 20, 2015, Piscataway, NJ, B7.
10. O. B. Garbuzenko, A. Kuzmov, J. E. Sapiezynski, O. Taratula, V. Shah, M. Zhang, R. Savla, S. John, L. Rodriguez-Rodriguez, **T. Minko**, Tumor-targeted nanotherapeutics, AACR Annual Meeting 2015, April 18-22, 2015, Philadelphia, PA.
11. J. Sapiezynski, P. Zhou, O. Taratula, V. Shah, M. Zhang, J. Gong, S. John, O. B. Garbuzenko, L. Rodriguez-Rodriguez, **T, Minko**, Nanotechnology approaches for personalized treatment of cancer, Targeted Therapeutics and Translational Medicine 2014 Symposium, November 12, 2014, Philadelphia, PA.
12. M. Dorrani, O. B. Garbuzenko, **T. Minko**, B. Michniak-Kohn, Topical delivery of sirna by novel ultradeformable liposomal system to knockdown the over expression of BRAF protein involved in cell proliferation pathways in melanoma, Annual Meeting of the American Association of Pharmaceutical Scientists, November 02-06, 2014, San Diego, CA, T2117.
13. J. Sapiezynski, J. Gong, O. B. Garbuzenko, L. Rodriguez-Rodriguez, **T. Minko**, Biomarkers for personalized selection of targets for treatment of ovarian cancer, Annual Meeting of the American Association of Pharmaceutical Scientists, November 02-06, 2014, San Diego, CA, T3367.
14. R. Savla, O. B. Garbuzenko, S. Chen, L. Rodriguez-Rodriguez. **T. Minko**, Targeted, tumor responsive theragnostic nanoparticle system for magnetic resonance imaging and therapy for various cancers, Annual Meeting of the American Association of Pharmaceutical Scientists, November 02-06, 2014, San Diego, CA, T3076.
15. V. Ivanova, R. Savla, **T. Minko**, Nanoparticle formulations of Ivacaftor for inhalation treatment of respiratory manifestations of cystic fibrosis, Annual Meeting of the American Association of Pharmaceutical Scientists, November 02-06, 2014, San Diego, CA, R6047.
16. M. Shah, **T. Minko**, Novel formulations of paclitaxel using β-cyclodextrin derivatives as solubility and permeability enhancers, Annual Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2013, San Antonio, TX, W4190.

17. V. Ivanova, O. B. Garbuzenko, K. R. Reuhl, and **T. Minko**, Solid lipid nanoparticles (SLN) for topical pulmonary co-delivery of prostaglandin E and siRNA, Annual Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2013, San Antonio, TX, W4011.

18. M. Dorrani, O. B. Garbuzenko, R. Salva, **T. Minko**, B. Michniak-Kohn, Lipid nano particle-based skin delivery of siRNA, Annual Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2013, San Antonio, TX, W4051.

19. J. Praskavich, L. Rodriguez-Rodriguez, **T. Minko**, Stem cell and mesenchymal properties correlate with increased L-type voltage gated calcium ion channel expression in primary and metastatic ovarian carcinoma, Annual Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2013, San Antonio, TX, M1396.

20. R. Savla, O. Taratula, O. Garbuzenko, V. Shah, **T. Minko**, Tumor pH-responsive, mucin-1 targeted quantum dot-doxorubicin conjugate for imaging and treatment of ovarian cancer, Annual Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2013, San Antonio, TX, W4038.

21. O. Taratula, O. B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, **T. Minko**, Dendrimer-based multifunctional nanomedicine platforms for targeted delivery of siRNA, 10th International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ, P. 42-43.

22. V. Ivanova, O. Garbuzenko, K. R. Reuhl, W. Sun, **T. Minko**, Inhalation treatment of pulmonary fibrosis by liposomal form of prostaglandin E2, 10th International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ., #18, P. 73.

23. A. Ghosh, M. Vasanthavada, **T. Minko**, Development of solid dispersion formulation by formulation of *in-situ* amorphous salt using melt extrusion, 10th International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ., #11, P. 63-64.

24. A. Kuzmov, O. Taratula, O. B. Garbizenko, M. Shah, V. Shah, W. Sun, **T. Minko**, Inhalation delivery of siRNA and paclitaxel by nanostructured lipid carriers for treatment of lung cancer, 10th International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ., #24, P. 82-83.

25. M. Patel, P. L. Chiu, A. Hemmarine, C. Floristean, A. A. Khoshi, V. Shah, **T. Minko**, H. He, Direct and rapid production of monodispersed amphiphilic graphene nanosheets for multifunctional drug delivery vehicles, 10th International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ., #32, P. 94-95.

26. J. Praskavich, V. Shah, L. Rodriguez, **T. Minko**, Characterization of CACNA1D and CACNA1C L-type voltage-dependent calcium ion channel expression in sensitive, multidrug resistant and metastatic ovarian cancer cells, 10th International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ., #35, P. 99.

27. R. Savla, O. Taratula, O. Garbizenko, **T. Minko**, Targeted, pH-responsive quantum dot-mycin-1-aptamer-doxorubicin conjugates for imaging and treatment of cancer, 10th International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ., #39, P. 105.

28. M. Shah, V. Shah, **T. Minko**, Physicochemical characterization and *in vitro* cytotoxicity studies of molecular inclusion complexes of paclitaxel with β-cyclodextrin derivatives, 10th International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ., #41, P. 108.

29. V. Shah, O. Taratula, O. R. Taratula, O. Garbizenko, **T. Minko**, Suppression of CD44 protein and cell death induction in cancer stem cells by utilizing a PPI-based targeted nanodrug delivery system, 10th

International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ., #42, P. 109.

30. J. Winkler, O. Garbuzenko, **T. Minko**, M. S. Tomassone, Synthesis and application of biodegradable Janus particles for combination therapy, 10th International Nanomedicine and Drug Delivery (NanoDDS'12) Symposium, December 6-7, 2012, Atlantic City, NJ., #47, P. 116.

31. **T. Minko**, Nanothechnology - Based Targeted Cancer Treatment, Annual Meeting of the American Association of Pharmaceutical Scientists, October 14-18, 2012, Chicago, IL.

32. V. Ivanova, O. B. Garbuzenko, K. R. Reuhl, **T. Minko**, Local Inhalation Delivery of Liposomal Prostaglandin E2 for Treatment of Pulmonary Fibrosis, Annual Meeting of the American Association of Pharmaceutical Scientists, October 14-18, 2012, Chicago, IL.

33. A. Ghosh, M. Vasanthavada, **T. Minko**, Dissolution enhancement of a weakly basic drug from its salt solid dispersion and amorphous dispersions containing acidic counterions, Annual Meeting of the American Association of Pharmaceutical Scientists, October 14-18, 2012, Chicago, IL.

34. M. N. Shah, V. Shah, **T. Minko**, Low Molar Ratio Inclusion Complexes of Paclitaxel With β-Cyclodextrin Derivatives Suitable for Oral and Intravenous administration, Annual Meeting of the American Association of Pharmaceutical Scientists, October 14-18, 2012, Chicago, IL.

35. J. Praskavich, V. Shah, L. Rodriguez, **T. Minko**, Characterization of CACNA1D Voltage-Dependent Calcium Ion Channel and CD44 Expression in Primary and Metastatic Ovarian Carcinoma, Annual Meeting of the American Association of Pharmaceutical Scientists, October 14-18, 2012, Chicago, IL.

36. V. Shah, O. Taratula, O. Garbuzenko, **T. Minko**, PPi Dendrimer- based nano-drug delivery systems for the simultaneous suppression of CD44 Protein and Cell death induction in cancer stem cells, Annual Meeting of the American Association of Pharmaceutical Scientists, October 14-18, 2012, Chicago, IL.

37. **T. Minko**, L. Rodriguez-Rodriguez, M. Zhang, O. B. Garbuzenko, V. Shah, O. Taratula, K. R. Reuhl, Combined Targeted Chemo and Gene Therapy for Tumor Suppression and Prevention of Metastasis", Oligonucleotide Delivery: Biology, Engineering and Development, October 8, 2012, Hernstein, Austria.

38. A. Kuzmov, M. N Shah, O. Taratula, O. B. Garbuzenko, V. Shah, **T. Minko**, Targeted Nanostructure Lipid Carriers for Local Delivery of Drug and siRNA, Pharmacy Research Day, April 17, 2012, Piscataway, NJ, #24.

39. J. Praskavich, **T. Minko**, Contrasting expression of voltage-dependent calcium ion channels in A2780 drug sensitive ovarian cancer cells and malignant ascites from patients with advanced ovarian cancer, Annual Meeting of the American Association of Pharmaceutical Scientists, October 23-27, 2011, Washington, DC, R6049.

40. M. Zhang, M. L. Patil, O. B. Garbuzenko, **T. Minko**, Multifunctional triblock nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing, Annual Meeting of the American Association of Pharmaceutical Scientists, October 23-27, 2011, Washington, DC, T2061.

41. V. Shah, O. Taratula, O. Garbuzenko, R. Savla, M. Zhang, M. Patil, **T. Minko**, Cyto- and genotoxicity of different nanocarriers: challenges and approaches, Annual Meeting of the American Association of Pharmaceutical Scientists, October 23-27, 2011, Washington, DC, M1018.

42. M. N Shah, A. Kuzmov, O. Taratula, O. Garbuzenko, T. Minko, Lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA, Annual Meeting of the American Association of Pharmaceutical Scientists, October 23-27, 2011, Washington, DC, T3121.

43. O. Garbuzenko, V. Ivanova, **T. Minko**, Inhalation treatment of pulmonary fibrosis, Annual Meeting of the American Association of Pharmaceutical Scientists, October 23-27, 2011, Washington, DC, T2063.

44. N. Dayan, V. Shah, **T. Minko**, Evaluation of the genotoxic potential of whey proteins used for topical application, Annual Meeting of the American Association of Pharmaceutical Scientists, October 23-27, 2011, Washington, DC, M1425.

45. O. Taratula, M. Shah, O. Garbuzenko, **T. Minko**, Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA, The 2011 Annual Retreat on Cancer Research in New Jersey, May 26, 2011, Piscataway, NJ, P16, p. 56.

46. M. Zhang, O. B. Garbuzenko, K. R. Reuhl, L. Rodriguez, **T. Minko**, Two-in-one: Combined targeted chemo and gene therapy for tumor suppression and prevention of metastases, The 2011 Annual Retreat on Cancer Research in New Jersey, May 26, 2011, Piscataway, NJ, P21, p. 59.

47. O. Garbuzenko, O. Taratula, **T. Minko**, The influence of composition, size, and shape of nanocarriers on their accumulation and retention in lungs after pulmonary (or inhalatorial) delivery, The 2011 Annual Retreat on Cancer Research in New Jersey, May 26, 2011, Piscataway, NJ, B2, p. 33.

48. D. Banerjee, X. Xie, J. E. Kerrigan, **T. Minko**, A. Scarborough, E. Ercikan-Abali, T. Budak-Alpdogan, N. Johnson-Farley, K. W. Scotto, J. R. Bertino, Generation and antitumor effects of a penetratin-peptide that targets E2F, The 2011 Annual Retreat on Cancer Research in New Jersey, May 26, 2011, Piscataway, NJ, P2, p. 49.

49. L. Peddada, A. Joy, D. Devore, O. Garbuzenko, **T. Minko**, C. M. Roth, Novel carrier for delivery of antisense therapeutics, The 2011 Annual Retreat on Cancer Research in New Jersey, May 26, 2011, Piscataway, NJ, P14, p. 55.

50. M. N. Shah, A. Kuzmov, O. Taratula, O. Garbuzenko, **T. Minko**, Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA, Ernest Mario School of Pharmacy Research Day, April 25, 2011, Piscataway, NJ, Abstract #10.

51. R. Savla, O.Taratula, O. Garbuzenko, **T. Minko**, Targeted, pH-responsive quantum dot-mucin 1 aptamer doxorubicin conjugate for imaging and treatment of ovarian cancer, Ernest Mario School of Pharmacy Research Day, April 25, 2011, Piscataway, NJ, Abstract #11.

52. M. Zhang, O. B. Garbuzenko, K. R. Reuhl, L. Rodriguez, **T. Minko**, Two-in-one: Combined targeted chemo and gene therapy for tumor suppression and prevention of metastases, Ernest Mario School of Pharmacy Research Day, April 25, 2011, Piscataway, NJ, Abstract #12.

53. V. V. Shah, **T. Minko**, N. Dayan, Evaluation of genotoxicity of a powder and a hydrophilic polymer using chromosomal aberration assay, Ernest Mario School of Pharmacy Research Day, April 25, 2011, Piscataway, NJ, Abstract #43.

54. O. Taratula, O. Garbuzenko, R. Savla, A. Wang, H. He, **T. Minko**, Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes, Annual Meeting of the American Association of Pharmaceutical Scientists, November, 14-18, 2010, New Orleans, LA, T2102.

55. O. Garbuzenko, O. Taratula, **T. Minko**, The influence of composition, size, and shape of nanocarriers on the delivery efficiency to the lungs, Annual Meeting of the American Association of Pharmaceutical Scientists, November, 14-18, 2010, New Orleans, LA, M1302.

56. M. Zhang, O. B. Garbuzenko, K. R. Reuhl, L. Rodriguez-Rodriguez, **T. Minko**, Receptor-mediated tumor targeting of drugs with different mechanisms of action and simultaneous suppression of cellular resistance inhibits tumor growth and prevents metastases, Annual Meeting of the American Association of Pharmaceutical Scientists, November, 14-18, 2010, New Orleans, LA, M1044.

57. V. Shah, **T. Minko**, N. Dayan, Evaluation of genotoxicity of a powder and a hydrophilic polymer using chromosomal aberration assay, Annual Meeting of the American Association of Pharmaceutical Scientists, November, 14-18, 2010, New Orleans, LA, W4458.

58. **T. Minko,** Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges, 8th International Nanomedicine and drug Delivery Symposium, October, 3-5, 2010, Omaha, NB, p. 24.

59. **T. Minko**, Nanotechnology strategies to overcome limitations in cancer treatment, Particles 2010: Medical/biochemical diagnostic, pharmaceutical, and drug delivery applications of particle technology, May, 22-25, 2010, Lake Buena Vista, FL, #100, p. 115-116.

60. **T. Minko**, Nanotechnology strategies to overcome limitations in drug delivery: Opportunities and challenges, Clinical applications of quantum dot and nanoparticle technology, UIC Center for Clinical and Translational Science, April 13, 2010, Chicago, IL, #3.

61. **T. Minko**, O. B. Garbuzenko, M. Saad, K. R. Reuhl, G. Mainelis, New horizons in treatment of lung cancer: Combinatorial liposomal inhalation delivery of drugs and suppressors of cellular resistance, Liposome advances: Recent trends and progress, December 12-15, 2009, London, UK, p.27.

62. O. Taratula, O. Garbuzenko, Z. Wang, G. Mainelis, **T. Minko**, Pulmonary co-delivery of anticancer drug and therapeutic antisense oligonucleotides by mesoporous silica nanoparticles, Annual Meeting of the American Association of Pharmaceutical Scientists, November 8-12, 2009, Los Angeles, CA, R6410.

63. O. Garbuzenko, G. Mainelis, S. Seshadri, **T.Minko**, Inhalatory vs. Intravenous Co-Delivery of Anticancer Drugs and Antisense Oligonucleotides/siRNA for Lung Cancer Treatment, Annual Meeting of the American Association of Pharmaceutical Scientists, November 8-12, 2009, Los Angeles, CA, R6409.

64. M. Zhang, O. Garbuzenko, L. Rodriguez, **T. Minko**, Targeted Combinatorial Treatment of Ovarian Cancer and Intraperitoneal Metastases, Annual Meeting of the American Association of Pharmaceutical Scientists, November 8-12, 2009, Los Angeles, CA, T2249.

65. L. Shehet, O. Garbuzenko, **T. Minko**, J. Kohn, Nanospheres-paclitaxel formulation as a potential anti-caner agent, Annual Meeting of the American Association of Pharmaceutical Scientists, November 8-12, 2009, Los Angeles, CA, T3373.

66. Z. Wang, G. Mainelis, O. Taratula, O. Garbuzenko, **T. Minko**, Anticancer drug pulmonary delivery by mesoporous silica nanoparticles, The 28th Annual Meeting of the American Association for Aerosol Research, October 26-30, 2009, Minneapolis, MN, #1192.

67. O. Garbuzenko, M. Saad, M. Zhang, E. Ber, A. A. Vetcher, V. A. Soldatenkov, D. Reimer, **T. Minko**, Intratracheal versus intravenous delivery of doxorubicin, antisense oligonucleotides and siRNA for efficient treatment of lung cancer, The 2009 Annual Retreat on Cancer Research in New Jersey, May 27, 2009, Piscataway, NJ, P67, p.75.

68. O. Taratula, O. B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Salva, V. P. Pozharov, H. He, **T. Minko**, Surface-engineered targeted siRNA-PPI dendrimer complexes for efficient intracellular and intratumoral delivery, The 2009 Annual Retreat on Cancer Research in New Jersey, May 27, 2009, Piscataway, NJ, P79, p.81.

69. M. Zhang, M. L. Patil, O. Taratula, H. He, **T. Minko**, Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery, The 2009 Annual Retreat on Cancer Research in New Jersey, May 27, 2009, Piscataway, NJ, P82, p.83.

70. **T. Minko**, Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges, AAPS Workshop on Evolving Science and Technology in Physical Pharmacy and Biopharmaceutics, May 13-15, 2009, Baltimore, MD.

71. O. B. Garbuzenko, **T. Minko**, Distribution and retention of anticancer drug, antisense oligonucleotides and siRNA after their systemic and local liposomal delivery, The International Nanotechnology Conference, March 30-31, 2009, Jerusalem, Israel.

72. S. Seshadri, T. Han, O. Garbuzenko, **T. Minko**, G. Mainelis, Comparison of different aerosolization methods used for inhalation delivery of liposomal drugs in exposure chambers, The 27th Annual Meeting of the American Association for Aerosol Research, October 20-24, 2008, Orlando, Florida, 3F.02.

73. S. Betigeri, M. Zhang, O. Garbuzenko, **T. Minko**, Non-viral nanoscale-based delivery of antisense oligonucleotides and small interfering RNA targeted to JNK1 for remediation of cellular hypoxic damage, Annual Meeting of the American Association of Pharmaceutical Scientists, November 16-20, 2008, Atlanta, GA, W4031.

74. M. Saad, O. B. Garbuzenko, E. Ber, P. Chandna, J. J. Khandare, V. P. Pozharov, **T. Minko**, Receptor-targeted nanocarriers for tumor-specific treatment and imaging, Annual Meeting of the American Association of Pharmaceutical Scientists, November 16-20, 2008, Atlanta, GA, W4109.

75. M. Zhang, M. L. Patil, S. Betigeri, O. Taratula, H. He, **T. Minko**, Efficient siRNA delivery systems for cancer therapy: Internally quaternized PAMAM-OH dendrimers, Annual Meeting of the American Association of Pharmaceutical Scientists, November 16-20, 2008, Atlanta, GA, W4059.

76. O. Garbuzenko, M. Saad, , M. Zhang, E. Ber, A. A. Vetcher, V. A. Soldatenkov, D. Reimer, **T. Minko**, Intratracheal versus intravenous delivery of doxorubicin, antisense oligonucleotides and siRNA for efficient treatment of lung cancer, Annual Meeting of the American Association of Pharmaceutical Scientists, November 16-20, 2008, Atlanta, GA, T3106.

77. P. Chandna, M. Saad, M. Zhang, O. Garbuzenko, E. Ber, J. J. Khandare, **T. Minko**, Design, synthesis and evaluation of a novel targeted proapoptotic anticancer drug delivery system for the treatment of different stages of ovarian cancer, Annual Meeting of the American Association of Pharmaceutical Scientists, November 16-20, 2008, Atlanta, GA, W4095.

78. M. Zhang, M. L. Patil, S. Betigeri, O. Taratula, H. He, **T. Minko**, Internally quaternized PAMAM-OH dendrimers as efficient siRNA delivery systems for cancer therapy, The 9th New Jersey Symposium on Biomaterials Science and Regenerative Medicine, October 29-31, 2008, New Brunswick, NJ, #19.

79. O. Garbuzenko, M. Saad, E. Ber, M. Zhang, **T. Minko**, Intratracheal versus intravenous delivery of liposomal Doxorubicin, Antisense oligonucleotides and siRNA for lung cancer treatment, The 9th New Jersey Symposium on Biomaterials Science and Regenerative Medicine, October 29-31, 2008, New Brunswick, NJ, #18.

80. O. Taratula, R. Savla, I. Pandya, A. Wang, **T. Minko**, H. He, Targeted co-delivery of nanoheaters and siRNAs for efficient cancer therapy, 40th Middle Atlantic Regional Meeting (MARM 2008) of the American Chemical Society, May 17-21. Bayside, Queens, NY.

81. O. Taratula, P. Kirkpatrick, R. Savla, I. Pandya, **T. Minko**, H. He, Layer-by-layer surface engineering approach for in vivo targeting delivery of siRNA, 40th Middle Atlantic Regional Meeting (MARM 2008) of the American Chemical Society, May 17-21. Bayside, Queens, NY.

82. O. Taratula, P. Kirkpatrick, R. Salva, I. Pandya, **T. Minko**, H. He, Layer-by-layer surface engineering approach for in vivo targeting delivery of siRNA, ACS National Meeting August 17-21, 2008, Philadelphia, PA, Abstracts of Papers of the American Chemical Society, Volume: 236.

83. O. Taratula, R. Salva, I. Pandya, A. Wang, **T. Minko**, H. He, Novel SPIO nanoparticles for a multifunctional nanomedicine platform, ACS National Meeting August 17-21, 2008, Philadelphia, PA, Abstracts of Papers of the American Chemical Society, Volume: 236, Meeting Abstract: 70-COLL.

84. **T. Minko**, M. Zhang, M. Saad, O. B. Garbuzenko, M. L. Patil, Efficient Co-Delivery of siRNA/Antisense Oligonucleotides and Drug for Lung Cancer Treatment, 36th Annual Scientific Session of the New Jersey Thoracic Society, June 6, 2008, New Brunswick, NJ, p.4.

85. P. Chandna, M. Saad, Y. Wang, E. Ber, J. Khandare, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, A novel targeted proapoptotic anticancer drug delivery system, The Annual Retreat on Cancer Research in New Jersey, Piscataway, NJ, May 28, 2008, P71, p. 85.

86. M. Zhang, M. L. Patil, O. Taratula, H. He, **T. Minko**, Internally quaternized PAMAM-OH dendrimers as efficient siRNA delivery systems for cancer therapy: The effect of targeting moiety and degree of quaternization, The Annual Retreat on Cancer Research in New Jersey, Piscataway, NJ, May 28, 2008, P82, p.90.

87. M. L. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, **T. Minko**, Modified PAMAM dendrimer as efficient siRNA delivery system for cancer treatment, The effect of targeting moiety and degree of quaternization, The Annual Retreat on Cancer Research in New Jersey, Piscataway, NJ, May 28, 2008, P79, p. 89.

88. O. Garbuzenko, M. Saad, E. Ber, M. Zhang, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, Influence of size, charge, shape, and route of liposomes administration on their cellular uptake, tumor and organ distribution in mice, The Annual Retreat on Cancer Research in New Jersey, Piscataway, NJ, May 28, 2008, P72, p.85.

89. M. Saad, O. B. Garbuzenko, J. J. Khandare, Y. Wang, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, Noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research, The Annual Retreat on Cancer Research in New Jersey, Piscataway, NJ, May 28, 2008, E6, p.43.

90. O. Taratula, R.Salva, I. Pandya, H. Geng, A. Wang, **T. Minko**, H. He, Toward a multifunctional nanomedicine platform for efficient cancer therapy, The Annual Retreat on Cancer Research in New Jersey, Piscataway, NJ, May 28, 2008, P81, p.90.

91. O. Taratula, P. Kirkpatrick, R.Salva, I. Pandya, **T. Minko**, H. He, Toward in vivo targeted delivery of siRNA for efficient cancer therapy, The Annual Retreat on Cancer Research in New Jersey, Piscataway, NJ, May 28, 2008, E5, p.43.

92. **T. Minko**, Targeted multifunctional nanocarriers for tumor treatment and imaging, 2nd Annual Meeting "Toward the Development of Drug Delivery Systems", March 7-8, 2008, Perugia, Italy.

93. P. Chandna, M. Saad, Y. Wang, E. Ber, J. Khandare, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, A novel targeted proapoptotic anticancer drug delivery system, Annual Meeting of the American Association of Pharmaceutical Scientists, November 11-15, 2007, San Diego, CA, M1224.

94. O. Garbuzenko, M. Saad, E. Ber, M. Zhang, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, The influence of liposomal size on their uptake by cancer cells, tumor and organ distribution in mice bearing xenografts of human ovarian carcinoma, Annual Meeting of the American Association of Pharmaceutical Scientists, November 11-15, 2007, San Diego, CA, T3011.

95. M. Saad, O. B. Garbuzenko, J. J. Khandare, Y.Wang, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, Noninvasive In Vivo Bioluminescent and Fluorescent Optical Imaging in Cancer Research, Annual Meeting of the American Association of Pharmaceutical Scientists, November 11-15, 2007, San Diego, CA, T2038.

96. S. Betigeri, O. B. Garbuzenko, **T. Minko**, JNK1 as a molecular target to limit cellular damage under hypoxia, Annual Meeting of the American Association of Pharmaceutical Scientists, November 11-15, 2007, San Diego, CA, T3039.

97. S. Cai, **T. Minko**, D. Discher, Micelles in different morphologies: Advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery for lung cancer therapy, Annual Meeting of the American Association of Pharmaceutical Scientists, November 11-15, 2007, San Diego, CA, W4141.

98. **T. Minko**, S.Betigeri, E. Ber, P. Chandna, O. Garbuzenko, J. J. Khandare, R. I. Pakunlu, M. Saad, V. A. Soldatenkov, M. Zhang, A. A. Vetcher, Y. Wang, Targeted multicomponent nanocarriers for cancer treatment and diagnostics, The Fifth International Nanomedicine and Drug Delivery Symposium, November 2-3, 2007, Boston, MA.

99. **T. Minko**, S.Betigeri, E. Ber, P. Chandna, O. Garbuzenko, J. J. Khandare, M. Saad, V. A. Soldatenkov, M. Zhang, A. A. Vetcher, Targeted multicomponent nanocarriers in cancer treatment, The 6th Annual Meeting of the Israeli Chapter of the Controlled Release Society (ICRS), September 5-6, 2007, Caesarea, Israel, p. 16.

100. O. Garbuzenko, M. Saad, S.Betigeri, E. Ber, M. Zhang, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, The influence of size, charge, shape and route of liposomes administration on their cellular uptake, tumor and organs distribution in mice with subcutaneous and orthotopic models of ovarian and lung carcinomas, The 6th Annual Meeting of the Israeli Chapter of the Controlled Release Society (ICRS), September 5-6, 2007, Caesarea, Israel, p. 40.

101. **T. Minko**, O. B. Garbuzenko, M. Saad, Complex liposomal drug delivery system for inhalatory treatment of lung cancer, 35th Annual Scientific Session of the New Jersey Thoracic Society, June 1, 2007, New Brunswick, NJ, p. 5.

102. P. Chandna, M. Saad, Y. Wang, E. Ber, J. J. Khandare, A. A. Vetcher, V. A. Soldatenkov, **T. Minko**, A novel targeted proapoptotic anticancer drug delivery system, GRASP 2007, 27th Annual Meeting, New Brunswick, NJ, June 1-3, 2007, pp. 36-37.

103. M. Saad, J. J. Khandare, Y. Wang, **T. Minko**, Noninvasive in vivo bioluminescent and fluorescent optical imaging for cancer treatment and diagnostics, GRASP 2007, 27th Annual Meeting, New Brunswick, NJ, June 1-3, 2007, pp. 28-29.

104. O. Taratula, R. Salva, I. Pandya, A. Wang, **T. Minko**, H. He, Multifunctional siRNA delivery system for cancer therapy, GRASP 2007, 27th Annual Meeting, New Brunswick, NJ, June 1-3, 2007, pp. 33-34.

105. S. Betigeri, O. B. Garbuzenko, **T. Minko**, Efficient liposomal delivery of antisense oligonucleotides and small interfering RNA targeted to JNK1 for limiting cellular hypoxic damage, GRASP 2007, 27th Annual Meeting, New Brunswick, NJ, June 1-3, 2007, pp. 39-40.

106. Y. Wang, M. Saad, J. J. Khandare, **T. Minko**, In vitro and in vivo evaluation of hypoxia inducible factor antisense oligonucleotides as an enhancer of antitumor activity, GRASP 2007, 27th Annual Meeting, New Brunswick, NJ, June 1-3, 2007, p. 53.

107. **T. Minko**, J. J. Khandare, R. I. Pakunlu, P. Chandna, M. S. Saad, Y. Wang, LHRH-receptor targeting of polymer therapeutics and imaging agents to tumor, International Symposium on Polymer Therapeutics, February 19-21, 2007, Berlin, Germany.

108. P. Chandna, J. J. Khandare, Y. Wang, **T. Minko**, Multivalent targeted polymeric prodrug for cancer therapy, Annual Meeting of the American Association of Pharmaceutical Scientists, October 29-November 2, 2006, San Antonio, TX, T2087.

109. R. I. Pakunlu, J. J. Khandare, **T. Minko**, Modulation of pump and nonpump cellular resistance in cancer by liposomal antisense oligonucleotides, Annual Meeting of the American Association of Pharmaceutical Scientists, October 29-November 2, 2006, San Antonio, TX, W4028.

110. J. J. Khandare, Y. Wang, S. Jayant, A. Singh, P. Chandna, N. Vorsa, **T. Minko**, Dendrimers versus peg polymers: influence of polymer architecture in delivery of paclitaxel for cancer, Annual Meeting of the American Association of Pharmaceutical Scientists, October 29-November 2, 2006, San Antonio, TX, T2089.

111. S. Jayant, J. J. Khandare, **T. Minko**, Molecular modeling studies of anticancer prodrugs, Annual Meeting of the American Association of Pharmaceutical Scientists, October 29-November 2, 2006, San Antonio, TX, W5100.

112. M. Saad, J. J. Khandare, Y. Wang, R. I. Pakunlu, **T. Minko**, Targeted delivery of near-infrared cyanine dye enhances cancer imaging, Annual Meeting of the American Association of Pharmaceutical Scientists, October 29-November 2, 2006, San Antonio, TX, T3141.

113. M. Saad, J. J. Khandare, Y. Wang, **T. Minko**, Targeted nanocarier-based delivery of near-infrared cyanine dye enhances tumor imaging, The Fourth Nanomedicine and Drug Delivery Symposium, October 8-10, 2006, Omaha, NE, p.135.

114. S. Cai, Y. Geng, **T. Minko**, D. E. Discher, Poly(ethylene-oxide)-based worm-like micelles as potential nanocarriers for delivery of paclitaxel and short antigenic peptides. The Fourth Nanomedicine and Drug Delivery Symposium, October 8-10, 2006, Omaha, NE, p. 85.

115. **T. Minko**, R. I. Pakunlu, Y. Wang, Molecular targeting of drug delivery system to lung cancer, 34th Annual Scientific Session of New Jersey Thoracic Society, June 2, 2006, New Brunswick, NJ, p.10.

116. **T. Minko**, Advanced targeted drug delivery systems for cancer therapy, International Conference on Advances in Pharmaceutical Research and Technology, Mumbai, India, November 25-29, 2005, p. 39-40.

117. S. Dharap, P. Chandna, Y. Wang, B. Qiu, S. Gunaseeian, P. Sinko, S. Stein, **T. Minko**, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide, Annual Meeting of the American Association of Pharmaceutical Scientists, November 6-10, 2005, Nashville, TN, #T2080.

118. R. Pakunlu, J. Khandare, **T. Minko**, Suppression of tumor cellular resistance by liposomal antisense oligonucleotides, Annual Meeting of the American Association of Pharmaceutical Scientists, November 6-10, 2005, Nashville, TN, #T3120.

119. S. Betigeri, R. I. Pakunlu, Y. Wang, **T. Minko**, Remediation of cellular hypoxic damage by antisense oligonucleotides and small interfering RNA Targeted to JNK1, Annual Meeting of the American Association of Pharmaceutical Scientists, November 6-10, 2005, Nashville, TN, #T3047.

120. J. Khandare, **T. Minko**, Polyamidoamine (PAMAM) G4- hydroxyl dendrimer – paclitaxel nanoconjugates for cancer therapeutics, Annual Meeting of the American Association of Pharmaceutical Scientists, November 6-10, 2005, Nashville, TN, #T2144.

121. Y. Wang, J. Khandare, **T. Minko**, Hypoxia Inducible factor – targeted polymeric prodrug, Annual Meeting of the American Association of Pharmaceutical Scientists, November 6-10, 2005, Nashville, TN, #T3047.

122. P. Chandna, J. Khandare, T. Minko, Design, synthesis and evaluation of targeted multicomponent pegylated anticancer drug delivery system, Annual Meeting of the American Association of Pharmaceutical Scientists, November 6-10, 2005, Nashville, TN, #T2138.

123. F. Ahmed, R. I. Pakunlu, G. Srinivas, M. L. Klein, **T. Minko**, D. E. Discher, Degradable polymersomes that create new pathways for anti-cancer drugs, The 2005 Annual Meeting of American Institute of Chemical Engineers (AIChE), October 30-November 4, 2005, Cincinnati, OH, #489a.

124. **T. Minko**, S. Betigeri, R. I. Pakunlu, Y. Wang, Delivery system for remediation of cellular hypoxic damage, Third International Nanomedicine and Drug Delivery Symposium, Baltimore, MD, September 26-27, 2005.

125. S. Betigeri, R. I. Pakunlu, **T. Minko**, JNK1 as a molecular target to decrease cellular mortality under hypoxia, The 25th Anniversary Conference, GRASP 2005, New York, NY, June 10-12, 2005.

126. P. Chandna, J. J. Khandare, **T. Minko**, Design, synthesis and evaluation of targeted multicomponent pegylated anticancer drug delivery system, The 25th Anniversary Conference, GRASP 2005, New York, NY, June 10-12, 2005.

127. R. I. Pakunlu, J. J. Khandare, **T. Minko**, Modulation of pump and nonpump cellular resistance by liposomal antisense oligonucleotides, The 25th Anniversary Conference, GRASP 2005, New York, NY, June 10-12, 2005.

128. Y. Wang, J. J. Khandare, **T. Minko**, Inhibition of hypoxia-inducible factor increases the efficacy of cancer chemotherapy, The 25th Anniversary Conference, GRASP 2005, New York, NY, June 10-12, 2005.

129. R. I. Pakunlu, **T. Minko**, Modulation of pump and nonpump cellular resistance in cancer, 2005 Annual Retreat on Cancer Research in New Jersey, April 27, 2005, Princeton, NJ, P86, p. 83.

130. Y. Wang, J. J. Khandare, **T. Minko**, 2005 Annual Retreat on Cancer Research in New Jersey, April 27, 2005, Princeton, NJ, P87, p. 84.

131. O. Appenzeller, **T. Minko**, C. Qualls, V. Pozharov, J. Gamboa, A. Gamboa, R. I. Pakunlu, Cytoprotection in chronic hypoxia in the Andes; lessons for neurology at sea level. Neurology, 65 A66 Suppl.1, 2005.

132. O. Appenzeller, **T. Minko**, C. Qualls, V. Pozharov, J. Gamboa, A. Gamboa, Y. Wang, An experiment of nature relevant to ANS function and disease? Neurology, 65 A169 Suppl.1, 2005.

133. O. Appenzeller, **T. Minko**, V. Pozharov, C. Qualls, J. Gamboa, A. Gamboa, Lessons for headache at sea level? In: High Altitude Medicine & Biology, Abstracts of the 14th International Hypoxia Symposium, February 22-27, 2005, Chateau Lake Louise, Alberta, Canada, December 2004, Vol. 5, No. 4: 510-512.

134. R. I. Pakunlu, Y. Wang, **T. Minko**, A novel multicomponent delivery system to enhance the efficacy of lung cancer chemotherapy, Ann. Meeting of the American Association of Pharmaceutical Scientists, November 7-11, 2004, Baltimore, MD, #T2241.

135. Y. Wang, R. I. Pakunlu, **T. Minko**, A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug, Ann. Meeting of the American Association of Pharmaceutical Scientists, November 7-11, 2004, Baltimore, MD, #T3085.

136. S. S. Dharap, S. Gunaseelan, B. Qiu, S. Stein, P. J. Sinko, **T. Minko**, Development of a multicomponent/four tier, targeted, anticancer drug delivery system, Ann. Meeting of the American Association of Pharmaceutical Scientists, November 7-11, 2004, Baltimore, MD, #T2066.

137. A. Lalloo, P. Chao. P. Hu, S-H. Lee, **T. Minko**, S. Stein, P. Sinko, Pharmacokinetics and pharmacodynamic evaluation of topotecan from a novel subcutaneously administered in situ forming hydrogel, Ann. Meeting of the American Association of Pharmaceutical Scientists, November 7-11, 2004, Baltimore, MD, #T2150.

138. **T. Minko**, Extracellular and Intracellular Molecular Targeting of Drug Delivery System to Cancer Cells, World Conference on Dosing of Antiinfectivnes – Dosing the Magic Bullets, September 9-11, 2004, Nurnberg, Germany, #336, p. A-85.

139. Y. Wang, **T. Minko**, Potential use of the combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and doxorubicin as a novel anticancer therapy, 2004 AAPS Pharmaceutics and Drug Delivery Conference, June 7-9, 2004, Philadelphia, PA, #2003, p.66-67.

140. S. S. Dharap, S. Gunaseelan, S. Stein, P. J. Sinko, **T. Minko**, Site specific anticancer therapy via a four tier drug delivery system, 2004 AAPS Pharmaceutics and Drug Delivery Conference, June 7-9, 2004, Philadelphia, PA, #2005, p.67-68.

141. **T. Minko**, R. I. Pakunlu, A novel multicomponent delivery system to enhance the efficacy of lung cancer therapy, 32nd Annual Scientific Section of the New Jersey Thoracic Society, June 4, 2004, New Brunswick, NJ, #12.

142. R. I. Pakunlu, Y. Wang, **T. Minko**, Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: Novel multicomponent delivery system, 24th Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), June 4-6, 2004, Atlanta, GA, #5.

143. Y. Wang, R. I. Pakunlu, **T. Minko**, Potential use of the combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and doxorubicin as a novel anticancer therapy, 24th Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), June 4-6, 2004, Atlanta, GA, #4.

144. S. S. Dharap, S. Gunaseelan, S. Stein, P. J. Sinko, **T. Minko**, Site specific anticancer therapy via a four tier drug delivery system, 24th Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), June 4-6, 2004, Atlanta, GA, #37.

145. Y. Wang, R. I Pakunlu, W. Tsao, **T. Minko**, Bimodal effect of hypoxia in cancer: the role of hypoxia inducible factor, Philadelphia Pharmaceutical Forum 2004, March 11, Philadelphia, PA, p.27.

146. Y. Wang, **T. Minko**, Bimodal effect of hypoxia in cancer: the role of hypoxia inducible factor, 2003 Annual Meeting of the Division of Bio/Pharmaceutical Sciences Society of Chinese Bioscientists in America, November 8-9, 2003, Piscataway, NJ, p. 23.

147. S. Jin, A. S. Mathis, K. Gioia, **T. Minko**, G. S. Friedman, J. Rosenblatt, F. Feng, G. T. Knipp, The effect of sirolimus in combination with cyclosporine on the expression of macrophage scavenger and nuclear hormone receptors in THP-1 derived human macrophages, 2003 Annual Meeting of the Division of Bio/Pharmaceutical Sciences Society of Chinese Bioscientists in America, November 8-9, 2003, Piscataway, NJ, p. 8.

148. S. Jin, A. S. Mathis, K. Gioia, **T. Minko**, G. S. Friedman, F. Feng, G. T. Knipp, The effects of sirolimus on macrophage scavenger receptors and nuclear receptors in atherosclerosis, 2003 Annual Meeting of the Division of Bio/Pharmaceutical Sciences Society of Chinese Bioscientists in America, November 8-9, 2003, Piscataway, NJ, p. 10.

149. S. Jin, G. T. Knipp, K. Gioia, **T. Minko**, G. S. Friedman, J. Rosenblatt, F. Feng, D. S. Serur, A. S. Mathis, The effect of sirolimus-tacrolimus combination on the expression of macrophage scavenger and nuclear hormone receptors in THP-1 derived human macrophages, 2003 Annual Meeting of the Division of Bio/Pharmaceutical Sciences Society of Chinese Bioscientists in America, November 8-9, 2003, Piscataway, N J, p.12.

150. **T. Minko**, Molecular targeting of cellular resistance in cancer, 8th World Congress on Advances in Oncology and 6th International Symposium on Molecular Medicine, October 16-18, 2003, Hersonissos, Crete, Greece, Int. J. Mol. Med., 12, Sup. 1, S11, #127 (2003).

151. S. S. Dharap, B. Qiu, S. Stein, P. J. Sinko, **T. Minko**, Molecular targeting of proapoptotic drug delivery systems to cancer by BH3 and LHRH peptides, Ann. Meeting of the American Association of Pharmaceutical Scientists, October 26-30, 2003, Salt Lake City, UT, #W5053.

152. R. I. Pakunlu, T. J. Cook, **T. Minko**, Novel anticancer drug delivery system for molecular targeting of pump and non-pump cellular resistance, Ann. Meeting of the American Association of Pharmaceutical Scientists, October 26-30, 2003, Salt Lake City, UT, #T2163.

153. Y. Wang, **T. Minko**, Combining hypoxia with chemotherapy in cancer cell treatment - effects on chemo-resistance and cell death, Ann. Meeting of the American Association of Pharmaceutical Scientists, October 26-30, 2003, Salt Lake City, UT, #W5080.

154. S. Jin, S. A. Mattis, **T. Minko**, G. T. Knipp, The effects of sirolimus on macrophage scavenger receptors and nuclear receptors in atherosclerosis, Ann. Meeting of the American Association of Pharmaceutical Scientists, October 26-30, 2003, Salt Lake City, UT, #W4077.

155. S. Jin, S. A. Mattis, **T. Minko**, G. T. Knipp, The effect of sirolimus in combination with cyslosporine on the expression of macrophage scavenger and nuclear hormone receptors in THP-1 derived human macrophages, October 26-30, 2003, Salt Lake City, UT, #W4078.

156. S. Jin, S. A. Mattis, **T. Minko**, G. T. Knipp, The effect of sirolimus in combination with tacrolimus on the expression of macrophage scavenger and nuclear hormone receptors in TH-1 derived human macrophages, October 26-30, 2003, Salt Lake City, UT, #4079.

157. **T. Minko**, P. J. Sinko, T. J. Cook, S. Stein, S. S. Dharap, R. I. Pakunlu, B. Qiu, Molecular targeting of pump and nonpump cellular resistance in cancer, The 2003 Annual Retreat on Cancer Research in New Jersey, June 11, 2003, Princeton, NJ, p. 59.

158. S. S. Dharap, B. Qiu, S. Stein, P. J. Sinko, **T. Minko**, Molecular targeting of drug delivery systems to cancer cells by BH3 and LHRH peptides, 23rd Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), May 30 - June 1, 2003, Richmond, VA, p. 20.

159. R. I. Pakunlu, T. J. Cook, **T. Minko**, Combination of BCL-2 and MDR1/MRP antisense oligonucleotides and doxorubicin – potential use in cancer therapy, 23rd Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), May 30 - June 1, 2003, Richmond, VA, p. 77.

160. Y. Wang, R. Won, S. Jin, A. S. Mathis, G. T. Knipp, G. S. Friedman, **T. Minko**, The effect of cyclosporine A and tacrolimus on the apoptosis induction and gene expression in human macrophages, 23rd Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), May 30 - June 1, 2003, Richmond, VA, p. 82.

161. S. S. Dharap, B. Qiu, S. Stein, P. Sinko, **T. Minko**, Targeted Proapoptotic Anticancer Drug Delivery Systems, Philadelphia Pharmaceutical Forum 2003, March 13th, Philadelphia, PA, p. 15.

162. R. I. Pakunlu, T. J. Cook, **T. Minko**, Molecular Targeting of Cellular Resistance in Cancer by Antisense Oligonucleotides, Philadelphia Pharmaceutical Forum 2003, March 13th, Philadelphia, PA, p.14.

163. Y. Wang, R. Won, S. Jin, A. S. Mathis, G. T. Knipp, G. S. Friedman, **T. Minko**, Influence of Immunosuppressors on Apoptosis in Human Macrophages, Philadelphia Pharmaceutical Forum 2003, March 13th , Philadelphia, PA, p. 11.

164. **T. Minko**, P. J. Sinko, T. J. Cook, S. Stein, S. S. Dharap, R. I. Pakunlu, B. Qiu, Novel Targeted Drug Delivery Systems Combining Anticancer Drug, Targeting Moiety and Suppressors of Multidrug Resistance and Antiapoptotic Cellular Defense, CRS Winter Symposia & 11th International Symposium on Recent Advances in Drug Delivery Systems, March 3-6, 2003, Salt Lake City, UT, #015.

165. **T. Minko**, P. J. Sinko, T. J. Cook, S. Stein, S. S. Dharap, R. I. Pakunlu, B. Qiu, Molecular targeting of drug delivery systems to cancer cells by peptides and antisense oligonucleotides, 2nd International Congress "Molecular Biopharmaceutics: A New Era in Drug Absorption, Transport and Delivery", January 22-24, 2003, Honolulu, HI, p. 98.

166. P. J. Sinko, S. Stein, **T. Minko**, M. Leibowitz, Targeted macromolecular drug conjugates for enhanced cellular uptake, disposition and activity, 2nd International Congress "Molecular Biopharmaceutics: A New Era in Drug Absorption, Transport and Delivery", January 22-24, 2003, Honolulu, HI, p. 26.

167. S. S. Dharap, **T. Minko**, Molecular Targeting of Ovarian Carcinoma Cells Using BH3 and LHRH Peptides Enhances the Efficacy of Chemotherapy, Ann. Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2002, Toronto, Canada, 2002, W 4054.

168. R. I. Pakunlu, T. J. Cook, **T. Minko**, Simultaneous Modulation of Multidrug Resistance and Antiapoptotic Cellular Defense Using a Combination Drug Delivery System Containing MDR1 and BCL-2 Targeted Antisense Oligonucleotides, Ann. Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2002, Toronto, Canada, 2002, W 5047.

169. Y. Wang**,** R. Won, S. Jin, S. Mathis, G. T. Knipp, G. S. Friedman, **T. Minko**, Bimodal Effect of Immunosuppressors on Apoptosis in Human Macrophages, Ann. Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2002, Toronto, Canada, 2002, T 2142.

170. P. V. Paranjpe, **T. Minko**, B. Qiu, R. Won, A. Lalloo, S. Stein, P. J. Sinko, Enhancing the anticancer efficacy of camptothecin using poly(ethylene glycol) conjugates in human ovarian carcinoma cells, Ann. Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2002, Toronto, Canada, 2002, R. 6109.

171. S. Jin, A. S. Mathis, J. Rosenblatt, **T. Minko**, G. S. Friedman, K. Gioia, G. T. Knipp, Additional investigations into the effect of cyclosporine on macrophage scavenger receptors regulation associated with atherosclerotic risk, Ann. Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2002, Toronto, Canada, W 4066.

172. S. Jin, A. S. Mathis, **T. Minko**, G. S. Friedman, K. Gioia, J. Rosenblatt, G. T. Knipp, Insights into tacrolimus induced atherosclerotic risk in transplant recipients: macrophage scavenger receptor regulation, Ann. Meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2002, Toronto, Canada, T 2143.

173. **T. Minko**, P. J. Sinko, T. J. Cook, S. Stein, Targeted proapoptotic drug delivery systems in cancer chemotherapy, 7th World Congress on Advances in Oncology and 5th International Symposium on Molecular Medicine, October 10-12, 2002, Hersonissos, Crete, Greece, Int. J. Mol. Med., 10, Sup. 1, S10, #124 (2002).

174. O. Appenzeller, **T. Minko**, V. Pozharov, M. Bonfichi, L. Malcovati, L. Bernardi, L. J. Gamboa, Gene expression in the Andes & autonomics at sea level, 13th International Symposium On The Autonomic Nervous System, Hilton Head Island, SC, October 24-27, 2002.

175. S. S. Dharap, **T. Minko**, Synthetic BCL-2 homology 3 domain (BH3) peptide enhances proapoptotic activity of anticancer drug doxorubicin, Philadelphia Pharmaceutical Forum 2002, March 14, Philadelphia, PA, p. 3, 2002.

176. R. I. Pakunlu, Y. Wang, T. J. Cook, **T. Minko**, Suppression of multidrug resistance and antiapoptotic cellular defense using MDR1- and BCL-2 targeted antisense oligonucleotides and anticancer drug combination, Philadelphia Pharmaceutical Forum 2002, March 14, Philadelphia, PA, p. 5, 2002.

177. **T. Minko**, S. S. Dharap, Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense, 6th International Symposium "Predictive Oncology and Intervention

Strategies", 2002, February 9-12, Pasteur Institute, Paris, France, Cancer Detect. Prevent., 26, S92, 2002.

178. S. S. Dharap, A. T. Fabbricatore, **T. Minko**, Synthetic BCL-2 homology 3 domain (BH3) peptide enhances proapoptotic activity of doxorubicin, Rutgers Pharmaceutics Conference 2001 "Current and future issues in dermal drug delivery and pharmaceutics", East Brunswick, NJ, November 9, 2001.

179. **T. Minko**, Advanced drug delivery systems in cancer chemotherapy, Rutgers Pharmaceutics Conference 2001 "Current and future issues in dermal drug delivery and pharmaceutics", East Brunswick, NJ, November 9, 2001.

180. S. Jin, J. Rosenblatt, S. Mathis, G. Friedman, **T. Minko**, G. Knipp, Immunosuppressive agents and arteriosclerosis risk factors, Ann. Meeting of the American Association of Pharmaceutical Scientists, October, 2001, Denver, CO, AAPS PharmSci., 2001.

181. **T. Minko**, P. Kopeckova, J. Kopecek, Caspases-Dependent Apoptosis Signaling Pathways of Free and Polymer-Bound Doxorubicin in Human Ovarian Carcinoma, Keystone Symposium "Molecular Mechanisms of Apoptosis", Keystone, CO, January 16-22, 2001, p. 112.

182. **T. Minko**, P. Kopeckova, J. Kopecek, Caspases and Their Role in Signaling Pathways of Apoptosis Induced by Free and Polymer-Bound Doxorubicin, Ann. Meeting of the American Association of Pharmaceutical Scientists, October 29-November 2, 2000, Indianapolis, Indiana, AAPS PharmSci. 2, 2000, Abstract # 4112.

183. **T. Minko**, P. Kopeckova, J. Kopecek, Antitumor activity and apoptosis signaling pathways of HPMA copolymer-bound doxorubicin, Int. Symposium on Tumor Targeted Delivery Systems, National Institute of Health, Bethesda, MD, September 25-27, 2000, p. 14.

184. Y. Kasuya, Z.R. Lu, P. Kopeckova, **T. Minko**, S. E. Tabibi, J. Kopecek, Synthesis of HPMA copolymer-bound aminopropylgeldanamycin, Int. Symposium on Tumor Targeted Delivery Systems, National Institute of Health, Bethesda, MD, September 25-27, , 2000, p. 17.

185. W. K. Nichols, **T. Minko**, F. T. Lauer, S. W. Burchiel and G. S. Yost, Bioactivated 3-methylyindole (3MI) induces apoptosis in human lung cells, 18th Annual Meeting of Mountain West Chapter of Society of Toxicology, Snowbird, CO, September 2000.

186. **T. Minko**, P. Kopeckova, J. Kopecek, Mechanism of anticancer action of HPMA copolymer-bound doxorubicin, 40th Microsymposium "Polymers in Medicine", Czech Republic, 2000, Special Lecture #4.

187. P. Kopeckova, **T. Minko**, K. Jensen, J. Kopecek, The influence of cytotoxicity of macromolecules on the EPR effect in resistant solid tumor, 4th International Symposium on Polymer Therapeutics: from Laboratory to Clinical Practice, London, UK, 2000, p.53.

188. **T. Minko**, P. Kopeckova, J. Kopecek, Cell death signaling pathways and antitumor activity of HPMA copolymer-bound adriamycin, American Association of Pharmaceutical Scientists Annual Meeteng, New Orleans, LA, 1999, Abstract # 3265, S-436.

189. M. Demoy, **T. Minko**, P. Kopeckova, J. Kopecek, Time and concentration dependent apoptosis induced by free and HPMA copolymer-bound adriamycin, American Association of Pharmaceutical Scientists Annual Meeteng, New Orleans, LA, 1999, Abstract # 3264, S-436.

190. J. Kopecek, P. Kopeckova, **T. Minko**, Mechanism of action of HPMA copolymer-bound anticancer drugs, Biosurf III/Annual Meeting of the Swiss Biomaterials Society, Zurich, Switzerland, 1999, p.13.

191. **T. Minko**, P. Kopeckova, J. Kopecek, Cell death signaling pathways, toxicity and antitumor activity of free and polymer-bound doxorubucin, "Molecular Genetics in Toxicology", 17th Annual Meeting of Mountain West Chapter of Society of Toxicology, Breckenridge, CO, 1999, Abstract #4

192. **T. Minko**, P. Kopeckova, J. Kopecek, Peculiarities of signaling in apoptosis induced by free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells, Keystone Symposia on Molecular and Cellular Biology, Breckenridge, CO, 1999, p.63.

193. **T. Minko**, P Kopeckova, V. Pozharov, V. Omelyanenko, J. Kopecek, HPMA copolymer bound adriamicyn does not induce multidrug resistance in a human ovarian cacinoma cell line, 89th annual Meeting of American Association for Cancer Research, 1998, New Orleans, LA, p.73.

194. **T. Minko**, P. Kopeckova, V. Pozharov, J. Kopecek, Free and HPMA copolymer bound adriamycin differ in the mechanism of multidrug resistance induction in a human ovarian carcinoma cell line, 3rd International Symposium on Polymer Therapeutics: from Laboratory to Clinical Practice, London, UK, 1998, p. 54.

195. F. Meerson, V. Pozharov, **T. Minko**. Role of heat shock proteins and phenomenon of adaptive stabilization of structures (PhASS) in the protection of DNA against ischemic and mutagenic damages. Physiotherapeutic induction of PhASS, 5th Congress of International Society for Adaptive Medicine, Boston, MA, 1997, p. 2.

196. V. Pozharov, T. Minyailenko **(Minko)**, O. Appenzeller, A. Stefanov, Hypoxic hypoxia in rats: Circulating and tissue levels of endothelin: Effects of exogenous phospholipids ("Lipin"), 10 th International Hypoxia Symposium, Lake Louise, Canada, 1995, p.91.

197. V. Pozharov, T. Minyailenko **(Minko)**, O. Appenzeller, Hypoxic hypoxia in rats: Circulating and tissue levels of endothelin, 10th International Hypoxia Symposium, Lake Louise, Canada, 1995, p.90.

198. V. Pozharov, T. Minyailenko **(Minko)**, F. Meerson, Comparative estimation of antihypoxic effects of adaptation to stress and to high altitude, III World Congress of ISAM , Tokyo, Japan, 1993, p. 84.

199. T. Minyailenko **(Minko)**, V. Pozharov, V. Bystrjukov, F. Meerson, Mechanisms of the increase in the work load after preliminary adaptation to intermittent hypoxia and training, III World Congress of ISAM , Tokyo, Japan, 1993, p. 76.

200. F. Z. Meerson, T.D. Minyailenko **(Minko)**, V. P. Pozharov, Superresistance to hypoxic hypoxia in animals adapted to stress exposure, III World Congress of ISAM, Tokyo, Japan, 1993, p. 72.

201. Stefanov, V. Pozharov, T. Minyailenko **(Minko)**, Towards a new way of treating hypoxia, 8th International Hypoxia Symposium, Lake Louise, Canada, 1993, p. 18.

202. T. Minyailenko **(Minko)**, O. Ezhova, Changes in lung phospholipid pattern and compliance during acute severe hypoxia, 8th International Hypoxia Symposium, Lake Louise, Canada, 1993, p. 18.

203. V. Pozharov, T. Minyailenko **(Minko)**, Towards a new way to elevate the resistance against damaging environmental impacts, 1st American – Ukrainian Workshop "Health Care: Clinical and Basic Research", Kiev, Ukraine, 1993, p. 4.

204. V. P. Pozharov, T. D. Minyailenko **(Minko)**, O. A. Ezhova, V. R. Tyutyunnik, A. V. Stefanov, Usage of exogenous phospholipids as liposomes for the protection of heart against hypoxic damage, Physiology and pathophysiology of heart and coronary blood flow, Kiev, Ukraine, 1992, pp. 131-132.

205. Z. A. Serebrovskaya, T. D. Minyailenko **(Minko)**, Influence of hypoxic training on parameters of serum chemolumeniscence and other hematological indices in human, Actual Aspects of Physiology, Kiev, Ukraine, 1992, pp. 34-35.

206. A.V. Stefanov, V. P. Pozharov, T. D. Minyailenko **(Minko)**, A.V. Zubarenko, Usage of exogenous phospholipids for the prevention and treatment of hypoxic tissue damage, 2nd International. Symposium. on Hypoxia, Berlin, Germany, 1991, pp. 75-75a.

207. T. D. Minyailenko **(Minko)**, V. P. Pozharov, M. M. Seredenko, Oxygen supply-consumption ration as the criterion of tissue hypoxia, 2nd International. Symposium on Hypoxia, Berlin, Germany, 1991, pp. 23-23a.

208. A.V. Stefanov, V.P. Pozharov, T.D. Minyailenko **(Minko)**, Correction of severe hypoxia and stress by liposomes, 7th International Hypoxia Symposium, Lake Louise, Canada, 1991, p. 34.

209. T. D. Minyailenko **(Minko)**, Hypoxic acid-base changes, lipid peroxidation and oxygen supply-consumption ratio, 7th International Hypoxia Symposium, Lake Louise, Canada, 1991, p. 47.

210. T. D. Minyailenko **(Minko)**, V. A. Bistryukov, Adaptation to high altitude limits tissue hypoxia and lipid peroxidation under severe acute environmental hypoxia, International Congress of Mountain Medicine, Crans-Montana, Switzerland, 1991, p. 32.

211. V. Pozharov, T. Minyailenko **(Minko)**, O. Ezhova, V. Bystrjukov, A. Sidorenko, Changes in the respiratory sensitivity to carbon dioxide under severe hypoxia, 4th International Symposium on High-Altitude Medicine Science, Matsumoto, Japan 1991, p. 20.

212. T. Minyailenko **(Minko)**, V. Pozharov, V. Bystrjukov, O. Ezhova, Adaptation to moderate stress increases the resistance to severe hypoxia, 4th International Symposium on High-Altitude Medicine Science, Matsumoto, Japan, 1991, p. 33.

213. T. Serebrovskaya, G. Afonina, Z. Serebrovskaya, T. Minyailenko **(Minko)**, Effect of hypoxic training on human respiration, free radical process and immunity, 4th International Symposium on High-Altitude Medicine Science, Matsumoto, Japan, 1991, p. 20.

214. M. Seredenko, V. Pozharov, T. Minyailenko **(Minko)**, V. Bystrjukov, Energy metabolism and fatigue, Muscle fatigue: Biochemical and Physiological Aspects, Paris, France, 1991, p. 248.

215. T.D. Minyailenko **(Minko)**, Interrelation of lipid peroxidation and tissue hypoxia under hypoxic states of different genesis, Constituent Congress of International Society for Pathophysiology, Moscow, Russia, 1991, pp. 314-315.

216. V. P. Pozharov, T.D. Minyailenko **(Minko)**, V. A. Bystrjukov, V.R. Tyutyunnik, Peculiarities of adaptation to exercise in rats with different types of breathing pattern, Constituent Congress of International Society for Pathophysiology, Moscow, Russia, 1991, p. 243.

217. T.D. Minyailenko **(Minko)**, O. A. Ezhova, Role of lipid peroxidation, changes in organs phospholipid composition and free fatty acids acculation in the development of secondary tissue hypoxia, Pharmacological Correction of Hypoxic States, Grodno, Belorussia, 1991, pp. 449-450.

218. O. V. Melnik, I. L. Babij, A. V. Zubarenko, T. D. Minyailenko **(Minko)**, V. P. Pozharov, B. Ya. Reznik, E. V. Rozova, M. M. Seredenko, A. V. Stefanov, Correction of hypoxic disturbances under muco-viscidosis in children, 2nd National Congress of Lung Diseases, Chelyabinsk, Russia, 1991, p. 161.

219. L. L Poplavskaya, L. G. Zelinskaya, A. V. Zubarenko, T. D. Minyailenko **(Minko)**, V. P. Pozharov, E. V. Rozova, M. M. Seredenko, A. V. Stefanov, Phospholipid liposomes in complex therapy of bronchial asthma in children, 2nd National Congress of Lung Diseases, Chelyabinsk, Russia, 1991, p.101.

220. L. G. Zelinskaya, A. V. Zubarenko, T. D. Minyailenko **(Minko)**, V. P. Pozharov, L. L Poplavskaya, E. V. Rozova, M. M. Seredenko, A. V. Stefanov, Phospholipid liposomes in complex therapy of chronic pneumonia in children, 2nd National Congress of Lung Diseases, Chelyabinsk, Russia, 1991, p. 84.

221. T. D. Minyailenko **(Minko)**, Influence of adaptation to high altitude hypoxia on the resistance of an organism to oxygen deficiency and stress, Functional Reserves and Adaptation, Kiev, Ukraine, 1990, pp. 88-90.

222. V. A. Bystrjukov, V. P. Pozharov, T. D. Minyailenko **(Minko)**, V. R. Tyutyunnik, M. M. Seredenko, Peculiarities of energy supply of working muscles in the rats with different types of breathing, Structural and Energetic Supply of Mechanical Muscle Work, Moscow, Russia, 1990, p. 77-78.

223. M. Seredenko, V. Pozharov, T. Minyailenko **(Minko)**, V. Bystrjukov, Energy metabolism and fatigue, Biochemical and Physiological Aspects of Muscle Fatigue, Paris, France, 1990, p. 126.

224. L. L Poplavskaya, M. M. Seredenko, T. D. Minyailenko **(Minko)**, V. P. Pozharov, E. V. Rozova, A. V. Stefanov, A. V. Zubarenko, S. A. Bryginsky, Usage of liposomes in acute period of bronchial asthma in children, 1st National Congress of Lung Diseases, Kiev, Ukraine, 1990, p. 544.

225. T. D. Minyailenko **(Minko)**, V. P. Pozharov, O. A. Ezhova, Phospholipid pattern of organs and lipid peroxidation during hypoxia, Physiology and Bioenergetics of Hypoxia, Minsk, Belorussia, 1990, p. 50.

226. M. M. Seredenko, T. D. Minyailenko **(Minko)**, V. P. Pozharov, E. V Rozova, Development of hypoxic state in organism during hyperthermia, System of Thermoregulation During Adaptation of Organism to Environmental Impacts, Vol. 2, Novosibirsk, Russia, 1990, p. 211.

227. V. P. Pozharov, T. D. Minyailenko **(Minko)**, O.A. Ezhova, Factors, which ensure the conformity between lung gas exchange and metabolism under hypoxia, 13th Congress of Ukrainian Physiological Society, Kiev, Ukraine, 1990, 2, p. 79.

228. V. P. Pozharov, T. D. Minyailenko **(Minko)**, M. M. Seredenko, F. Z. Meerson, Disturbances of respiration and gas exchange under stress and a possibility of its correction, 4th All-Union Congress for Pathophysiology, Vol. 2, Kishinev, Moldova, 1989, p. 628.

229. M. M. Seredenko, T. D. Minyailenko **(Minko)**, V. P. Pozharov, O. A. Knish, Oxygen deficiency and lipid peroxidation in the brain tissue during adaptation to hypoxic impact, Principles and Mechanisms of Human Brain Activities, Leningrad, Russia, 1989, p. 137.

230. T. D. Minyailenko **(Minko)**, Role of primary disturbances of blood buffer capacity in the compensation of metabolic acidosis, Actual Problems of Pathology of Respiration, Kujbyshev, Russia, 1989, pp. 216-217.

231. L. M. Ulrihina, T. D. Minyailenko **(Minko)**, Hygienic basic for possibilities to use new technology fish ground products in the nutrition of population, Improvement of Technological Processes of Manufacturing of New Nutrient Products and Supplements, Kiev, Ukraine, 1989, p. 53.

232. M. M. Seredenko, V. P. Pozharov, T. D. Minyailenko **(Minko)**, F. Z. Meerson, Mechanisms of hypoxia development under stress, Ecologo-Physiological Problems of Adaptation, Moscow, Russia, 1988, p. 207.

233. Z. B. Levinton, Z. B. Rogovaya, T. I. Fliss, A. V. Kryshevich, T. D. Minyailenko **(Minko)**, V. P. Pozharov, Experimental basis of possible use of marine food products under injury of digestion organs, Modern Digestion and Illness, Dushanbe, Tadjikistan, 1988, pp. 274-275.

234. V. P. Pozharov, T. D. Minyailenko **(Minko)**, Estimation of conformity between brain circulation and metabolism during hypoxia, Physiology, Phathophysiology and Pharmacology of Brain Circulation, Tbilisi, Georgia, 1988, p. 147.

235. T. D. Minyailenko **(Minko)**, Factors which determine resistance of blood active reaction under hypoxia, in: Reactivity and Resistance: Fundamental and Applied Aspects, V. A. Antonenko, Ed., Kiev, Naukova Dumka, 1987, pp. 215-217.

236. M. M. Seredenko, A. V. Stefanov, V. P. Pozharov, T. D. Minyailenko **(Minko)**, E. V. Rozova, S. A. Bryginsky, A. V. Zubarenko, Mechanisms of the increase in the resistance to hypoxia after the injection of liposomes, in: Reactivity and Resistance: Fundamental and Applied Aspects, V. A. Antonenko, Ed., Kiev, Naukova Dumka, 1987, pp. 233-235.

237. S. A. Bryginsky, A. V. Stefanov, M. M. Seredenko, V. P. Pozharov, T. D. Minyailenko **(Minko)**, E. V. Rozova, An influence of liposomes on the development of acute hypoxia in animals, 5th Ukrainian Biochemical Congress, Vol. 1, Kiev, Ukraine 1987, p. 21.

238. V. Stefanov, V. P. Pozharov, S. A. Bryginsky, V. K. Lishko, M. M. Seredenko, T. D. Minyailenko **(Minko)**, A. V. Zubarenko, Influence of liposome incapsulated vitamin E on the development of hypoxia, Oxygen Regimen, Working Capacity and Fatigue During Endurance Exercise, Kaunas, Lithuania 1987, p. 86.

239. M. M. Seredenko, T. D. Minyailenko **(Minko)**, V. P. Pozharov, Development of hypoxic state during endurance exercise in healthy untrained men, Oxygen Regimen, Working Capacity, Fatigue During Endurance Exercise, Kaunas, Lithuania. 1987, p. 78.

240. M. M. Seredenko, E. V. Rozova, T. D. Minyailenko **(Minko)**, V. P. Pozharov, Yu. A. Krupko-Bolshova, V. F. Peterburgskaya, Peculiarities of the functional state of an organism oxygen supply systems in healthy girls and patients with juvenile bleeding, Problems and Methods of Investigation in Age Physiology, Baku, Azerbaidjan, 1987, p. 80-81.

241. M. M. Seredenko, V. P. Dudarev, I. I. Lanovenko, I. N. Mankovskaya, T. D. Minyailenko **(Minko)**, N. N. Nagnibeda, V. P. Pozharov, E. V. Rozova, M. M. Filippov, System, tissue and molecular mechanisms of organism adaptation to hypoxia of different genesis, 15th Congress of Pavlov Physiological Society of USSR, Vol. 3, Leningrad, Russia, 1987, p. 83.

242. M. M. Seredenko, T. D. Minyailenko **(Minko)**, V. P. Pozharov, P. A. Radzievskiy, N. V. Shtuchenko, Perculiarities of hemodinamics in healhty subjects and patients with bronchial asthma during adaptation to high altitude, Circulation in the Conditions of High Altitude and Experimental Hypoxia, Frunze, Kirgizia, 1986, pp. 156-157.

243. M. M. Seredenko, T. D. Minyailenko **(Minko)**, V. P. Pozharov, Study of compensation mechanisms of hypoxic state during hypoxia of different genesis, 12 Congress of Ukrainian Physiological Society, L'vov, Ukraine, 1986, pp. 365-366.

244. N. G. Sidoryak, T. D. Minyailenko **(Minko)**, Changes of acid-base status and lactic acid concentration under methemoglobinemia, 12 Congress of Ukrainian Physiological Society, L'vov, Ukraine, 1986, p.370.

245. V. P. Dudarev, I. I. Lanovenko, N. N. Nagnibeda, T. D. Minyailenko **(Minko)**, Mechanisms of development and compensation of hemic hypoxia in high altitude conditions, Actual Problems of Modern Physioloigy, Kiev, Ukraine, 1986, pp. 174-175.

246. T. D. Minyailenko **(Minko)**, The conformity between oxygen mass transfer and its consumption during hypoxia of different genesis, Regulation of Respiration and Gas Mass Transfer in the Organism, Leningrad, Russia, 1985, p. 57.

247. M. M. Seredenko, T. D. Minyailenko **(Minko)**, V. P. Pozharov, V. P. Rozova, Development of the hypoxic state during acute graded blood loss, Neural and Humoral Mechanisms of Compensation During the Action of Pathogenic Factors, Zaporozie, Ukreine, 1985, p. 122.

248. P. A. Radzievskiy, T. D. Minyailenko **(Minko)**, Z. R. Yatsenko, Estimation of organism functional state young and adult athletes, Problems of Estimation and Prognosis of Organism Functional, Frunze, Kirgizia, 1984, p. 223.

249. N. N. Nagnibeda, T. D. Minyailenko **(Minko)**, Influence of hemic hypoxia on sympato-adrenal system and blood acid-base status, Endocrine System and Damaging Environmental Factors, Leningad, Russia, 1983, p. 145.

250. P. A. Radzievskiy, T. D. Minyailenko **(Minko)**, N. V. Shtuchenko, Changes in respiration, circulation and oxygen regimen of organism under exercise in trained female 14-15 years old teenagers, Medical Problems of Mass Physical Culture, Tallin, Estonia, 1983, p. 132.

251. K. A. Dzintsaradze, T. D. Minyailenko **(Minko)**, Blood buffer properties and acid-base status in Aphalina dolphin, Control and Rational Usage of Sea Mammalians, Astrakhan, Russia, 1982, pp. 112-113.

252. P. A. Beloshitskiy, V. S. Minakov, A. P. Andreeva, A. G. Reznikov, N. V. Makarenko, P. P. Slin'ko, L. V. Voronina, A. A. Zanchiy, I. A. Tselnokova, V. I. Voronovskaya, V. Ya. Zhivitsa, T. D. Minyailenko **(Minko)**, P. A. Radzievskiy, N. A. Shtuchenko, Influence of mountain climate on healthy and suffering from iron-deficiency anemia arid zone residents, Adaptation of Organisms to Environment, Syktyvkar, Russia, 1982, p. 120.

253. I. I. Lanovenko, T. D. Minyailenko **(Minko)**, Disturbances of oxygen mass transfer and metabolism and their compensation after acute graduated blood lose, 11 Congress of the Ukrainian Physiological Society, Dnepropetrovsk, Ukraine, 1982, p. 245.

254. T. D. Minyailenko **(Minko)**, P. A. Radzievskiy, N. V. Shtuchenko, Respiration, circulation, blood acid-base balance and oxygen regimen of organism in women-arid zone lenders with iron deficit anemia under the influence of mountain climate, Human Adaptation in Different Climatogeographic and Industrial Environment, Vol. 3, Novosibirsk, Russia, 1981, pp. 155-157.

255. P. A. Beloshitskiy, V. I. Voronovskaya, V., A. Z. Kolchinskaya, A. N. Krasyuk, N. V. Makarenko, V. S. Minakov, T. D. Minyailenko **(Minko)**, P. A. Radzievskiy, A. G. Reznikov, I. S. Tselnokova, N. V. Shtuchenko, Study of functional changes in iron-deficit anemia arid zone residents during adaptation to high mountain conditions, Human Adaptation in Different Climatogeographic and Industrial Environment, Vol. 3, Novosibirsk, Russia, 1981, pp. 154-155.

256. T. D. Minyailenko **(Minko)**, P. A. Radzievskiy, N. V. Shtuchenko, Peculiarities of respiration, blood oxygen transport function, oxygen regimen of organism and blood acid-base equilibrium in teenagers under hypox hypoxia, Physiological and Clinical Aspects of Adaptation to Hypoxia, Hypodynamia and Hyperthermia, Vol. 2, Moscow, Russia, 1981, pp. 235-236.

257. N. N. Sirotinin, A. Z. Kolchinskaya, M. G. Bukhman, I. I. Girzanich, S. A. Gulyar, V. P. Dudarev, K. F. Jikhareva, A. A. Ivashkevich, M. T. Kerefov, I. I. Lanovenko, I. N. Man'kovskaya, T. D. Minyailenko **(Minko)**, A. G. Misyura, N. N. Nagnibeda, P. A. Radzievskiy, I. F. Sokolyanskiy, M. M. Filippov, Hypoxic conditions, their quantitative criteria and ways of correction, III International Congress for Pathological Physiology, Varna, Bulgaria, 1978, p. 111.

258. M. M. Filippov, P. A. Radzievskiy, T. D. Minyailenko **(Minko)**, Peculiarities of respiration and oxygen transport function of blood in female teenagers under endurance exercise, 1st All Union Conference "Physiology of Human Development", Moscow, Russia, 1977, pp. 179-180.

259. S. A. Gulyar, M. M. Filippov, V. A. Grinevich, K. D. Starodub, E. V. Moiseenko, A. S. Spakhov, V. G. Gmyrya, T. D. Minyailenko **(Minko)**, Oxygen mass transfer, carbon dioxide and inert gases under elevated pressure and exercise, 10th Congress of Ukrainian Physiological Society, Odessa, Ukraine, 1977, pp. 101-102.